

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60850 A1

(51) International Patent Classification⁷: **C07K 14/17**,
C12N 5/10, 15/12, 15/63, 15/64

(21) International Application Number: PCT/US01/04703

(22) International Filing Date: 14 February 2001 (14.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/182,172 14 February 2000 (14.02.2000) US
60/186,084 29 February 2000 (29.02.2000) US
60/198,583 18 April 2000 (18.04.2000) US
60/237,963 4 October 2000 (04.10.2000) US

(71) Applicants (*for all designated States except US*):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US). **SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New
Horizons Court, Great West Road, Brentford, Middlesex
TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **AGARWAL, Pankaj** [IN/US]; 251 West DeKalb Pike, King of Prussia, PA 19406 (US). **KABNICK, Karen, S.** [US/US]; 4138 Presidential Drive, Lafayette Hill, PA 19444 (US). **MURDOCH, Paul, R.** [GB/GB]; New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

RIZVI, Safia, K. [PK/US]; 4617 Pine Street, Philadelphia, PA 19143 (US). **SMITH, Randall, F.** [US/US]; 4138 Presidential Drive, Lafayette Hill, PA 19444 (US). **XIANG, Zahoying** [CN/US]; 2413 Ridgeway, Fort Lee, NJ 07024 (US).

(74) Agents: **HECHT, Elisabeth, J.** et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW 2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (*national*): AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.



WO 01/60850 A1

Novel Compounds

Field of Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane). The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in eukaryotes and the inner membrane in prokaryotes (Palade, 1975, Science, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, Nature New Biol., 239, 117; Blobel, and Dobberstein, 1975, J. Cell. Biol., 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells). Therefore targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited to all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic hormones, neuropsin, neurotrophins, pituitary hormones, pleiotrophins,

prostaglandins, secretogranins, selectins, thromboglobulins, thymosins), the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several families of serine
5 proteinases (including but not limited to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease I, etc.

Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, calcitonin,
10 adrenocorticotrophic hormone (ACTH), vasopressin, interleukines, interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaluronidase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme by Genentech), Chymodiactin (chymopapain by Knoll), alglucerase (Ceredase by Genzyme), streptokinase (Kabikinase by Pharmacia)
15 (Streptase by Astra), etc. This indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, including but not limited to diabetes, breast-, prostate-, colon cancer and other malignant
20 tumors, hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. The proteins of the present invention which include the signal sequences are also useful to further elucidate
25 the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.

Summary of the Invention

The present invention relates to particular polypeptides and polynucleotides of the genes
30 set forth in Table I, including recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, the diseases set forth in Tables III and V, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (*e.g.*, inhibitors) using the materials provided by the invention,
35 and treating conditions associated with imbalance of polypeptides and/or polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention

relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels the genes set forth in Table I. Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases) caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present invention.

Description of the Invention

In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when referring to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the Sequence Listing;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (e) a polypeptide sequence set forth in the Sequence Listing; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;
- (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the gene families set forth in Table II. They are therefore of therapeutic and diagnostic interest for the reasons set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes

set forth in Table I are hereinafter referred to as "the biological activity" of polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.

Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence Listing. Preferred fragments are biologically active fragments that mediate the biological activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of a polypeptide of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. A polypeptide of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;

- (b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
- (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide set forth in the Sequence Listing;
- (d) an isolated polynucleotide set forth in the Sequence Listing;
- 5 (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
- 10 (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
- (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity
- 15 Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;
- (j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and
- 20 polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide

25 comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from a sequence set forth in the Sequence Listing.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

30 Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set forth in the Sequence Listing;

(b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the Sequence Listing;

(c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing; or

(d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing;

and RNA polynucleotides that are complementary thereto.

The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the Sequence Listing is related to other proteins of the gene families set forth in Table II, having homology and/or structural similarity with the polypeptides set forth in Table II. Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one activity of the genes set forth in Table I.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments

of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than , may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the

polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end.

Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adapter specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook *et al. (ibid)*. Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and

Aspergillus cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, *e.g.*, vectors derived from bacterial plasmids, from bacteriophage, from
5 transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as
10 engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion
15 of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the
20 cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid
25 extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during
30 intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a
35 diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-

expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for
5 detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified
10 DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1
15 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising polynucleotide sequences or fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology
20 methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein. Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention.
25 Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of
30 skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing, or a fragment or an RNA transcript thereof;
- 35 (b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide set forth in the Sequence Listing or a fragment thereof; or

(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing .

5 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

 The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

 The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well

known in the art and include in situ hybridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used.

Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including,

for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use as a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such small molecules preferably have a molecular weight below 2,000 daltons, more

preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek et al, *Anal Biochem.*, 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and polypeptide of the genes set forth in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, *J Mol Recognition*, 8:52-58 (1995); and K. Johanson *et al.*, *J Biol Chem*, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is

labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, *e.g.*, a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
 - (b) a recombinant cell expressing a polypeptide of the present invention;
 - (c) a cell membrane expressing a polypeptide of the present invention; or
 - (d) an antibody to a polypeptide of the present invention;
- which polypeptide is preferably that set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

5 The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

10 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is
15 introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said
20 secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said secreted protein.

"Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

25 "Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that
30 may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases
35 such as inosine. A variety of modifications may be made to DNA and RNA; thus,

“polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.

5 “Polypeptide” refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. “Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either
10 by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be
15 present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation,
20 biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation,
25 hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and*
30 *Prospects*, 1-12, in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, “Analysis for protein modifications and nonprotein cofactors”, *Meth Enzymol*, 182, 626-646, 1990, and Rattan *et al.*, “Protein Synthesis: Post-translational Modifications and Aging”, *Ann NY Acad Sci*, 663, 48-62, 1992).

“Fragment” of a polypeptide sequence refers to a polypeptide sequence that is shorter than
35 the reference sequence but that retains essentially the same biological function or activity as the

reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

"% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents

a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as

hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \bullet I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in a sequence set forth in the Sequence Listing,

I is the Identity Index,

\bullet is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, *e.g.*, EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Table I.

Gene Name	GSK Gene ID	Nucleic Acid SEQ ID NO's	Corresponding Protein SEQ ID NO's
sbgTango79a	14898	SEQ ID NO:1	SEQ ID NO:24
sbgPRO331a	14908	SEQ ID NO:2	SEQ ID NO:25
sbghPYYa	24835	SEQ ID NO:3	SEQ ID NO:26
sbghGTa	25306	SEQ ID NO:4	SEQ ID NO:27
SB-HDGF	42748	SEQ ID NO:5 SEQ ID NO:6	SEQ ID NO:28 SEQ ID NO:29
SBhACRP30a	34718	SEQ ID NO:7 SEQ ID NO:8	SEQ ID NO:30 SEQ ID NO:31
sbg35069DBIa	35069	SEQ ID NO:9	SEQ ID NO:32
sbg14862SPERCTa	14862	SEQ ID NO:10 SEQ ID NO:11	SEQ ID NO:33 SEQ ID NO:34
sbg24878SIa	24878	SEQ ID NO:12 SEQ ID NO:13	SEQ ID NO:35 SEQ ID NO:36
sbg34976IGBa	34976	SEQ ID NO:14	SEQ ID NO:37
sbg41608HDGFa	41608	SEQ ID NO:15	SEQ ID NO:38
sbg66804SPARCra	66804	SEQ ID NO:16 SEQ ID NO:17	SEQ ID NO:39 SEQ ID NO:40
sbg72825FOLATEa	72825	SEQ ID NO:18	SEQ ID NO:41
SBhPRO221	73255	SEQ ID NO:19	SEQ ID NO:42
sbg77153CYSa	77153	SEQ ID NO:20	SEQ ID NO:43
SBh80014.IAPa	80014	SEQ ID NO:21 SEQ ID NO:22	SEQ ID NO:44 SEQ ID NO:45
sbgFGF-19b	68602	SEQ ID NO:23	SEQ ID NO:46

Table II

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbgTango79a	Slit-like membrane glycoprotein	GB:AC004152 Joint Genome Institute, Lawrence Livermore National Laboratory, 7000 East Ave., Livermore, CA 94551, USA	The human Tango-79 protein, geneseq:W84596 Patent number and publication date: WO9906427-A1 11-Feb-99	membrane-bound
sbgPRO331a	Slit-like membrane glycoprotein	GB:AC008039 Human Genome Center, University of Washington, Box 352145, Seattle, WA 98195, USA	The human protein PRO331, geneseq:Y13394 Patent number and publication date: WO9914328-A2 25-Mar-99	membrane-bound
sbghPYYa	Peptide YY	GB:AJ239323	Human peptideYY,	secreted

		Max-Planck-Institute for Molecular Genetics	gi:1172796 Kohri,K., Nata,K., Yonekura,H., Nagai, A., Konno,K. and Okamoto,H. Biochim. Biophys. Acta 1173 (3), 345-349 (1993)	
sbghGTa	Gonadotropin beta chain	GB:AL049871 Genoscope – Centre National de Sequencage :BP 19191006 EVRY cedex FRANCE	Pacific herring gonadotropin II-beta,gi:4200297 Power,M.E., Carolsfield,J, Wallis, G.P. and Sherwood, N.M. J. Fish Biol. 50, 315-323 (1997)	secreted
SB-HDGF	Hepatoma derived growth factor (HDGF)	JGI:CIT978SKB_50L17 Found at Joint Genome Institute	Mouse HDGF, gi: 2558501 Biochem. Biophys. Res. Commun. 238(1), 26-32, 1997	secreted
SBhACRP3 0a	Complement C1q/TNF	GB:AC007016 Submitted (08-May-99) by Department of Genetics, Stanford Human Genome Center, 855 Miranda Avenue, Palo, CA 94304	Mouse30 Kda adipocyte complement-related protein ACRP30, gi: 1051268 P. Sherer et al., J.Biol. Chem. 270(18), 10697-10703, 1996.	secreted
sbg35069D BIa	Neuropeptide	EMBL:AC010999 Submitted (29-Sep-1999) by Multimegabase Sequencing Center, University of Washington, P.O. Box 357730. Seattle, WA 98195	ACYL-COA-BINDING PROTEIN HOMOLOG (ACBP), gi:1168274 Lihmann, I. et al. Proc. Natl. Acad. Sci. U.S.A. 91 (15), 6899-6903 (1994)	cytosolic
sbg14862S PERCTa	speract receptor	GB:AC005522 (WU:H_DJ1129E2) submitted by Genome Sequencing Center, Washington University, School of Medicine, 4444 Forest Park Parkway, St. Lous, MO 63108, USA	gp-340, a putative opsonin receptor for lung surfactant, gi:5733598 Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, Kliem A, Reid KB, Poustka A, Skjodt K, Proc Natl Acad Sci U S A 1999 Sep 14; 96(19):10794-9.	membrane-bound
sbg24878SI a	laminin type EGF, EGF2, ldla2, dlra2, ldla1 and EGF1	SC:AL109804 found at Sanger Center	Mouse sialoadhesin gene, gi:2769747 Mucklow S, Gordon S, Crocker PR. Mamm Genome 1997 Dec;8(12):934-7	secreted
sbg34976I GBa	Slit-like membrane glycoprotein	GB:AC010931 Submitted (30-JAN-1999) by Genome Sequencing Center, Washington University	Immunoglobulin superfamily containing leucine-rich repeat, gi:5031809 Nagasawa A, Kubota R,	membrane-bound

		School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Imamura Y, Nagamine K, Wang Y, Asakawa S, Kudoh J, Minoshima S, Mashima Y, Oguchi Y, Shimizu N, Genomics 1997 Sep 15;44(3):273-9	
sbg41608H DGFa	Hepatoma- derived growth factor	GB:AL033539 Submitted by Sanger Center Hinxton, Cambridgeshire, CB10 1SA, UK	Bovine hepatoma-derived growth factor, gi:945419 Biochem. Biophys. Res. Commun. 238(1):26-32, 1997	secreted
sbg66804S PARCra	Sparc-related protein	GB:AL135747 Submitted by Genoscope – Centre National de Sequencage :BP 19191006 EVRY cedex, FRANCE	Mouse SPARC-related rprotein, gi:5305327 Submitted (05-Jun-1998) by GeneCraft, Treskowst. 10, Muenster 48163, Germany.	membrane- bound
sbg72825F OLATEa	Folate receptor	SB:AP000765 Submitted (25-NOV- 1999) by Masahira Hattori, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC); 1-7-22 Suehiro-chou, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan	Sus scrofa membrane- bound folate binding protein, gi:4928859 Vallet, J.L., Smith, T.P.L., Sontegard, T., Pearson, P.L., Christenson, R.K. and Klemcke, H.G. Biol. Reprod. 61(2):372 (1999)	membrane- bound
SBhPRO221	Slit-like membrane glycoprotein	GB:AP001065 Submitted (12-JAN- 2000) by Nobuyoshi Shimizu, Keio University, School of Medicine, Molecular Biology; 35 Shinanomachi, Shinjuku- ku, Tokyo 160-8582, Japan	New isolated human gene, geneseqp:Y13356. WO9914328-A2, Chen, J. Goddard, A., Yuan, J., Genentech Inc. 25th June 1999 GPS	membrane- bound
sbg77153C YSa	Testatin	GB:AL121894 Submitted by Sanger Center	Mouse testatin precursor, gi:3928491 Tohonen, V., Osterlund, C. and Nordqvist, K. Proc. Natl. Acad. Sci. U.S.A. 95 (24), 14208-14213 (1998).	secreted
SBh80014.I APa	Inhibitor of apoptosis protein (IAP)	GB:AL121827 Submitted by Sanger Center	human putative inhibitor of apoptosis, gi: 3914339 C. Stehlik et al, Biochem. Biophys. Res. Commun. 243(3), 827-832, 1998	cytosolic

sbgFGF-19b	Fibroblast Growth Factor	GB:AB018122Homo sapiens mRNA for FGF-19, complete cds (Nishimura,T., Utsunomiya,Y., Hoshikawa,M., Ohuchi,H. and Itoh,N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta 1444 (1), 148-151 (1999))	FGF-19 (gi 5668601, gi 4826726, gi4514718, (Nishimura,T., Utsunomiya,Y., Hoshikawa,M., Ohuchi,H. and Itoh,N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta 1444 (1), 148-151 (1999))	secreted
------------	--------------------------	---	--	----------

Table III.

Gene Name	Uses	Associated Diseases
sbgTango79a	An embodiment of the invention is the use of sbgTango79a, a secreted protein, in the diagnosis and treatment of Tango-associated diseases and involvement in gastrointestinal ulceration. Close Homologs of sbgTango79a are Tango 79 and PRO227.	Alzheimers disease, ALS, abnormal keratinocyte differentiation, anti thrombosis, atrophia areata, cell growth, congenital microvillus atrophy, dermal scarring, enterocolitis, cancer, gastrointestinal ulceration, neuropathy, Parkinson's disease, psoriasis, skin diseases, Usher's syndrome, wound healing, and Zollinger-Ellison syndrome
sbgPRO331a	An embodiment of the invention is the use of sbgPRO331a, in the treatment of gastrointestinal ulceration and involved in nutritional activity, cytokine and cell proliferation/differentiation activity, immune stimulating (e.g. as vaccines) or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumour invasion suppressor activity, and tumour inhibition activity. The polynucleotides of sbgPRO331a may also be useful for gene therapy. Close Homologs of sbgPRO331a are PRO331 and AS209_1.	Alzheimers disease, ALS, abnormal keratinocyte differentiation, anti-thrombosis, atrophia areata, cell growth, hematopoietic disease, diseases of the immune system, inflammation, congenital microvillus atrophy, dermal scarring, enterocolitis, cancer, gastrointestinal ulceration, neuropathy, Parkinson's disease, psoriasis, skin diseases, Usher's syndrome, wound healing, and Zollinger-Ellison syndrome
sbghPYYa	An embodiment of the invention is the use of sbghPYYa, to identify new receptors and receptor agonists, antagonists, or protein agents. A close homolog of sbghPYYa is Peptide YY precursor, a clinically significant member of the neuropeptide family which include peptides such as pancreatic hormone, neuropeptide Y (NPY) and peptide YY (PYY). These neuropeptides are ligands for G-protein coupled receptors.	Anxiety, schizophrenia, feeding disorders, anorexia, depression, grooming, stretching, yawning, social, sexual and rewarded behavior, chronic and acute inflammation, cardiovascular disease, sleep disorder, learning and memory alteration and altered immune response, cancer, seizure, stroke, migraine, asthma, neuropathy and aging
sbghGTa	Human gonadotropin most similar to luteinizing hormone, sbghGTa, is exploitable in similar ways to luteinizing hormone or its releasing hormone. Luteinizing hormone is helpful in ovulation induction for reproductive procedures (Fertil. Steril.	Sexual disorders, infertility, blocking fertility, hypogonadism, prostate and other cancers, treatment of transsexuals

	1999, 71(3):405-414). Luteinizing hormone-releasing hormone and its agonists are exploited to reduce androgen levels in prostate cancer (Oncology. 1998, 12(4):499-505). Gonadotropin releasing hormone use is helpful in polycystic ovary syndrome (Eur. J. Contracept. Reprod. Health Care. 1997, 2(4):213-224).	
SB-HDGF	An embodiment of the invention is the use of SB-HDGF, to control cell growth and regulation of cell differentiation. Hepatoma-derived growth factors are members of a diverse family of cytokines. Like other cytokines, they are peptides involved in the control of cell growth regulation, differentiation and function (Thomson, The Cytokine Handbook, 2nd edition, Academic Press, Harcourt Brace & co. publishers, London). Another embodiment of the invention is the use of SB-HDGF for diagnosis or therapeutic treatment of human hepatoma. HDGFs are structurally related to Fibroblast growth factors (Klagsbrun M., Sasse, J., Proc. Natl. Acad. Sci. USA 1986 83(8) 2448-52). This putative growth factor may play an important role in autonomous growth of hepatoma and may lead to useful diagnosis or therapeutic approaches to Human Hepatoma (Nakamura, H., Kambe, H., Egawa, T Clin Chim Acta 1989, 183(3):273-84). A further embodiment of the invention is the use of SB-HDGF to prevent tumor growth. Inhibition of fibroblast growth factor-2 by the compound Suramin prevents neovascularisation and tumor growth in mice (Pesenti et al., British Journal of Cancer, 66:367-372.)	Cancer, inflammation, defective immune response, cardiovascular disease, growth abnormalities
SBhACRP30 a	Based on EST expression data, SBhACRP30a is primarily or exclusively expressed in heart. Based on the similarity of SBhACRP30a to ACRP30, Hib27, C1q complement proteins, TNF, and other members of the TNF superfamily, an embodiment of the invention is the use that the encoded protein of SBhACRP30a may play a role in inflammation, cell proliferation, cell death, immunity, and/or energy homeostasis processes. SBhACRP30a show highest similarity to one member of this superfamily, ACRP30 (Adipocyte Complement-Related Protein of 30 kDa). ACRP30 is made exclusively in adipocytes, and its expression is dysregulated in various forms of obesity (Hu, E, Liang, P and Spiegelman, BM. J. Biol. Chem 271, 10697-10703, 1996). ACRP30 secretion is acutely stimulated by insulin (Scherer, PE, Williams S., Fogliano, M., Baldini, G. and Lodish, J Biol. Chem. 270, 26746-26749, 1995) and is repressed by chronically elevated levels of insulin. A related molecule, the Hib27 protein from Siberian chipmunks, seems also to be involved in energy homeostasis, as its expression is specifically extinguished during hibernation (Takamatsu, N., Ohba, K., Kondo, J., Kondo, N., and Shiba, T. Mol. Cell Biol. 13 1516-1521, 1993). Recently, it has been shown that the three dimensional structure of ACRP30 is superimposable with that of the TNF's, suggesting	Cancer, obesity, anorexia, inflammation, cardiovascular disease, growth abnormalities

	that these proteins may have a similar function and mode of action (Shapiro, L and Scherer PE.,. Current Biology 8, 335-338, 1997). TNF's are known to play a role in energy homeostasis, where they are implicated in cachexia, obesity and in insulin resistance (Hotamisligil GS., and Spiegelman BM. Diabetes (1994) 43, 1271-1278; Teoman Uysal K., Wiesbrock SM, Marina MW and Hotamisligil GS, Nature 389, 610-614, 1997).	
sbg35069DBI a	An embodiment of the invention is the use of sbg35069DBIa to function as a neuropeptide, modulating the activity of the GABA receptor. A similar homologue can displace diazepam from benzodiazepine (BZD) recognition site on GABA type A receptors. As such, it may function as a neuropeptide, modulating the activity of the GABA receptor (J.B.C. 1986. 261(21):9727-31). Two forms, short and long (Biochem. J. 1995. 306:327-30), are predicted to be intracellular and secreted, respectively.	Anxiety, schizophrenia, feeding disorders, anorexia, depression, grooming, stretching, yawning, social, sexual and rewarded behavior, chronic and acute inflammation, cardiovascular disease, sleep disorder, learning and memory alteration and altered immune response, cancer, seizure, stroke, migraine, asthma, neuropathy and aging
sbg14862SPERCTa	An embodiment of the invention is the use of sbg14862SPERCTa, a secreted protein, in the diagnosis and treatment of cancers. A close homolog of sbg14862SPERCTa is human secreted protein SRCR.	Cancer, infections, autoimmune diseases, wound healing and hematopoietic disorder
sbg24878SIa	An embodiment of the invention is the use that the encoded protein of sbg24878SIa, a member of the immunoglobulin superfamily, may play a roll in cell-cell interactions. The closest homologue to this protein is the mouse sialoadhesin genes, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains, is proposed to function in both secreted and membrane-bound forms and involved in cell-cell interactions. A further embodiment of the invention is the use of sbg24878SIa to inhibit T-cell-B-cell interactions for treating auto-immune disease such as rheumatoid arthritis, systemic lupus erythematosus etc. Close Homologs of sbg24878SIa are mouse sialoadhesin genes and CD22 beta.	Auto-immune diseases such as rheumatoid arthritis, systemic lupus erythematosus and tumors
sbg34976IGB a	An embodiment of the invention is the use of sbg34976IGBa, a secreted protein, in the diagnosis and treatment of Bardet-Biedl syndrome type 4 (BBS4). A close homolog of sbg34976IGBa is leucine rich repeat (ISLR) mRNA.	Alzheimers disease, ALS, abnormal keratinocyte differentiation, anti-thrombosis, atrophia areata, cell growth, hematopoietic disease, diseases of the immune system, inflammation, congenital microvillus atrophy, dermal scarring, enterocolitis, cancer, gastrointestinal ulceration, neuropathy, Parkinson's disease, psoriasis, skin diseases, Usher's syndrome, wound healing, and Zollinger-Ellison syndrome
sbg41608HD GFa	An embodiment of the invention is the use of sbg41608HDGFa, to control cell growth and regulation of cell differentiation. Hepatoma-derived growth factors are members of a diverse family of cytokines. Like other cytokines, they are peptides involved in the control of cell growth, regulation,	Cancer, inflammation, defective immune response, cardiovascular disease, growth abnormalities

	differentiation and function (e.g. Thomson, The Cytokine Handbook, 2nd edition, Academic Press, Harcourt Brace & co. publishers, London). Another embodiment of the invention is the use of sbg41608HDGFa for diagnosis or therapeutic treatment of human hepatoma. HDGF are structurally related to Fibroblast growth factors (Klagsbrun M., Sasse, J., Proc. Natl.Acad. Sci. USA 1986 83(8) 2448-52). This putative growth factor may play an important role in autonomous growth of hepatoma and may lead to useful diagnosis or therapeutic approaches to Human Hepatoma (Nakamura, H., Kambe, H., Egawa, T Clin Chim Acta 1989, 183(3):273-84,). A further embodiment of the invention is the use of sbg41608HDGFa to prevent tumor growth. Inhibition of fibroblast growth factor-2 by the compound Suramin prevents neovascularisation and tumor growth in mice (Pesenti et al., British Journal of Cancer, 66:367-372)	
sbg66804SPARCra	An embodiment of the invention is the use of sbg66804SPARCra, in development, remodeling, cell turnover, tissue repair, and tumor growth. The closest homologue to this secreted protein is the mouse SPARC-related protein. SPARC (Secreted Protein, Acidic and Rich in Cysteine) is a unique matricellular glycoprotein that is expressed by many different types of cells and is associated with development, remodeling, cell turnover, and tissue repair. Its principal functions in vitro are counteradhesion and antiproliferation, which proceed via different signaling pathways. SPARC has demonstrated activities in angiogenesis, cataractogenesis, and wound healing. SPARC has also been identified in tumors.	Cataractogenesis, angiogenesis, wound healing, tumors
sbg72825FOLATEa	An embodiment of the invention is the use of sbg72825FOLATEa in the diagnostic and treatment applications of malignant, such as epithelial cancers, ovary, uterus, cervix cancer and future cancer vaccine developments. A close homolog of sbg72825FOLATEa is membrane bound folate binding protein.	Epithelial cancers, ovary, uterus and cervix cancer
SBhPRO221	An embodiment of the invention is the use of SBhPRO221 in disorders associated with preservation and maintenance of gastric mucosa, treatment of chronic and acute gastric ulcer, skin disease like epithelial cancer, lung squamous carcinoma, neuropathy, Parkinson disease, Alzheimer disease, tissue repair, problems of kidney, endometrium, blood vessels and other tissue in genital tract.	Disorders associated with healthy maintenance of gastric mucosa and repair of acute and chronic mucosal lesion, skin disease, lung carcinoma, growth abnormalities, Parkinson, Alzheimer's disease, ALS, neuropathy and cancer
sbg77153CYSa	An embodiment of the invention is the use of sbg77153CYSa in natural tissue remodeling events such as bone resorption and embryo implantation along with associations with tumor formation and metastasis. The closest homologue is the mouse testatin precursor (Cystatin 9), is related to a group of genes that encodes cysteine protease inhibitors known as cystatins. Cystatins and their target	Tumors and metastasis, remodeling bone resorption and embryo implantation

	proteases have been associated with tumor formation and metastasis, but also are involved in natural tissue remodeling events such as bone resorption and embryo implantation.	
SBh80014.IA Pa	An embodiment of the invention is the use of SBh80014.IAPa in inhibition of apoptosis and thus in, cell proliferation, cancer, metastasis, cell death, immunity, and energy homeostatis processes. A close homolog to SBh80014.IAPa is PIAP(putative inhibitor of apoptosis protein) (C. Stehlik et al, Biochem. Biophys. Res. Commun. 243(3), 827-832, 1998). PIAP is made primarily in tumor cells and is strongly upregulated in response to inflammatory cytokine TNF- α , IL-1 and lipopolysaccharides. The members of this family are conserved across species.	Suppression of apoptosis, cell proliferation, cancer, metastasis, Inflammation, defective immune response, growth abnormalities
sbgFGF-19b	An embodiment of the invention is the use of sbgFGF-19b in cell growth, regulation, differentiation, function, angiogenesis, neovascularisation, wound healing, astrogliosis, glial cell proliferation and differentiation, cerebral vasodilation, neurotrophic/neuromodulatory processes, improves the outcome in cerebral ischemia, promotes neoangiogenesis in ischemic myocardium, and enhances functional recovery and/or promotes neuronal sprouting following focal cerebral infarct. Fibroblast growth factors are a diverse family of cytokines. Like other cytokines, they are peptides involved in the control of cell growth, regulation, differentiation and function (e.g. Thomson, The Cytokine Handbook, 2nd edition, Academic Press, Harcourt Brace & co. publishers, London). Fibroblast growth factors are so called because they are fibroblast mitogens (Gospodarawicz, Journal of Biological Chemistry, (1975) 250: 2515-2520,). Inhibition of fibroblast growth factor-2 by the compound Suramin prevents neovascularisation and tumor growth in mice (Pesenti et al., British Journal of Cancer, 66:367-372). Fibroblast growth factors also function in angiogenesis (Lyons, M.K., et al., Brain Res. (1991) 558:315-320), wound healing (Uhl, E., et al., Br. J. Surg. (1993) 80:977-980, 1993), astrogliosis, glial cell proliferation and differentiation (Biagini, G. et al., Neurochem. Int. (1994) 25:17-24), cerebral vasodilation (Tanaka, R. et al., Stroke (1995) 26:2154-2159), and neurotrophic/neuromodulatory processes. Fibroblast growth factor also has multiple positive effects including blood flow and protection from calcium toxicity to improve outcome in cerebral ischemia (Mattson, M.P. et al., Semin. Neurosci. (1993) 5:295-307; Doetrocj. W.D. et al., J. Neurotrauma (1996) 13:309-316). Basic FGF treatment promotes neoangiogenesis in ischemic myocardium (Schumacher et al., Circulation (1998) 97: 645-650). Basic FGF enhances functional recovery and promotes neuronal sprouting following focal cerebral infarct (Kawamata et al., Proc.Natl. Acad. Sci.(1997) 94 (15):8179-84).	Cerebral ischemia, cancer, atherosclerosis, rheumatoid arthritis, cirrhosis, psoriasis, sarcoidosis, idiopathic pulmonary fibrosis, tumor development, developmental disorders, skeletal disorders, wound repair

Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan or TaqMan.

Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA) or TaqMan PCR (Perkin Elmer, see Lie et al. Current Opinion in Biotechnology 9:43-48, 1998; Gibson et al., Genome Methods 6:995-1001, 1996) and human cDNAs prepared from various human tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. Results are presented as the number of copies of each specific gene's mRNA detected in 1ng mRNA pool from each tissue. Two replicate mRNA measurements were made from each tissue RNA.

SybrMan Results:

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm range for 2 data points per tissue)									
	Brain	Heart	Lung	Liver	Kidney	Skeletal muscle	Intestine	Spleen/lymph	Placenta	Testis
sbgTango79a	358 \pm 7	278 \pm 55	239 \pm 100	53 \pm 20	247 \pm 29	461 \pm 60	83 \pm 1	202 \pm 18	300 \pm 55	770 \pm 106
sbgPRO331a	1541 \pm 861	1831 \pm 25	2409 \pm 103	656 \pm 2	2283 \pm 82	625 \pm 47	510 \pm 5	2096 \pm 74	2596 \pm 68	4692 \pm 472
sbghPYYa	-3 \pm 1	-1 \pm 0	0 \pm 0	-7 \pm 8	8 \pm 2	-5 \pm 9	-4 \pm 1	2 \pm 1	-1 \pm 0	38 \pm 5
sbghGTa	24 \pm 10	5 \pm 4	5 \pm 3	-4 \pm 8	2 \pm 1	-3 \pm 5	-1 \pm 3	4 \pm 2	4 \pm 0	92 \pm 8
SB-HDGF	4362 \pm 359	3387 \pm 11	2425 \pm 120	972 \pm 82	3270 \pm 152	7106 \pm 1647	1133 \pm 164	2058 \pm 101	2528 \pm 50	9024 \pm 652
SBhACRP30a	10751 \pm 954	7443 \pm 294	9900 \pm 780	6463 \pm 45	8530 \pm 225	7638 \pm 405	6040 \pm 438	8912 \pm 1021	8931 \pm 617	8098 \pm 612
sbg35069DB1a	142 \pm 15	180 \pm 17	94 \pm 10	37 \pm 3	257 \pm 15	73 \pm 8	27 \pm 10	76 \pm 29	184 \pm 5	158 \pm 2
sbg14862SPERCTa	31 \pm 3	18 \pm 6	23 \pm 4	10 \pm 6	49 \pm 1	8 \pm 7	7 \pm 0	23 \pm 1	18 \pm 2	30 \pm 1
sbg24878S1a	327 \pm 29	1251 \pm 8	1740 \pm 103	552 \pm 20	514 \pm 182	636 \pm 65	582 \pm 64	5200 \pm 222	5151 \pm 271	695 \pm 30
sbg34976IGBa	1500 \pm 64	451 \pm 21	123 \pm 14	9 \pm 6	55 \pm 6	156 \pm 6	38 \pm 12	80 \pm 4	76 \pm 3	1975 \pm 183
sbg41608HDGFa	11 \pm 4	3 \pm 0	4 \pm 4	2 \pm 0	0 \pm 1	1 \pm 2	1 \pm 0	7 \pm 5	0 \pm 0	14909 \pm 926
sbg66804SPARCra	296 \pm 53	24 \pm 0	4 \pm 1	457 \pm 21	7 \pm 0	68 \pm 3	9 \pm 1	439 \pm 11	128 \pm 1	1037 \pm 17
sbg72825FOLATEa	289 \pm 40	381 \pm 12	100 \pm 78	92 \pm 3	494 \pm 102	289 \pm 52	101 \pm 3	219 \pm 30	405 \pm 121	270 \pm 44
SBhPRO221	14 \pm 6	109 \pm 43	102 \pm 30	221 \pm 44	19 \pm 9	6 \pm 5	61 \pm 13	60 \pm 19	33 \pm 11	119 \pm 40
sbg77153CYSa	50 \pm 8	80 \pm 32	181 \pm 3	10 \pm 2	234 \pm 50	54 \pm 7	25 \pm 8	93 \pm 0	151 \pm 3	26223 \pm 604
SBh80014.IAPa	6 \pm 10	82 \pm 70	31 \pm 3	-2 \pm 3	110 \pm 1	88 \pm 24	17 \pm 4	29 \pm 1	62 \pm 3	65 \pm 20

Table IV (cont).
TaqMan Results:

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm SD for 4 data points per tissue)									
	Brain	Heart	Lung	Liver	Kidney	Skeletal muscle	Intestine	Spleen	Placenta	Pancreas
sbgFGF-19b	9 \pm 9	25 \pm 30	8 \pm 11	1612 \pm 1711	9 \pm 16	10 \pm 9	9 \pm 15	16 \pm 20	0 \pm 3	123 \pm 144

Table V. Additional diseases based on mRNA expression in specific tissues

Tissue Expression	Additional Diseases
Brain	Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis
Heart	Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias
Lung	Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult respiratory distress syndrome
Liver	Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, impaired glucose tolerance
Kidney	Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular hypertension
Skeletal muscle	Eulenburg's Disease, hypoglycemia, obesity, tendinitis, periodic paralyses, malignant hyperthermia, paramyotonia congenita, myotonia congenita
Intestine	Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tropical Sprue, Pseudomembranous Enterocolitis
Spleen/lymph	Lymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macroglobulinemia, malignant lymphomas, rheumatoid arthritis
Placenta	Choriocarcinoma, hydatidiform mole, placenta previa
Testis	Testicular cancer, male reproductive diseases, including low testosterone and male infertility
Pancreas	Diabetic ketoacidosis, Type 1 & 2 diabetes, obesity, impaired glucose tolerance

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - 5 (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
 - (b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to a polypeptide sequence set forth in Table I;
 - (c) an isolated polypeptide comprising a polypeptide sequence set forth in Table I;
 - 10 (d) an isolated polypeptide having at least 95% identity to a polypeptide sequence set forth in Table I;
 - (e) a polypeptide sequence of a gene set forth in Table I; and
 - (f) fragments and variants of such polypeptides in (a) to (e)
- 15 2. An isolated polynucleotide selected from the group consisting of:
 - (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to a polynucleotide sequence set forth in Table I;
 - (b) an isolated polynucleotide comprising a polynucleotide set forth in Table I;
 - (c) an isolated polynucleotide having at least 95% identity to a polynucleotide set forth in Table I;
 - 20 (d) an isolated polynucleotide of a gene set forth in Table I;
 - (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence set forth in Table I;
 - (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
 - 25 (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to a polypeptide sequence set forth in Table I;
 - (h) an isolated polynucleotide encoding a polypeptide set forth in Table I;
 - (i) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labelled probe having a sequence set forth in Table I or a fragment thereof having at least 15 nucleotides;
 - 30 (j) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (i);
 - or a polynucleotide sequence complementary to said isolated polynucleotide
 - and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

35

3. An antibody immunospecific for the polypeptide of claim 1.
4. An antibody as claimed in claim 3 which is a polyclonal antibody.
- 5 5. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.
6. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a
10 cell such that the host cell, under appropriate culture conditions, produces said polypeptide.
7. A recombinant host cell produced by the process of claim 6.
8. A membrane of a recombinant host cell of claim 7 expressing said polypeptide.
15
9. A process for producing a polypeptide which comprises culturing a host cell of claim 7 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION
SMITHKLINE BEECHAM p.l.c.

<120> NOVEL COMPOUNDS

<130> GP50013

<140> TO BE ASSIGNED

<141> 2001-02-14

<150> 60/182,172

<151> 2000-02-14

<150> 60/186,084

<151> 2000-02-29

<160> 46

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1779

<212> DNA

<213> Homo sapiens

<400> 1

atgacctgct ggctgtgct cctgagcctg cccctgctcc tgctgcccgc ggcgccgccc	60
ccggctggag gctgcccggc ccgctgctgag tgcaccgtgc agaccgcgc ggtggcctgc	120
acgcgccgcc gcctgaccgc cgtgcccgcac ggcattccgg ccgagaccgc cctgctggag	180
ctcagccgca accgcattcc ctgcctgaac ccgggctgacc tggccgcgct gcccgctg	240
gaggagctgg acctgagcga gaacgccatc gcgcacgtgg agcccggcgc cttcgccaac	300
ctgccgcgcc tgcgcgtcct gcgtctccgt ggcaaccagc tgaagctcat cccgcccggg	360
gtcttcacgc gcctggacaa cctcacgtg ctggacctga gcgagaacaa gctggtaatc	420
ctgctggact acactttcca ggacctgcac agcctgcgcc ggctggaagt gggcgacaac	480
gacctggtat tegtctcgcg ccgcgccttc gcggggctgc tggccctgga ggagctgacc	540
ctggagcgct gcaacctcac ggctctgtcc ggggagctgc tgggccatct gcgcagcctg	600
ggcgccctgc ggtgctgcca cctggccatc gcctccctgg aggaccagaa cttccgcagg	660
ctgcccgggc tgctgcacct ggagattgac aactggccgc tgctggagga ggtggcggcg	720
ggcagcctgc ggggcctgaa cctgacctgc ctgtcggtca cccacaccaa catcaccgcc	780

gtgccggccg	ccgcgctgcg	gcaccaggcg	cacctcacct	gcctcaatct	gtcgcacaaac	840
cccatcagca	cgggtgccg	ggggtcggtc	cgggacctgg	tccgcctgcg	cgagctgcac	900
ctggccgggg	ccttgcctggc	tgtggtggag	ccgcaggcct	tccctgggcct	gcgccagatc	960
cgctgctca	acctctccaa	caacctgctc	tccacgttgg	aggagagcac	cttccactcg	1020
gtgaacacgc	tagagacgct	gcgcgtggac	gggaaccgcg	tggcctgcga	ctgtcgctcg	1080
ctgtggatcg	tgcagcgctg	caagaccctc	aacttcgacg	ggcggtgcc	ggcctgcgcc	1140
accccgggcg	aggtgcgcgg	cgacgcgctg	cgaaacctgc	cggactccgt	gctgttcgag	1200
tacttcgtgt	gccgcaaacc	caagatccgg	gagcggcgcc	tgcagcgctg	cacggccacc	1260
gcggggcgaag	acgtccgctt	cctctgccgc	gccgagggcg	agccggcgcc	caccgtggcc	1320
tgggtgaccc	cccagcaccg	gccggtgacg	gccaccagcg	cgggcccggc	gcgcgtgctc	1380
cccgggggga	cgctggagat	ccaggacgcg	cggccgcagg	acagcggcac	ctacacgtgc	1440
gtggccagca	acgcgggcgg	caacgacacc	tacttcgcc	cgctgaccgt	gcgccccgag	1500
ccggcccgca	accggacccc	gggcgaggcc	cacaacgaga	cgctggcgcc	cctgcgcgcg	1560
ccgctcgacc	tcaccaccat	cctggtgtcc	accgccatgg	gctgcatcac	cttccctggc	1620
gtggtcctct	tctgcttcgt	gctgctgttc	gtgtggagcc	gcggccgcgg	gcagcacaaa	1680
aacaacttct	cggtggagta	ctccttccgc	aaggtggatg	ggccggccgc	cgcggggggc	1740
cagggaggcg	cgcgcaagtt	caacatgaag	atgatctga			1779

<210> 2

<211> 1962

<212> DNA

<213> Homo sapiens

<400> 2

atgaagctct	tgtggcaggt	aactgtgcac	caccacacct	ggaatgccat	cctgctcccc	60
ttcgtctacc	tcacggcgca	agtgtggatt	ctgtgtgcag	ccatcgctgc	tgcgcctca	120
gccggggccc	agaactgcc	ctccgtctgc	tcgtgcagta	accagttcag	caagtggtg	180
tgcacgcgcc	ggggcctctc	cgagggtccc	cagggtattc	cctcgaacac	ccggtacctc	240
aacctcatgg	agaacaacat	ccagatgatc	caggccgaca	ccttcgccca	cctccaccac	300
ctggagggtcc	tgcagttggg	caggaactcc	atccggcaga	ttgagggtggg	ggccttcaac	360
ggcctggcca	gcctcaacac	cctggagctg	ttcgacaact	ggctgacagt	catccctagc	420
ggggcctttg	aatacctgtc	caagctgcgg	gagctctggc	ttcgcaacaa	ccccatcgaa	480
agcatcccct	cttacgcctt	caaccgggtg	ccctccctca	tgcgcctgga	cttgggggag	540
ctcaagaagc	tggagtatat	ctctgaggga	gcttttgagg	ggctgttcaa	cctcaagtat	600
ctgaacttgg	gcatgtgcaa	cattaaagac	atgcccaatc	tcacccccct	ggtggggctg	660
gaggagctgg	agatgtcagg	gaaccacttc	cctgagatca	ggcctggctc	cttccatggc	720
ctgagctccc	tcaagaagct	ctgggtcatg	aactcacagg	tcagcctgat	tgagcggaat	780
gcttttgacg	ggctggcctt	acttgtggaa	ctcaacttgg	cccacaataa	cctctcttct	840
ttgccccatg	acctctttac	cccgtgagg	tacctggtgg	agttgcatct	acaccacaac	900
ccttggaaact	gtgattgtga	cattctgtgg	ctagcctggt	ggcttcgaga	gtatataccc	960
accaattcca	cctgctgtgg	ccgctgtcat	gctcccatgc	acatgcgagg	ccgctacctc	1020
gtggagggtg	accaggcctc	cttccagtgc	tctgccccct	tcatcatgga	cgcacctcga	1080

gacctcaaca	tttctgaggg	tgggatggca	gaacttaagt	gtcggactcc	ccctatgtcc	1140
tccgtgaagt	gggtgctgcc	caatgggaca	gtgctcagcc	acgcctccc	ccaccaagg	1200
atctctgtcc	tcaacgacgg	caccttgaac	ttttcccacg	tgctgctttc	agacactggg	1260
gtgtacacat	gcatggtgac	caatgttgca	ggcaactcca	acgcctcggc	ctacctcaat	1320
gtgagcacgg	ctgagcttaa	cacctccaac	tacagcttct	tcaccacagt	aacagtggag	1380
accacggaga	tctcgctga	ggacacaacg	cgaaagtaca	agcctgttcc	taccacgtcc	1440
actgggttacc	agccggcata	taccacctct	accacggtgc	tcattcagac	taccctgtgt	1500
ccaagcagg	tggcagtacc	cgcgacagac	accactgaca	agatgcagac	cagcctggat	1560
gaagtcatga	agaccaccaa	gatcatcatt	ggctgctttg	tggcagtgc	tctgctagct	1620
gccgccatgt	tgattgtctt	ctataaactt	cgtaagcggc	accagcagcg	gagtacagtc	1680
acagccgccc	ggactgttga	gataatccag	gtggacgaag	acatcccagc	agcaacatcc	1740
gcagcagcaa	cagcagctcc	gtccggtgta	tcaggtgagg	gggcagtagt	gctgcccaca	1800
attcatgacc	atattaacta	caacacctac	aaaccagcac	atggggccca	ctggacagaa	1860
aacagcctgg	ggaactctct	gcaccccaca	gtcaccacta	tctctgaacc	ttatataatt	1920
cagacccata	ccaaggacaa	ggtacaggaa	actcaaatat	ga		1962

<210> 3

<211> 213

<212> DNA

<213> Homo sapiens

<400> 3

atggtgtcgg	tgtgcaggcc	gtggcctgct	gtggccatag	cacttctggc	tctgctggtc	60
tgctggggg	cgctggtcga	cacctgcccc	atcaaaccgc	aggctcctgg	cgaagacgag	120
tccctggagg	agctgagcca	ctattatgct	tccctgtgcc	actacctcaa	cgtggtcacc	180
agacagtgg	gggagggtgc	agacatgtgg	tga			213

<210> 4

<211> 393

<212> DNA

<213> Homo sapiens

<400> 4

atgaagctgg	cattcctctt	ccttggcccc	atggccctcc	tccttctggc	tggctatggc	60
tgtgtcctcg	gtgcctccag	tgggaacctg	cgcacctttg	tgggctgtgc	cgtgaggag	120
tttactttcc	tggccaagaa	gccaggctgc	aggggccttc	ggatcaccac	ggatgcctgc	180
tggggctcgct	gtgagacctg	ggagaaacct	attctggaac	ccccctatat	tgaagcccat	240
catcgagtct	gtacctacaa	cgagacccaa	caggtgactg	tcaagctgcc	caactgtgcc	300
cggggagtcg	acccttctta	cacctatccc	gtggccatcc	gctgtgactg	cggagcctgc	360
tccactgcc	ccacggagtg	tgagaccatc	tga			393

<210> 5

<211> 2031

<212> DNA

<213> Homo sapiens

<400> 5

attccaaacg	ccttttaaacc	cgggggacttg	gtttttcccta	aaattaaggg	ctaccctcaa	60
tggccttcca	ggatcgacga	catcgcggat	ggcgccgtga	agccccacc	caacaagtac	120
cccatctttt	tctttggcac	acacgaaaca	gccttccttg	gacccaagga	cctgttcccc	180
tacgacaaat	gtaaagacaa	gtacgggaag	cccaacaaga	ggaaaggctt	caatgaaggg	240
ctgtgggaga	tccagaacaa	ccccacgcc	agctacagcg	cccctccgcc	agtgaagctc	300
tccgacagcg	aggccccga	ggccaacccc	gccgacggca	gtgacgctga	cgaggacgat	360
gaggaccggg	gggtcatggc	cgtcacagcg	gtaaccgcc	cagctgccag	cgacaggatg	420
gagagcgact	cagactcaga	caagagtagc	gacaacagtg	gcctgaagag	gaagacgcct	480
gcgctaaaga	tgtcggcttc	gaaacgagcc	cgaaaggcct	ccagcgacct	ggatcaggcc	540
agcgtgtccc	catccgaaga	ggagaactcg	gaaagctcat	ctgagtcgga	gaagaccagc	600
gaccaggact	tcacacctga	gaagaaagca	gcggtccggg	cgccacggag	gggccctctg	660
ggggggacgga	aaaaaaagaa	ggcgccatca	gcctccgact	ccgactccaa	ggccgattcg	720
gacggggcca	agcctgagcc	ggtggccatg	gcgcggtcgg	cgtcctcctc	ctcctcttcc	780
tcctcctcct	ccgactccga	tgtgtctgtg	aagaagcctc	cgagggggcag	gaagccagcg	840
gagaagcctc	tcccgaagcc	gcgagggcgg	aaaccgaagc	ctgaacggcc	tccgtccagc	900
tccagcagtg	acagtgacag	cgacgaggtg	gaccgcatca	gtgagtggaa	gcggcgggac	960
gaggcgcgga	ggcgcgagct	ggaggcccg	cggcggcgag	agcaggagga	ggagctgcgg	1020
cgcctgcggg	agcaggagaa	ggaggagaa	gagcggaggc	gcgagcgggc	cgaccgcggg	1080
gaggctgagc	ggggcagcgg	cggcagcagc	ggggacgagc	tcagggagga	cgatgagccc	1140
gtcaagaagc	ggggacgcaa	gggccggggc	cggggtcccc	cgtcctcctc	tgactccgag	1200
cccagggccg	agctggagag	agaggccaag	aatcagcga	agaagccgca	gtcctcaagc	1260
acagagcccg	ccaggaaacc	tggccagaag	gagaagagag	tgcgggccga	ggagaagcaa	1320
caagccaagc	ccgtgaaggt	ggagcggacc	cgaagcgg	ccgagggtt	ctcgatggac	1380
aggaaggtag	agaagaagaa	agagccctcc	gtggaggaga	agctgcagaa	gctgcacagt	1440
gagatcaagt	ttgccctaaa	ggtcgacagc	ccggacgtga	agagggtgct	gaatgcccta	1500
gaggagctgg	gaaccctgca	ggtgacctct	cagatcctcc	agaagaacac	agacgtggtg	1560
gccaccttga	agaagattcg	ccgttacaaa	gcgaacaagg	acgtaatgga	gaaggcagca	1620
gaagtctata	cccggctcaa	gtcgcgggtc	ctcgggccaa	agatcgaggc	ggtgcagaaa	1680
gtgaacaagg	ctgggatgga	gaaggagaa	gccgaggaga	agctggccgg	ggaggagctg	1740
gccggggagg	agctggccgg	ggaggaggcc	cccaggaga	aggcggagga	caagcccagc	1800
accgatctct	cagccccagt	gaatggcgag	gccacatcac	agaaggggga	gagcgagag	1860
gacaaggagc	acgaggaggg	tcgggactcg	gaggaggggc	caaggtgtgg	ctcctctgaa	1920
gacctgcacg	acagcgtacg	ggagggtccc	gacctggaca	ggcctgggag	cgaccggcag	1980
gagcgcgaga	gggcacgggg	ggactcggag	gccctggacg	aggagagctg	a	2031

<210> 6

<211> 2154

<212> DNA

<213> Homo sapiens

<400> 6

atggcggtcc	tggaacctgag	ggagctgcgc	cgtggggatc	tggggggtgt	ccagggcctg	6
aaggagctgc	ggcgccaatg	gtctgggggt	cctgggcctg	aggaagctgc	gctctggggg	12
tctggggctt	ctgtgcctga	gggagctgca	ccatggggat	ctggggttgc	cctggccccag	18
agggagccac	gcctcatcga	cgacatcgcg	gatggcgccg	tgaagcccc	acccaacaag	24
taccccatct	ttttcttttg	cacacacgaa	acagccttcc	tgggacccaa	ggacctgttc	30
ccctacgaca	aatgtaaaga	caagtacggg	aagcccaaca	agaggaaagg	cttcaatgaa	36
gggctgtggg	agatccagaa	caacccccac	gccagctaca	gcgcccctcc	gccagtgagc	42
tcctccgaca	gcgaggcccc	cgaggccaac	cccgcgcagc	gcagtgacgc	tgacgaggac	48
gatgaggacc	gggggggtcat	ggccgtcaca	gcggtaaccc	ccacagctgc	cagcgacagg	54
atggagagcg	actcagactc	agacaagagt	agcgacaaca	gtggcctgaa	gaggaagacg	60
cctgcgctaa	agatgtcggg	ctcgaaacga	gcccgaagg	cctccagcga	cctggatcag	66
gccagcgtgt	ccccatccga	agaggagaac	tcggaaagct	catctgagtc	ggagaagacc	72
agcgaccagg	acttcacacc	tgagaagaaa	gcagcgggtc	gggcgcacag	gagggggcct	78
ctggggggac	ggaaaaaaaa	gaaggcgcca	tcagcctccg	actccgactc	caaggccgat	84
tcggacgggg	ccaagcctga	gccggtggcc	atggcgcggt	cggcgctctc	ctcctcctct	90
tcctcctcct	cctccgactc	cgatgtgtct	gtgaagaagc	ctccgagggg	caggaagcca	96
gcggagaagc	ctctcccgaa	gccgcgaggg	cggaaaccga	agcctgaacg	gcctccgtcc	102
agctccagca	gtgacagtga	cagcgacgag	gtggaccgca	tcagtgagtg	gaagcggcgg	108
gacgaggcgc	ggaggcgcgga	gctggaggcc	cggcggcggc	gagagcagga	ggaggagctg	114
cggcgctctg	gggagcagga	gaaggaggag	aaggagcggg	ggcgcgagcg	ggccgaccgc	120
ggggaggctg	agcggggcag	cggcggcagc	agcggggacg	agctcaggga	ggacgatgag	126
cccgtcaaga	agcggggacg	caaggggccg	ggccgggggtc	ccccgtcctc	ctctgactcc	132
gagcccagag	ccgagctgga	gagagaggcc	aagaaatcag	cgaagaagcc	gcagtccctc	138
agcacagagc	ccgccaggaa	acctggccag	aaggagaaga	gagtgcggcc	cgaggagaag	144
caacaagcca	agcccgtgaa	ggtggagcgg	acccggaagc	ggtccgaggg	cttctcgatg	150
gacaggaagg	tagagaagaa	gaaagagccc	tccgtggagg	agaagctgca	gaagctgcac	156
agtgagatca	agttttgccct	aaaggtcgac	agcccggacg	tgaagagggtg	cctgaatgcc	162
ctagaggagc	tgggaaccct	gcaggtgacc	tctcagatcc	tccagaagaa	cacagacgtg	168
gtggccacct	tgaagaagat	tcgccgttac	aaagcgaaca	aggacgtaat	ggagaaggca	174
gcagaagtct	atacccggtc	caagtcgcgg	gtcctcggcc	caaagatcga	ggcgggtgcag	180
aaagtgaaca	aggctgggat	ggagaaggag	aaggccgagg	agaagctggc	cggggaggag	186
ctggccgggg	aggagctggc	cggggaggag	gccccccagg	agaaggcgga	ggacaagccc	192
agcaccgatc	tctcagcccc	agtgaatggc	gaggccacat	cacagaaggg	ggagagcgca	198
gaggacaagg	agcacgagga	gggtcgggac	tcggaggagg	ggccaagggtg	tggctcctct	204
gaagacctgc	acgacagcgt	acgggagggg	cccgaacctg	acaggcctgg	gagcgaccgg	210
caggagcgcg	agaggggcacg	gggggactcg	gaggccctgg	acgaggagag	ctga	215

<210> 7

<211> 870

<212> DNA

<213> Homo sapiens

<400> 7

atgtttgtct	tgctctatgt	tacaagtttt	gccatttgtg	ccagtggaca	accccggggt	60
aatcagttga	aaggagagaa	ctactcccc	aggtatatct	gcagcattcc	tggtctgcct	120
ggacctccag	ggccccctgg	agcaaatggt	tcacctgggc	cccatggtcg	catcggcctt	180
ccaggaagag	atggtagaga	cggcaggaaa	ggagagaaag	gtgaaaagg	aactgcaggt	240
ttgagaggta	agactggacc	gctagggtctt	gccggtgaga	aaggggacca	aggagagact	300
gggaagaaa	gacccatagg	accagaggga	gagaaaggag	aagtaggtcc	aattggctct	360
cctggacca	agggagacag	aggagaacaa	ggggaccctg	ggctgcctgg	agtttgcaga	420
tgtggaagca	tcgtgctcaa	atccgccttt	tctgttggca	tcacaaccag	ctaccagaa	480
gaaagactac	ctattatatt	taacaaggtc	ctcttcaacg	agggagagca	ctacaaccct	540
gccacaggga	agttcatctg	tgctttccca	gggatctatt	acttttctta	tgatatcaca	600
ttggctaata	agcatctggc	aatcggactg	gtacacaatg	ggcaataaccg	gataaagacc	660
ttcgacgcca	acacaggaaa	ccatgatgtg	gcttcgggg	ccacagtcac	ctatctgcag	720
ccagaagatg	aagtctggct	ggagattttc	ttcacagacc	agaatggcct	cttctcagac	780
ccaggttggg	cagacagctt	attctccggg	tttctcttat	acgttgacac	agattaccta	840
gattccatat	cagaagatga	tgaattgtga				870

<210> 8

<211> 912

<212> DNA

<213> Homo sapiens

<400> 8

atggggaagg	aggacactca	agaaactcgc	acagagccaa	agatgtttgt	cttgctctat	60
gttacaagtt	ttgccatttg	tgccagtggg	caacccggg	gtaatcagtt	gaaaggagag	120
aactactccc	ccaggtatat	ctgcagcatt	cctggcttgc	ctggacctcc	agggccccct	180
ggagcaaatg	gttcccctgg	gccccatggt	cgcatcggcc	ttccaggaag	agatggtaga	240
gacggcagga	aaggagagaa	aggtgaaaag	ggaactgcag	gtttgagagg	taagactgga	300
ccgctaggtc	ttgccggtga	gaaaggggac	caaggagaga	ctgggaagaa	aggaccata	360
ggaccagagg	gagagaaagg	agaagtaggt	ccaattggtc	ctcctggacc	aaaggagac	420
agaggagAAC	aaggggaccc	ggggctgcct	ggagtttgca	gatgtggaag	catcgtgctc	480
aaatccgcct	tttctgttgg	catcacaacc	agctaccag	aagaaagact	acctattata	540
tttaacaagg	tcctcttcaa	cgaggagag	cactacaacc	ctgccacagg	gaagttcatc	600
tgtgctttcc	cagggatcta	ttacttttct	tatgatata	cattggctaa	taagcatctg	660
gcaatcggac	tggtacacaa	tgggcaatac	cggataaaga	ccttcgacgc	caacacagga	720
aaccatgatg	tggtctcggg	gtccacagtc	atctatctgc	agccagaaga	tgaagtctgg	780
ctggagattt	tcttcacaga	ccagaatggc	ctcttctcag	accaggttg	ggcagacagc	840
ttattctccg	ggtttctctt	atacgttgac	acagattacc	tagattccat	atcagaagat	900

gatgaattgt ga

912

<210> 9

<211> 267

<212> DNA

<213> Homo sapiens

<400> 9

atgtccctgc	aggctgattt	tgacatggtc	acagaagatg	tgaggaagct	gaaaacaaga	60
ccagatgatg	aagaactgaa	agaactttat	gggctttaca	aacaagctgt	aattggaaac	120
attaatattg	agtgttcaga	aatgctagaa	ttaaaaggca	aggccaaatg	ggaagcacag	180
aacccccaaa	aaggattgtc	agaggaagat	atgatgcgtg	cctttatttc	taaagccgaa	240
gagctgatag	aaaaatatgg	aatttag				267

<210> 10

<211> 1269

<212> DNA

<213> Homo sapiens

<400> 10

atgcacggtg	gctcctgggg	cagcgtctgt	gatgacgact	gggacgtggt	ggacgccaac	60
gtagtggtg	gccagctggg	ctgtggcctg	gcactgccc	tgccacggcc	ccttgccctt	120
ggccaaggcc	gaggcccat	cctgctggac	aacgtggagt	gccgcgggca	ggaagctgcg	180
ctgagcgagt	gcggcagccg	cggctggggc	gtccacaatt	gctttcacta	cgaggatgtg	240
gctgtcctgt	gtgatgggtga	gggcagcgta	cgcctggtag	ggggcgcgaa	cctgtgtcag	300
ggccgagtg	agatcctgca	cagtggcctg	tggggcaccg	tgtgtgacga	cgactggggg	360
ctgccggatg	ccgctgtggt	ctgtcgtcag	ctgggctgcg	gggcggccat	ggccgccacc	420
accaacgcct	tcttcggcta	tggcaccgga	cacatcctgc	tggacaacgt	gcactgcgaa	480
ggcggcgagc	cccgcctggc	agcctgccag	agcctgggct	ggggtgtgca	caactgcggc	540
caccacgagg	acgcggggcg	gctctgcgca	ggtgcgggct	ctagggggcg	tgggcggggc	600
cggggcagcc	cctctggccg	cgggcctgtg	cgccccgcag	gtggacggct	gcgactggtg	660
ggcggccccg	gtccgtgccg	cggccgcgtg	gaggtgttgc	acgccggggg	ctggggcacc	720
gtgtgcgacg	atgactggga	ctttgcggac	gcgcgcgtgg	cctgccgcga	agcgggctgc	780
gggcctgcgc	tgggcgctac	gggactgggc	cacttcggct	acggccgcgg	ccccgtgctg	840
ctggacaacg	tgggctgcgc	cggcaccgag	gctcgcctga	gcgactgctt	ccacctgggc	900
tggggccagc	acaactgcgg	ccaccacgag	gacgcgggag	cgctctgcgc	agggcattcta	960
cgtctgggtca	atggagccca	ccgatgcgag	ggacgtgtag	agctctacct	agggcaacgg	1020
tggggcactg	tctgtgatga	tgcttgggac	ctgcgggcag	ccggtgtcct	gtgccgccag	1080
ctgggctgtg	gccaggccct	cgcagccctt	ggcgaggctc	actttggccc	aggccgaggc	1140
ccattctctc	tggacaatgt	caagtgccgt	ggggaagaaa	gtgctctgct	gctctgctct	1200
catatccgct	gggatgccca	caactgtgac	cacagcgagg	atgccagtgt	cctgtgccag	1260
ccttcatga						1269

<210> 11
 <211> 1659
 <212> DNA
 <213> Homo sapiens

<400> 11

atggccacat	taccagagaa	ggccctgaaa	gaggcctgga	agggattgat	cccaagggttc	60
ccatggcttc	atggcaaagc	ggagctgagg	ctggtggggg	gccccagccg	ctgccggggc	120
cgcttggaa	tcattgcacg	tggctccttg	ggcagcgtct	gtgatgacga	ctgggacgtg	180
gtggacgcca	acgtagtgtg	tcgccagctg	ggctgtggcc	tggcactgcc	cgtgccacgg	240
ccccttgctc	ttggccaagg	cggaggcccc	atcctgcttg	acaacgtgga	gtgccgcggg	300
caggaagctg	cgctgagcga	gtgcggcagc	cgcggtctgg	gcgtccacaa	ttgctttcac	360
tacgaggatg	tggctgtcct	gtgtgatgaa	ttcttgccaa	cgcagccccc	aacaagggaag	420
atgttaacca	gtagagcacc	tcctacgaca	ctgccgaatg	gaaaaagtga	gggcagcgta	480
cgcctggtag	ggggcgcgaa	cctgtgtcag	ggccgagtgg	agatcctgca	cagtggcctg	540
tggggcaccg	tgtgtgacga	cgactggggg	ctgccggatg	ccgctgtggt	ctgtcgtcag	600
ctgggctgcg	gggcgggcat	ggccgccacc	accaacgcct	tcttcggcta	tggcaccgga	660
cacatcctgc	tggacaacgt	gcactgcgaa	ggcggcgagc	cccgcctggc	agcctgccag	720
agcctgggct	ggggtgtgca	caactgcggc	caccacgagg	acgcggggcg	gctctgcgca	780
ggcctgggtc	ccccaacgct	cacagcactg	ccatcctcag	ccacaagaga	ggactgggct	840
tggcagacag	atccgtccgc	tacaggagtt	ggcccccagc	cttcccggga	gacagcactg	900
ctcaccaccg	ccgcctgggc	cgcgggggaa	aaaagtggac	ggctgcgact	ggtgggcggc	960
ccgggtccgt	gccgcggccg	cgtggaggtg	ttgcacgccg	ggggctgggg	caccgtgtgc	1020
gacgatgact	gggactttgc	ggacgcgcgc	gtggcctgcc	gcgaagcggg	ctgcgggcct	1080
gcgctgggcg	ctacgggact	gggccacttc	ggctacggcc	gcggccccgt	gctgctggac	1140
aacgtgggct	gcgccggcac	cgaggctcgc	ctgagcgact	gcttccacct	gggctggggc	1200
cagcacaact	gcggccacca	cgaggacgcg	ggagcgctct	gcgcagggtga	ggctgacagc	1260
gaaggcccag	aggagctggg	actgcaagtc	cagcaggatg	gttctgagac	cacgcgggtg	1320
cccactcctc	ggcccaggga	cgggcatcta	cgtctggtca	atggagccca	ccgatgcgag	1380
ggacgtgtag	agctctacct	agggcaacgg	tggggcactg	tctgtgatga	tgcttggggc	1440
ctgcgggcag	ccggtgtcct	gtgccgccag	ctgggctgtg	gccaggccct	cgcagcccct	1500
ggcgaggctc	actttggccc	aggccgaggc	cccattctcc	tggacaatgt	caagtgccgt	1560
ggggaagaaa	gtgctctgct	gctctgctct	catatccgct	gggatgccca	caactgtgac	1620
cacagcgagg	atgccagtgt	cctgtgccag	ccttcatga			1659

<210> 12
 <211> 5130
 <212> DNA
 <213> Homo sapiens

<400> 12

atgggcttct	tgcccaagct	tctcctcctg	gcctcattct	tcccagcagg	ccaggcctca	60
tggggcgctct	ccagtcacca	ggacgtgcag	ggtgtgaagg	ggtcttgctt	gcttatcccc	120
tgcattcttca	gcttccttgc	cgacgtggag	gtgcccgcag	gcatacaggc	catctggtac	180
tacgactact	cgggccagcg	gcagggtggtg	agccactcgg	cggaccccaa	gctggtggag	240
gcccgccttc	gcggccgcac	cgagttcatg	gggaaccccg	agcacagggt	gtgcaacctg	300
ctgctgaagg	acctgcagcc	cgaggactct	ggttcctaca	acttcgcgtt	cgagatcagt	360
gaggtcaacc	gctggtcaga	tgtgaaaggc	accttgggtca	cagtaacaga	ggagcccagg	420
gtgcccacca	ttgcctcccc	ggtggagctt	ctcgagggca	cagagggtga	cttcaactgc	480
tccactccct	acgtatgcct	gcaggagcag	gtcagactgc	agtggcaagg	ccaggaccct	540
gctcgctctg	tcaccttcaa	cagccagaag	tttgagccca	cgggcgtcgg	ccacctggag	600
accctccaca	tggccatgtc	ctggcaggac	cacggccgga	tcctgcgctg	ccagctctcc	660
gtggccaatc	acagggctca	gagcgagatt	cacctccaag	tgaagtatgc	ccccaaaggt	720
gtgaagatcc	tcctcagccc	ctcggggagg	aacatccttc	caggtgagct	ggtcacactc	780
acctgccagg	tgaacagcag	ctaccctgca	gtcagttcca	ttaagtggct	caaggatggg	840
gtacgcctcc	aaaccaagac	tgggtgtgctg	cacctgcccc	aggcagcctg	gagcgatgct	900
ggcgtctaca	cctgccaagc	tgagaacggc	gtgggctctt	tgggtctcacc	ccccatcagc	960
ctccacatct	tcattggctga	ggtccagggtg	agcccagcag	gtcccatcct	ggagaaccag	1020
acagtgcac	tagtctgcaa	cacacccaat	gaggcaccca	gtgatctccg	ctacagctgg	1080
tacaagaacc	atgtcctgct	ggaggatgcc	cactcccata	ccctccgggt	gcacttggcc	1140
actagggctg	atactggctt	ctacttctgt	gaggtgcaga	acgtccatgg	cagcgagcgc	1200
tcggggccctg	tcagcgtggt	agtcaacctc	ctgacagcct	tcctggagac	ccaggcggga	1260
cttgtgggca	tccttcaactg	ctctgtggtc	agtgcagccc	tggccacact	ggtgctgtca	1320
catgggggtc	atatactggc	ctccacctcc	ggggacagtg	atcacagccc	acgcttcagt	1380
ggtacctctg	gtcccaactc	cctgcgcctg	gagatccgag	acctggagga	aactgacagt	1440
ggggagtaca	agtgtctcagc	caccaactcc	cttggaaatg	caacctccac	cctggacttc	1500
catgccaatg	ccgcccgtct	cctcatcagc	ccggcagccg	aggtggtgga	aggacaggca	1560
gtgacactga	gctgcagaag	cggcctaagc	cccacacctg	atgcccgcgtt	ctcctggtac	1620
ctgaatggag	ccctgcttca	cgagggtccc	ggcagcagcc	tcctgctccc	cgcggcctcc	1680
agcactgacg	ccggtcata	ccactgccgg	gcccgggacg	gccacagtgc	cagtggcccc	1740
tcttcgccag	ctgttctcac	tgtgctctac	ccccctcgac	aaccaacatt	caccaccagg	1800
ctggaccttg	atgccgctgg	ggccggggct	ggacggcgag	gcctcctttt	gtgccgtgtg	1860
gacagcgacc	ccccgccag	gctgcagctg	ctccacaagg	accgtgttgt	ggccacttcc	1920
ctgccatcag	ggggtggctg	cagcacctgt	gggggctgtt	ccccacgcac	gaaggtcacc	1980
aaagccccc	acttgctgcg	tgtggagatt	cacaacctt	tgctggaaga	ggagggcttg	2040
tacctctgtg	aggccagcaa	tgccttgggc	aacgcctcca	cctcagccac	cttcaatggc	2100
caggccactg	tcctggccat	tgcacatca	cacacacttc	aggagggcac	agaagccaac	2160
ttgacttgca	acgtgagccg	ggaagctgct	ggcagccctg	ctaacttctc	ctggttccga	2220
aatgggggtg	tgtgggcccc	gggtccccctg	gagaccgtga	cactgctgcc	cgtggccaga	2280
actgatgctg	ccctttacgc	ctgcgcacac	ctgactgagg	ctgggtgccc	gctctccact	2340
cccgctgctc	tgagtgtact	ctatcccccg	gaccgtccaa	agctgtcagc	cctcctagac	2400
atggggccagg	gccacatggc	tctgttcatc	tgcactgtgg	acagccgccc	cctggccttg	2460
ctggccttgt	tccatgggga	gcacctcctg	gccaccagcc	tgggtcccca	ggtcccatcc	2520

catggtcggt	tccaggctaa	agctgaggcc	aactccctga	agttagaggt	ccgagaactg	2580
ggccttgggg	actctggcag	ctaccgctgt	gaggccacaa	atgttcttgg	atcatccaac	2640
acctcactct	tcttccaggt	ccgaggagcc	tgggtccagg	tgtcaccatc	acctgagctc	2700
caagagggcc	aggctgtggt	cctgagctgc	caggtaacac	caggagtccc	agaggggacc	2760
tcatatcgtt	ggtatcggga	tggccagccc	ctccaggagt	cgacctcggc	cacgtccgc	2820
tttgcagcca	taactttgac	acaagctggg	gcctatcatt	gccaaagcca	ggccccaggc	2880
tcagccacca	cgagcctagc	tgcacccatc	agcctccacg	tgtcctatgc	cccacgccac	2940
gtcacactca	ctaccctgat	ggacacaggc	cctggacgac	tggtgctcct	cctgtgccgt	3000
gtggacagtg	accctccggc	ccagctgcgg	ctgctccacg	gggatcgctt	tgtggcctcc	3060
accctacaag	gtgtgggggg	acccgaaggc	agctctccca	ggctgcatgt	ggctgtggcc	3120
cccaacacac	tgcgtctgga	gatccacggg	gctatgctgg	aggatgaggg	tgtctatatc	3180
tgtgaggcct	ccaacaccct	gggccaggcc	tgggcctcag	ctgacttcga	cgctcaagct	3240
gtgaatgtgc	aggtgtggcc	cggggctacc	gtgctggagg	ggcagctggt	gaacctgacc	3300
tgccttgtgt	ggaccactca	cccgcccag	ctcacctaca	catggtacca	ggatgggcag	3360
cagcgcctgg	atgcccactc	catccccctg	cccaacgtca	cagtcaggga	tgccacctcc	3420
taccgctgcg	gtgtggggcc	ccctggctcg	gcaccccgcc	tctccagacc	tatcaccttg	3480
gacgtcctct	acgcgccccg	caacctgcgc	ctgacctacc	tcttgagag	ccatggcggg	3540
cagctggccc	tggctactgt	cactgtggac	agccgcccgc	ccgccagct	ggcctcagc	3600
cacgccggtc	gcctcttggc	ctcctcgaca	gcagcctctg	tccccaacac	cctgcgcctg	3660
gagctgcgag	ggccacagcc	cagggatgag	ggtttctaca	gctgctctgc	ccgcagccct	3720
ctggggccagg	ccaacacgtc	cctggagctg	cggctggagg	gtgtgcgggt	gatcctggct	3780
ccggaggctg	ccgtgcctga	aggtgcccc	atcacagtga	cctgtgcgga	ccctgctgcc	3840
cacgcaccca	cactctatac	ttggtaccac	aacggctcgt	ggctgcagga	gggtccagct	3900
gcctcactct	cattcctggt	ggccacgcgg	gctcatgcag	gcgcctactc	ttgccaggcc	3960
caggatgccc	agggcacccg	cagctcccgt	cctgctgccc	tgcaagtcct	ctatgcccct	4020
caggacgctg	tctgtcctc	cttccgggac	tccagggcc	gatccatggc	tgtgatacag	4080
tgcactgtgg	acagtgagcc	acctgctgag	ctggccctat	ctcatgatgg	caaggtgctg	4140
gccacgagca	gcgggggtcca	cagcttggca	tcagggacag	gccatgtcca	ggtggcccga	4200
aacgccttac	ggctgcaggt	gcaagatgtg	cctgcaggtg	atgacaccta	tgtttgcaca	4260
gccccaaaact	tgctgggctc	aatcagcacc	atcgggcggg	tgcaggtaga	aggtgcacgc	4320
gtggtggcag	agcctggcct	ggacgtgcct	gagggcgctg	ccctgaacct	cagctgccgc	4380
ctcctgggtg	gccctgggcc	tgtgggcaac	tccacctttg	catggttctg	gaatgaccgg	4440
cggctgcacg	cggagcctgt	gcccactctc	gccttcaccc	acgtggctcg	tgtcaagct	4500
gggatgtacc	actgcctggc	tgaactcccc	actggggctg	ctgcctctgc	tccagtcatg	4560
ctccgtgtgc	tctaccctcc	caagacgccc	accatgatgg	tcttcgtgga	gcctgagggg	4620
ggcctccggg	gcacccctga	ttgccgagtg	gacagcgagc	cgctcgccag	cctgactctc	4680
caccttggca	gtcgactggt	ggcctccagt	cagccccagg	gtgctcctgc	agagccacac	4740
atccatgtcc	tggcttcccc	caatgccctg	aggggtggaca	tcgaggcgct	gaggcccagc	4800
gaccaagggg	aatacatctg	ttctgcctca	aatgtcctgg	gctctgcctc	tacctccacc	4860
tactttgggg	tcagagccct	gcaccgctcg	catcagttcc	agcagctgct	ctgggtcctg	4920
ggactgctgg	tgggcctcct	gctcctgctg	ttgggcctgg	gggcctgcta	cacctggaga	4980
aggaggcggtg	tttgtaagca	gagcatgggc	gagaattcgg	tggagatggc	ttttcagaaa	5040

gagaccacgc	agggttttct	ctgtgggaag	ctcattgata	ctgatgcagc	cacatgtgag	5100
acctcaacct	gtgccccacc	cctgggctga				5130

<210> 13

<211> 5158

<212> DNA

<213> Homo sapiens

<400> 13

atgggcttct	tgcccaagct	tctcctcctg	gcctcattct	tcccagcagg	ccaggcctca	60
tggggcgtct	ccagtcccca	ggacgtgcag	ggtgtgaagg	ggtcttgctt	gcttatcccc	120
tgcattctca	gcttccttgc	cgacgtggag	gtgcccgcag	gcatcacggc	catctggtac	180
tacgactact	cgggccagcg	gcagggtggtg	agccactcgg	cggaccccaa	gctggtggag	240
gcccgcttcc	gcggccgcac	cgagttcatg	gggaaccccg	agcacagggg	gtgcaacctg	300
ctgctgaagg	acctgcagcc	cgaggactct	ggttcctaca	acttcgctt	cgagatcagt	360
gaggtcaacc	gctggtcaga	tgtgaaaggc	accttgggtc	cagtaacaga	ggagcccagg	420
gtgcccacca	ttgcctcccc	ggtggagctt	ctcgagggca	cagaggtgga	cttcaactgc	480
tccactccct	acgtatgcct	gcaggagcag	gtcagactgc	agtggcaagg	ccaggacctt	540
gctcgctctg	tcaccttcaa	cagccagaag	tttgagccca	cgggcgtcgg	ccacctggag	600
accctccaca	tggccatgtc	ctggcaggac	cacggccgga	tcttgcgctg	ccagctctcc	660
gtggccaatc	acagggtctc	gagcgagatt	cacctccaag	tgaagtatgc	ccccagggtt	720
gtgaagatcc	tcctcagccc	ctcggggagg	aacatccttc	caggtgagct	ggtcacactc	780
acctgccagg	tgaacagcag	ctaccctgca	gtcagttcca	ttaagtgggt	caaggatggg	840
gtacgcctcc	aaaccaagac	tgggtgtgctg	cacctgcccc	aggcagcctg	gagcgatgct	900
ggcgtctaca	cctgccaagc	tgagaacggc	gtgggctctt	tgggtctcacc	ccccatcagc	960
ctccacatct	tcatggctga	ggtccagggtg	agcccagcag	gtcccatcct	ggagaaccag	1020
acagtgcac	tagtctgcaa	cacacccaat	gaggcaccca	gtgatctccg	ctacagctgg	1080
tacaagaacc	atgtcctgct	ggaggatgcc	cactcccata	ccctccgggt	gcacttggcc	1140
actagggctg	atactggctt	ctacttctgt	gaggtgcaga	acgtccatgg	cagcgagcgc	1200
tcgggcctctg	tcagcgtggg	agtcaacctc	ctgacagcct	tcctggagag	ccaggcggga	1260
cttgtgggca	tccttccactg	ctctgtggtc	agtgcagccc	tggccacact	ggtgctgtca	1320
catgggggtc	atatcctggc	ctccacctcc	ggggacagtg	atcacagccc	acgcttcagt	1380
ggtacctctg	gtcccaactc	cctgcgcctg	gagatccgag	acctggagga	aactgacagt	1440
ggggagtaga	agtgtctcagc	caccaactcc	cttggaatg	caacctccac	cctggacttc	1500
catgccaatg	ccgcccgtct	cctcatcagc	ccggcagccg	aggtgggtgga	aggacaggca	1560
gtgacactga	gctgcagaag	cggcctaagc	cccacacctg	atgcccgctt	ctcctggtac	1620
ctgaatggag	ccctgcttca	cgagggtccc	ggcagcagcc	tcttgcctcc	cgcggcctcc	1680
agcactgacg	ccggctcata	ccactgccgg	gcccgggacg	gccacagtgc	cagtggcccc	1740
tcttcgccag	ctgttctcac	tgtgctctac	ccccctcgac	aaccaacatt	caccaccagg	1800
ctggaccttg	atgccgctgg	ggccggggct	ggacggcgag	gcctcctttt	gtgccgtgtg	1860
gacagcgacc	ccccgccag	gctgcagctg	ctccacaagg	accgtgttgt	ggccacttcc	1920
ctgccatcag	ggggtggctg	cagcacctgt	gggggctgtt	ccccacgc	gaaggctcacc	1980

aaagccccc	acttgctg	tgtggagatt	cacaaccctt	tgctggaaga	ggagggcttg	2040
tacctctgtg	aggccagcaa	tgccctgggc	aacgcctcca	cctcagccac	cttcaatggc	2100
caggccactg	tcctggccat	tgcaccatca	cacacacttc	aggagggcac	agaagccaac	2160
ttgacttgca	acgtgagccg	ggaagctgct	ggcagccctg	ctaacttctc	ctgggtccga	2220
aatgggggtgc	tgtgggccc	gggtcccctg	gagaccgtga	cactgctgcc	cgtggccaga	2280
actgatgctg	ccctttacgc	ctgccgcata	ctgactgagg	ctgggtgccc	gctctccact	2340
cccgtgctcc	tgagtgtact	ctatcccccg	gaccgtccaa	agctgtcagc	cctcctagac	2400
atggggccagg	gccacatggc	tctgttctac	tgcactgtgg	acagccgccc	cctggccttg	2460
ctggccttgt	tccatgggga	gcacctcctg	gccaccagcc	tgggtcccca	ggtcccatcc	2520
catggtcggt	tccaggctaa	agctgaggcc	aactccctga	agttagaggt	ccgagaactg	2580
ggccttgggg	actctggcag	ctaccgctgt	gaggccacaa	atgttcttgg	atcatccaac	2640
acctcactct	tcttcaggt	ccgaggagcc	tgggtccagg	tgtcaccatc	acctgagctc	2700
caagagggcc	aggctgtggt	cctgaactgc	caggtagaca	caggagtccc	agaggggacc	2760
tcatatcggt	ggtatcgga	tggccagccc	ctccaggagt	cgacctcggc	cacgctccgc	2820
tttgcagcca	taactttgac	acaagctggg	gcctatcatt	gccaagccca	ggccccaggc	2880
tcagccacca	cgagcctagc	tgcacccatc	agcctccacg	tgtcctatgc	cccacgccac	2940
gtcacactca	ctaccctgat	ggacacaggc	cctggacgac	tgggcctcct	cctgtgccgt	3000
gtggacagtg	accctccggc	ccagctgcgg	ctgctccacg	gggatcgctt	tgtggcctcc	3060
accctacaag	gtgtgggggg	acccgaaggc	agctctccca	ggctgcatgt	ggctgtggcc	3120
cccaacacac	tgcgtctgga	gatccacggg	gctatgctgg	aggatgaggg	tgtctatata	3180
tgtgaggcct	ccaacaccct	gggccaggcc	tcggcctcag	ctgacttcga	cgctcaagct	3240
gtgaatgtgc	aggtgtggcc	cggggctacc	gtgcgggagg	ggcagctggt	gaacctgacc	3300
tgcccttgtg	ggaccactca	cccgcccag	ctcacctaca	catggtacca	ggatgggcag	3360
cagcgccctg	atgcccactc	catccccctg	cccaacgtca	cagtcaggga	tgccacctcc	3420
taccgctgcg	gtgtggggcc	ccctggctcg	gcaccccgcc	tctccagacc	tatcaccttg	3480
gacgtcctct	acgcgccccg	caacctgcgc	ctgacctacc	tcctggagag	ccatggcggg	3540
cagctggccc	tggtagctgt	cactgtggac	agccgcccgc	ccgccagct	ggccctcagc	3600
cacgcgggtc	gcctcttggt	ctcctcgaca	gcagcctctg	tcaccaaac	cctgcgcctg	3660
gagctgcgag	ggccacagcc	cagggatgag	ggtttctaca	gctgctctgc	ccgcagccct	3720
ctggggccagg	ccaacacgtc	cctggagctg	cggctggagg	gtgtgcgggt	gatcctggct	3780
ccggaggctg	ccgtgcctga	aggtgcccc	atcacagtga	cctgtgcgga	ccctgctgcc	3840
cacgcaccca	cactctatac	ttggtaccac	aacggtcgtt	ggctgcagga	gggtccagct	3900
gcctcactct	cattcctggt	ggccacggcg	gctcatgcag	gcgcctactc	ttgccaggcc	3960
caggatgccc	agggcacccg	cagctcccgt	cctgctgccc	tgcaagtcct	ctatgcccct	4020
caggacgctg	tcctgtcctc	cttcggggac	tcaggggcca	gatccatggc	tgtgatacag	4080
tgcactgtgg	acagtgagcc	acctgctgag	ctggccctat	ctcatgatgg	caagggtgctg	4140
gccacgagca	gcgggggtcca	cagcttggca	tcagggacag	gccatgtcca	ggtggcccga	4200
aacgccttac	ggctgcaggt	gcaagatgtg	cctgcaggtg	atgacaccta	tgtttgcaca	4260
gcccaaaact	tgctgggctc	aatcagcacc	atcgggcggt	tgcaggtaga	aggtgcacgc	4320
gtgggtggcag	agcctggcct	ggacgtgcct	gagggcgctg	ccctgaacct	cagctgccgc	4380
ctcctgggtg	gccctgggccc	tgtgggcaac	tcacactttg	catggttctg	gaatgaccgg	4440
cggctgcacg	cggagcctgt	gcccactctc	gccttcaccc	acgtggctcg	tgtcaagct	4500

gggatgtacc	actgcctggc	tgagctcccc	actggggctg	ctgcctctgc	tccagtcatg	4560
ctccgtgtgc	tctaccctcc	caagacgccc	accatgatgg	tcttcgtgga	gcctgagggg	4620
ggcctccggg	gcatectgga	ttgccgagtg	gacagcgagc	cgctcgccag	cctgactctc	4680
caccttggca	gtcgactggg	ggcctccagt	cagccccagg	gtgctcctgc	agagccacac	4740
atccatgtcc	tggtctcccc	caatgccctg	aggggtggaca	tcgaggcgct	gaggcccagc	4800
gaccaagggg	aatacatctg	ttctgcctca	aatgtcctgg	gctctgcctc	tacctccacc	4860
tactttgggg	tcagagccct	gcaccgcctg	catcagttcc	agcagctgct	ctgggtcctg	4920
ggactgctgg	tgggcctcct	gctcctgctg	ttgggcctgg	gggcctgcta	cacctggaga	4980
aggaggcgctg	tttghtaagca	gagcatgggc	gagaattcgg	tggagatggc	ttttcagaaa	5040
gagaccacgc	agggactggg	tactacctta	ctggccctta	caagagtggg	gggcagacac	5100
agatgttgct	agcatcctta	ttcctgctcc	agatgcatct	ctgttcatga	ctgtgtga	5158

<210> 14

<211> 2238

<212> DNA

<213> Homo sapiens

<400> 14

atgttcccc	ttcgggccct	gtggttggtc	tgggcgcttc	taggagtggc	cggatcatgc	60
ccggagccgt	gcgcctgcgt	ggacaagtac	gctcaccagt	tcgcggactg	cgcttacaaa	120
gagttgcgtg	aggtgcccga	aggactgcct	gccaacgtga	cgacgcttag	tctgtccgcg	180
aacaagatca	ctgtgctgcg	gcgcggggcc	ttcgccgacg	tcacacaggt	cacgtcgctg	240
tggctggcgc	acaatgaggt	gcgcaccgtg	gagccaggcg	cactggccgt	gctgagtcag	300
ctcaagaacc	tcgatctgag	ccacaacttc	atatccagct	ttcgtgggag	cgacctgcgc	360
aacctgagcg	cgctgcagct	gtcaaaaatg	aaccacaacc	gcctgggctc	tctgccccgg	420
gacgcactcg	gtgcgctacc	cgacctgcgt	tccttgcgca	tcaacaacaa	ccggctgcgt	480
acgctggcgc	ctggcacctt	cgacgcgctt	agcgcgctgt	cacacttgca	actctatcac	540
aatcccttcc	actgcggctg	cggccttggtg	tggctgcagg	cctggggccgc	gagcaccg	600
gtgtccttac	ccgagcccga	ctccattgct	tgtgcctcgc	ctcccgcgct	gcaggggggtg	660
ccggtgtacc	gcctgcccgc	cctgccctgt	gcaccgccca	gcgtgcatct	gagtgccgag	720
ccaccgcttg	aagcaccg	cacccactg	cgcgaggac	tggcgcttctg	gttacactgc	780
atcgccgacg	gccaccctac	gcctgcgctg	caatggcaac	ttcagatccc	cgggtggcacc	840
gtagtccttag	agccaccggt	tctgagcggg	gaggacgacg	gggttggggc	ggaggaagga	900
gagggagaa	gagatgggga	tttgcctgacg	cagacccaag	cccaaaccgc	gactccagca	960
cccgttggc	cggcgccccc	agccacaccg	cgcttccttg	ccctcgcaaa	tggctccctg	1020
ttggtgcccc	tctgagtg	caaggaggcg	ggcgtctaca	cttgccgtgc	acacaatgag	1080
ctgggcgcca	actctacgtc	aatacgcgctg	gcggtggcag	caaccggggc	ccaaaacac	1140
gcgcctggcg	ccgggggaga	acccgacgga	caggccccga	cctctgagcg	caagtccaca	1200
gccaagggcc	ggggcaacag	cgctcctgcct	tccaaaccgc	agggcaaaat	caaaggccaa	1260
ggcctggcca	aggtcagcat	tctcggggag	accgagacgg	agccggaggga	ggacacaagt	1320
gagggagagg	agggcgaaga	ccagatcctc	gcggaccg	cggaggagca	gcgctgtggc	1380
aacggggacc	cctctcggtg	cgttttcta	cacgcgttca	accagagcgc	agagctcaag	1440

ccgcacgtct	tcgagctggg	cgtcacgcgc	ctggatgtgg	cggagcgcga	ggcgcgggtg	1500
cagctgactc	cgctggctgc	gcgctggggc	cctgggccc	gcggggctgg	cggagccccg	1560
cgacccgggc	ggcgaccct	gcgcctactc	tatctgtgtc	cagcgggggg	cggcgcgcca	1620
gtgcagtgg	cccgcgtaga	ggaaggcgtc	aacgcctact	ggttccgcgg	cctgcggccg	1680
ggtaccaact	actccgtgtg	cctggcgctg	gcgggcgaag	cctgccacgt	gcaagtgggtg	1740
ttttccacca	agaaggagct	cccacgcgtg	ctggatcatag	tggcagttag	cgtattcctc	1800
ctgggtgctgg	ccacagtgcc	ccttctgggc	gccgcctgct	gccatctgct	ggctaaacac	1860
ccgggcaagc	cctaccgtct	gatcctgcgg	cctcaggccc	ctgaccctat	ggagaagcgc	1920
atcgccgcag	acttcgaccc	gcgtgcttcg	tacctcgagt	ccgagaaaag	ctaccggcca	1980
ggcggcgagg	cgggcggcga	ggagccagag	gacgtgcagg	gggagggcct	tgatgaagac	2040
gcggagcagg	gagaccaag	tggggacctg	cagagagagg	agagcctggc	ggcctgctca	2100
ctggtggagt	cccagtcctaa	ggccaaccaa	gaggagtctg	aggcgggctc	tgagtacagc	2160
gatcggctgc	ccctgggcgc	cgaggcggtc	aacatcgccc	aggagattaa	tggcaactac	2220
aggcagacgg	caggctga					2238

<210> 15

<211> 756

<212> DNA

<213> Homo sapiens

<400> 15

atgtcggcct	acggcatgcc	catgtacaag	agcggggacc	tgggtgtttgc	caagttaaag	60
ggctatgcc	actggccggc	gaggatagag	cacatgaccc	agcccaaccg	ctaccagggtg	120
tttttcttcg	ggaccacga	gacggccttc	ctgagtccca	aacgcctgtt	cccgtacaag	180
gagtgcagg	agaagtctcg	caagcccaac	aagaggcgcg	gcttcagcgc	ggggctgtgg	240
gaaatcgaga	acaacccac	ggtccaggcc	tccgactgcc	cattagcctc	agagaagggc	300
agcggagacg	ggccttgccc	ggagcccag	gccgcagagg	gcgacgagga	caagccgacc	360
cacgctgggtg	gcggcggcga	cgaattgggg	aagccggacg	acgacaagcc	cactgaggag	420
gagaaggggc	cgctgaagag	gagcgcgggg	gacccgccgg	aggacgcccc	caaacgaccc	480
aaggaggcag	ccccgacca	agaggaggag	gcggaggcgg	agagggcggc	ggaagcggag	540
agggcggcgg	cggcggcggc	ggcgacggcc	gtcgacgagg	agagtccgtt	cctcgtggcg	600
gtggagaacg	gcagcgcccc	tagcgagccg	ggcctggtct	gcgagccgcc	tcagccagag	660
gaggaggagc	tccgggagga	agaagtcgcg	gacgaggagg	cctcccagga	gtggcatgcc	720
gaggcaccgg	gcggcgagga	tcgcgacagc	ctgtag			756

<210> 16

<211> 1224

<212> DNA

<213> Homo sapiens

<400> 16

tttctaataa	gtgaccgtga	cccacagtgc	aacctccact	gctccaggac	tcaacccaaa	60
------------	------------	------------	------------	------------	------------	----

cccatctgtg	cctctgatgg	caggtcctac	gagtcctatgt	gtgagtagcca	gcgagccaag	120
tgccgagacc	cgaccctggg	cgtggtgcat	cgaggtagat	gcaaagatgc	tggccagagc	180
aagtgtcgcc	tggagcgggc	tcaagccctg	gagcaagcca	agaagcctca	ggaagctgtg	240
tttgtcccag	agtgtggcga	ggatgggtcc	tttaccagg	tgcagtgcc	tacttacact	300
gggtactgct	ggtgtgtcac	cccggatggg	aagcccatca	gtggctcttc	tgtgcagaat	360
aaaactcctg	tatgttcagg	ttcagtcacc	gacaagccct	tgagccagg	taactcagga	420
aggaaagatg	acgggtctaa	gccgacaccc	acgatggaga	cccagccgg	gttcgatgga	480
gatgaaatca	cagccccaac	tctatggatt	aaacacttgg	tgatcaagga	ctccaaactg	540
aacaacacca	acataagaaa	ttcagagaaa	gtctattcgt	gtgaccagga	gaggcagagt	600
gccctggaag	aggcccagca	gaatccccgt	gaggggtattg	tcatccctga	atgtgccct	660
gggggactct	ataagccagt	gcaatgccac	cagtccactg	gctactgctg	gtgtgtgctg	720
gtggacacag	ggcgcccgt	gcctgggacc	tccacacgct	acgtgatgcc	cagttgtgag	780
agcgacgcca	gggccaagac	tacagaggcg	gatgaccct	tcaaggacag	ggagctacca	840
ggctgtccag	aaggggaagaa	aatggagttt	atcaccagcc	tactggatgc	tctcaccact	900
gacatggttc	aggccattaa	ctcagcagcg	ccactggag	gtgggaggtt	ctcagagcca	960
gacccagcc	acaccctgga	ggagcgggta	gtgcactgg	atttcagcca	gctggacagc	1020
aatagcagca	acgacattaa	caagcgggag	atgaagccct	tcaagcgcta	cgtgaagaag	1080
aaagccaagc	ccaagaaatg	tgcccggcgt	ttcaccgact	actgtgacct	gaacaaagac	1140
aaggtcattt	cactgcctga	gctgaagggc	tgctgggtg	ttagcaaaga	aggtggtagc	1200
cttggcagtt	tccccaggc	aaaa				1224

<210> 17

<211> 1305

<212> DNA

<213> Homo sapiens

<400> 17

atggcaggct	ctgggccacc	tctgcccacg	tgcaatgcag	aagtgggatg	ggagaacatg	60
gctgaggacg	gcaaggcttt	tctaataagt	gaccgtgacc	cacagtgcaa	cctccactgc	120
tccaggactc	aacccaaacc	catctgtgcc	tctgatggca	ggtcctacga	gtccatgtgt	180
gagtaccagc	gagccaagtg	ccgagacccg	accctgggcg	tgggtgcatcg	aggtagatgc	240
aaagatgctg	gccagagcaa	gtgtcgcctg	gagcgggctc	aagccctgga	gcaagccaag	300
aagcctcagg	aagctgtgtt	tgtcccagag	tgtggcgagg	atggctcctt	taccaggtg	360
cagtgccata	cttacactgg	gtactgctgg	tgtgtcacc	cggatgggaa	gccatcagt	420
ggctcttctg	tgcagaataa	aactcctgta	tgttcaggtt	cagtcaccga	caagcccttg	480
agccagggtg	actcaggaag	gaaagatgac	gggtctaagc	cgacaccac	gatggagacc	540
cagccgggtg	tcgatggaga	tgaaatcaca	gcccactc	tatggattaa	acacttggtg	600
atcaaggact	ccaaactgaa	caacaccaac	ataagaaatt	cagagaaagt	ctattcgtgt	660
gaccaggaga	ggcagagtgc	cctggaagag	gccagcaga	atccccgtga	gggtattgtc	720
atccctgaat	gtgcccctgg	gggactctat	aagccagtgc	aatgccacca	gtccactggc	780
tactgctggt	gtgtgctgg	ggacacagg	cgcccgtgc	ctgggacctc	cacacgctac	840
gtgatgcca	gttgtgagag	cgacgccagg	gccaaagacta	cagagggcgga	tgacccttc	900

aaggacaggg	agctaccagg	ctgtccagaa	gggaagaaaa	tggagtttat	caccagccta	960
ctggatgctc	tcaccactga	catgggttcag	gccattaact	cagcagcgcc	cactggagggt	1020
gggaggttct	cagagccaga	ccccagccac	accctggagg	agcgggtagt	gcactgggtat	1080
ttcagccagc	tggacagcaa	tagcagcaac	gacattaaca	agcgggagat	gaagcccttc	1140
aagcgctacg	tgaagaagaa	agccaagccc	aagaaatgtg	cccggcgttt	caccgactac	1200
tgtgacctga	acaaagacaa	ggtcattttca	ctgcctgagc	tgaagggctg	cctgggtggt	1260
agcaaagaag	gtggtagcct	tggcagtttc	ccccaggcaa	aatga		1305

<210> 18

<211> 753

<212> DNA

<213> Homo sapiens

<400> 18

atggcatgct	ggtggccgct	cctgctagag	ctgtggacag	tcatgcccac	ctgggctggg	60
gacgagctgc	tcaacatctg	catgaatgcc	aaacaccaca	agagagtgcc	cagcccagaa	120
gacaagctct	atgaggagtg	catcccctgg	aaggacaatg	cctgctgcac	cctcacgaca	180
agctgggaag	cccattctgga	tgtatcccca	ctctacaact	tcagcctgtt	tactgtgga	240
ctgctgatgc	ctggctgtcg	gaagcacttc	atccaggcta	tctgcttcta	tgagtgtccc	300
ccaaacctgg	ggccctggat	ccagccagtg	ggaagcctgg	ggtgggaggt	ggccccgagt	360
gggcagggag	agcaggttgt	gaatgtgccg	ctgtgccagg	aggactgtga	ggagtgggtg	420
gaagactgtc	gcatgtctta	cacatgcaaa	tccaactggc	gtggtggctg	ggactggagt	480
caggggaaga	accgctgcc	caaaggggcc	cagtgcctcc	ctttctccca	ttacttcccc	540
acccagctg	acctgtgtga	gaagacttgg	agcaattcct	tcaaagccag	ccctgagcga	600
cggaacagtg	ggcgggtgtc	ccagaagtgg	tttgagcctg	ctcagggcaa	ccccaatgtg	660
gccgtggccc	gcctcttcgc	cagctctgcc	ccatcctggg	aactgtccta	caccatcatg	720
gtctgtctcc	tgttcctgcc	gttcctttcc	tga			753

<210> 19

<211> 774

<212> DNA

<213> Homo sapiens

<400> 19

atgggcaccg	tgcgcccacc	tcgcccctcg	ctcctgctgg	tctccacccg	ggagtcttgt	60
ctcttctctc	tcttctgcct	gcacctgggc	gccgcctgcc	cacagccctg	ccggtgccct	120
gaccacgcag	gggctgtggc	tgtcttctgc	agcttgcggg	gccttcagga	ggtccccgag	180
gacatcccgg	ccaacaccgt	gctcctgaag	ctcgatgcca	acaagatctc	ccacctcccg	240
gacggggcct	tccagcacct	gcaccggctc	agggagctgg	atctgtctca	caacgccatc	300
gaggccatcg	gctccgccac	cttcgcgggc	ctggccgggg	gcctgcggct	gctggacctg	360
tcttacaacc	gcatccagag	gatccccaa	gacgccctgg	gcaaactcag	cgccaagata	420
cgctgtccc	acaaccccct	gcactgcgag	tgcgccctgc	aggaggccct	gtgggagctg	480

aagctggacc	ccgactctgt	ggacgagatc	gcctgccaca	cctcagtgc	ggaggagttt	540
gtggggaagc	ctctgggttca	ggctctggat	gcgggtgcc	gcctctgcag	cgtccccac	600
aggaccacag	acgtggccat	gctggtcacc	atgttcggct	ggttcgccat	ggtgatcgcc	660
tacgtcgtgt	actatgtgcg	ccacaaccag	gaggatgcc	ggaggcacct	ggagtacctg	720
aagtctctgc	ccagcgcccc	cgcctccaag	gaccccatcg	gcccggggcc	ctag	774

<210> 20

<211> 447

<212> DNA

<213> Homo sapiens

<400> 20

atgctgggccc	tgccgtggaa	gggaggtctg	tcctggggcgc	tgctgctgct	tctcttaggc	60
tcccagatcc	tgctgatcta	tgccctggcat	ttccacgagc	aaagggactg	tgatgaacac	120
aatgtcatgg	ctcgttacct	ccctgccaca	gtggagtttg	ctgtccacac	attcaaccaa	180
cagagcaagg	actactatgc	ctacagactg	gggcacatct	tgaattcctg	gaaggagcag	240
gtggagtcca	agactgtatt	ctcaatggag	ctactgctgg	ggagaactag	gtgtgggaaa	300
tttgaagacg	acattgacaa	ctgccatttc	caagaaagca	cagagctgaa	caatgtaaga	360
caggacacca	gcttcctcc	tggatacagc	tgtggatgcc	acatgggggtg	tggtgtgggc	420
acaggtgcaa	ctgacaaaga	gacttag				447

<210> 21

<211> 1068

<212> DNA

<213> Homo sapiens

<400> 21

atgggaccta	aagacagtgc	caagtgcctg	caccgtggac	cacagccgag	ccactgggca	60
gccgggtgatg	gtcccacgca	ggagcgctgt	ggaccccgct	ctctgggcag	ccctgtccta	120
ggcctggaca	cctgcagagc	ctgggaccac	gtggatgggc	agatcctggg	ccagctgcgg	180
cccctgacag	aggaggaaga	ggaggagggc	gccggggcca	ccttgtccag	ggggcctgcc	240
ttccccggca	tgggctctga	ggagttgcgt	ctggcctcct	tctatgactg	gccgctgact	300
gctgaggtgc	cacccgagct	gctggctgct	gccggcttct	tccacacagg	ccatcaggac	360
aaggtgaggt	gcttcttctg	ctatgggggc	ctgcagagct	ggaagcgcg	ggacgacccc	420
tggacggagc	atgccaagtg	gttccccagc	tgtcagttcc	tgctccggtc	aaaaggaaga	480
gactttgtcc	acagtgtgca	ggagactcac	tcccagctgc	tgggctcctg	ggtgagcgcc	540
acctctcctc	ggggctccgg	gtggcagtg	ggctcctgcc	ctcctatttc	cccaaggcct	600
gatgggtctct	ggctccttcc	aggacccgtg	ggaagaaccg	gaagacgcag	cccctgtggc	660
cccctccggg	ccagtctgaa	agtcccagg	agccaggtgc	aggccccgga	cccctgggt	720
gagggtggg	gcaggggagg	gctgagggac	cccagccttc	catggcccat	agagggtggg	780
ggccaggggtg	tggggacatt	tcgcaggcct	gtcctcctag	gaggggtcag	tccagccgag	840
gcccagaggg	cgtgggtggg	tcttgagccc	ccaggagcca	gggatgtgga	ggcgcagctg	900

cggcggctgc	aggaggagag	gacgtgcaag	gtgtgcctgg	accgcgccgt	gtccatcgtc	960
tttgtgccgt	ggggccacct	ggtctgtgct	gagtgtgccc	ccggcctgca	gctgtgcccc	1020
atctgcagag	cccccgctccg	cagccgcgtg	cgcaccttcc	tgtcctag		1068

<210> 22

<211> 769

<212> DNA

<213> Homo sapiens

<400> 22

atgggaccta	aagacagtgc	caagtgcctg	caccgtggac	cacagccgag	ccactgggca	60
gccggtgatg	gtcccacgca	ggagcgctgt	ggaccccgt	ctctgggcag	ccctgtccta	120
ggcctggaca	cctgcagagc	ctgggaccac	gtggatgggc	agatcctggg	ccagctgcgg	180
cccctgacag	aggaggaaga	ggaggagggc	gccggggcca	ccttgtccag	ggggcctgcc	240
ttccccggca	tgggctctga	ggagttgcgt	ctggcctcct	tctatgactg	gccgctgact	300
gctgaggtgc	cacccgagct	gctggctgct	gccggcttct	tccacacagg	ccatcaggac	360
aaggtgaggt	gcttcttctg	ctatgggggc	ctgcagagct	ggaagcgcgg	ggacgacccc	420
tggacggagc	atgccaagtg	gttccccctg	tcagttcctg	ctccggtcaa	aaggaagaga	480
ctttgtccac	agtgtgcagg	agactcactc	ccagctgctg	ggctcctggg	acccgtggga	540
agaaccggaa	gacgcagccc	ctgtggcccc	ctccggagcc	agggatgtgg	aggcgcagct	600
gcggcggtcg	caggaggaga	ggacgtgcaa	ggtgtgcctg	gaccgcgccg	tgtccatcgt	660
ctttgtgccg	tgcgccacc	tggctctgtg	tgagtgtgcc	cccggcctgc	agctgtgccc	720
catctgcaga	gccccgtcc	gcagccgcgt	gcgcaccttc	ctgtcctag		769

<210> 23

<211> 756

<212> DNA

<213> Homo sapiens

<400> 23

atgttggggg	ccgcctcag	gctctgggtc	tgtgccttgt	gcagcgtctg	cagcatgagc	60
gtcctcagag	cctatcccaa	tgcctcccca	ctgctcggt	ccagctgggg	tggcctgata	120
cacctgtaca	cagccacagc	caggaacagc	taccacctgc	agatccacaa	gaatggccat	180
gtggatggcg	caccccatca	gaccatctac	agtgcctga	tgatcagatc	agaggatgct	240
ggcttttgtg	tgattacagg	tgtgatgagc	agaagatacc	tctgcatgga	tttcagaggc	300
aacatttttg	gatcacacta	tttcgacccg	gagaactgca	ggttccaaca	ccagacgctg	360
gaaaacgggt	acgacgtcta	ccactctcct	cagtatcact	tcctggtcag	tctgggccgg	420
gcgaagagag	ccttcctgcc	aggcatgaac	ccaccccgt	actcccagtt	cctgtcccgg	480
aggaacgaga	tccccctaat	tcaattcaac	acccccatac	cacggcggca	cacccggagc	540
gccgaggacg	actcggagcg	ggaccccctg	aacgtgctga	agccccgggc	ccggatgacc	600
ccggcccccg	cctcctgttc	acaggagctc	ccgagcgccg	aggacaacag	cccgatggcc	660
agtgacccat	taggggtggg	caggggcggg	cgagtgaaca	cgcacgctgg	gggaacgggc	720

ccggaaggct gccgcccctt cgccaagttc atctag

756

<210> 24

<211> 592

<212> PRT

<213> Homo sapiens

<400> 24

Met	Thr	Cys	Trp	Leu	Cys	Val	Leu	Ser	Leu	Pro	Leu	Leu	Leu	Leu	Pro
1				5					10					15	
Ala	Ala	Pro	Pro	Pro	Ala	Gly	Gly	Cys	Pro	Ala	Arg	Cys	Glu	Cys	Thr
				20				25					30		
Val	Gln	Thr	Arg	Ala	Val	Ala	Cys	Thr	Arg	Arg	Arg	Leu	Thr	Ala	Val
				35				40					45		
Pro	Asp	Gly	Ile	Pro	Ala	Glu	Thr	Arg	Leu	Leu	Glu	Leu	Ser	Arg	Asn
				50			55				60				
Arg	Ile	Arg	Cys	Leu	Asn	Pro	Gly	Asp	Leu	Ala	Ala	Leu	Pro	Ala	Leu
65					70				75					80	
Glu	Glu	Leu	Asp	Leu	Ser	Glu	Asn	Ala	Ile	Ala	His	Val	Glu	Pro	Gly
				85					90					95	
Ala	Phe	Ala	Asn	Leu	Pro	Arg	Leu	Arg	Val	Leu	Arg	Leu	Arg	Gly	Asn
				100					105					110	
Gln	Leu	Lys	Leu	Ile	Pro	Pro	Gly	Val	Phe	Thr	Arg	Leu	Asp	Asn	Leu
				115				120						125	
Thr	Leu	Leu	Asp	Leu	Ser	Glu	Asn	Lys	Leu	Val	Ile	Leu	Leu	Asp	Tyr
				130				135						140	
Thr	Phe	Gln	Asp	Leu	His	Ser	Leu	Arg	Arg	Leu	Glu	Val	Gly	Asp	Asn
145					150					155					160
Asp	Leu	Val	Phe	Val	Ser	Arg	Arg	Ala	Phe	Ala	Gly	Leu	Leu	Ala	Leu
				165						170				175	
Glu	Glu	Leu	Thr	Leu	Glu	Arg	Cys	Asn	Leu	Thr	Ala	Leu	Ser	Gly	Glu
				180					185					190	
Ser	Leu	Gly	His	Leu	Arg	Ser	Leu	Gly	Ala	Leu	Arg	Leu	Arg	His	Leu
				195				200						205	
Ala	Ile	Ala	Ser	Leu	Glu	Asp	Gln	Asn	Phe	Arg	Arg	Leu	Pro	Gly	Leu
				210				215						220	
Leu	His	Leu	Glu	Ile	Asp	Asn	Trp	Pro	Leu	Leu	Glu	Glu	Val	Ala	Ala
225					230						235				240
Gly	Ser	Leu	Arg	Gly	Leu	Asn	Leu	Thr	Ser	Leu	Ser	Val	Thr	His	Thr
				245					250					255	
Asn	Ile	Thr	Ala	Val	Pro	Ala	Ala	Ala	Leu	Arg	His	Gln	Ala	His	Leu
				260					265					270	

Thr	Cys	Leu	Asn	Leu	Ser	His	Asn	Pro	Ile	Ser	Thr	Val	Pro	Arg	Gly		
		275						280					285				
Ser	Phe	Arg	Asp	Leu	Val	Arg	Leu	Arg	Glu	Leu	His	Leu	Ala	Gly	Ala		
		290					295				300						
Leu	Leu	Ala	Val	Val	Glu	Pro	Gln	Ala	Phe	Leu	Gly	Leu	Arg	Gln	Ile		
305					310					315					320		
Arg	Leu	Leu	Asn	Leu	Ser	Asn	Asn	Leu	Leu	Ser	Thr	Leu	Glu	Glu	Ser		
				325					330					335			
Thr	Phe	His	Ser	Val	Asn	Thr	Leu	Glu	Thr	Leu	Arg	Val	Asp	Gly	Asn		
			340					345					350				
Pro	Leu	Ala	Cys	Asp	Cys	Arg	Leu	Leu	Trp	Ile	Val	Gln	Arg	Arg	Lys		
		355					360					365					
Thr	Leu	Asn	Phe	Asp	Gly	Arg	Leu	Pro	Ala	Cys	Ala	Thr	Pro	Ala	Glu		
		370				375					380						
Val	Arg	Gly	Asp	Ala	Leu	Arg	Asn	Leu	Pro	Asp	Ser	Val	Leu	Phe	Glu		
385					390					395					400		
Tyr	Phe	Val	Cys	Arg	Lys	Pro	Lys	Ile	Arg	Glu	Arg	Arg	Leu	Gln	Arg		
				405					410					415			
Val	Thr	Ala	Thr	Ala	Gly	Glu	Asp	Val	Arg	Phe	Leu	Cys	Arg	Ala	Glu		
			420					425					430				
Gly	Glu	Pro	Ala	Pro	Thr	Val	Ala	Trp	Val	Thr	Pro	Gln	His	Arg	Pro		
		435					440					445					
Val	Thr	Ala	Thr	Ser	Ala	Gly	Arg	Ala	Arg	Val	Leu	Pro	Gly	Gly	Thr		
		450				455					460						
Leu	Glu	Ile	Gln	Asp	Ala	Arg	Pro	Gln	Asp	Ser	Gly	Thr	Tyr	Thr	Cys		
465					470					475					480		
Val	Ala	Ser	Asn	Ala	Gly	Gly	Asn	Asp	Thr	Tyr	Phe	Ala	Thr	Leu	Thr		
				485					490					495			
Val	Arg	Pro	Glu	Pro	Ala	Ala	Asn	Arg	Thr	Pro	Gly	Glu	Ala	His	Asn		
			500					505					510				
Glu	Thr	Leu	Ala	Ala	Leu	Arg	Ala	Pro	Leu	Asp	Leu	Thr	Thr	Ile	Leu		
		515					520					525					
Val	Ser	Thr	Ala	Met	Gly	Cys	Ile	Thr	Phe	Leu	Gly	Val	Val	Leu	Phe		
		530				535					540						
Cys	Phe	Val	Leu	Leu	Phe	Val	Trp	Ser	Arg	Gly	Arg	Gly	Gln	His	Lys		
545					550					555					560		
Asn	Asn	Phe	Ser	Val	Glu	Tyr	Ser	Phe	Arg	Lys	Val	Asp	Gly	Pro	Ala		
				565					570				575				
Ala	Ala	Ala	Gly	Gln	Gly	Gly	Ala	Arg	Lys	Phe	Asn	Met	Lys	Met	Ile		
			580					585					590				

<210> 25

<211> 653

<212> PRT

<213> Homo sapiens

<400> 25

```

Met Lys Leu Leu Trp Gln Val Thr Val His His His Thr Trp Asn Ala
 1           5           10           15
Ile Leu Leu Pro Phe Val Tyr Leu Thr Ala Gln Val Trp Ile Leu Cys
      20           25           30
Ala Ala Ile Ala Ala Ala Ala Ser Ala Gly Pro Gln Asn Cys Pro Ser
      35           40           45
Val Cys Ser Cys Ser Asn Gln Phe Ser Lys Val Val Cys Thr Arg Arg
      50           55           60
Gly Leu Ser Glu Val Pro Gln Gly Ile Pro Ser Asn Thr Arg Tyr Leu
65           70           75           80
Asn Leu Met Glu Asn Asn Ile Gln Met Ile Gln Ala Asp Thr Phe Arg
      85           90           95
His Leu His His Leu Glu Val Leu Gln Leu Gly Arg Asn Ser Ile Arg
      100          105          110
Gln Ile Glu Val Gly Ala Phe Asn Gly Leu Ala Ser Leu Asn Thr Leu
      115          120          125
Glu Leu Phe Asp Asn Trp Leu Thr Val Ile Pro Ser Gly Ala Phe Glu
      130          135          140
Tyr Leu Ser Lys Leu Arg Glu Leu Trp Leu Arg Asn Asn Pro Ile Glu
      145          150          155          160
Ser Ile Pro Ser Tyr Ala Phe Asn Arg Val Pro Ser Leu Met Arg Leu
      165          170          175
Asp Leu Gly Glu Leu Lys Lys Leu Glu Tyr Ile Ser Glu Gly Ala Phe
      180          185          190
Glu Gly Leu Phe Asn Leu Lys Tyr Leu Asn Leu Gly Met Cys Asn Ile
      195          200          205
Lys Asp Met Pro Asn Leu Thr Pro Leu Val Gly Leu Glu Glu Leu Glu
      210          215          220
Met Ser Gly Asn His Phe Pro Glu Ile Arg Pro Gly Ser Phe His Gly
      225          230          235          240
Leu Ser Ser Leu Lys Lys Leu Trp Val Met Asn Ser Gln Val Ser Leu
      245          250          255
Ile Glu Arg Asn Ala Phe Asp Gly Leu Ala Ser Leu Val Glu Leu Asn
      260          265          270
Leu Ala His Asn Asn Leu Ser Ser Leu Pro His Asp Leu Phe Thr Pro
      275          280          285
Leu Arg Tyr Leu Val Glu Leu His Leu His His Asn Pro Trp Asn Cys

```

290	295	300
Asp Cys Asp Ile Leu Trp	Leu Ala Trp Trp	Leu Arg Glu Tyr Ile Pro
305	310	315
Thr Asn Ser Thr Cys Cys Gly Arg Cys His Ala Pro Met His Met Arg		320
	325	330
Gly Arg Tyr Leu Val Glu Val Asp Gln Ala Ser Phe Gln Cys Ser Ala		335
	340	345
Pro Phe Ile Met Asp Ala Pro Arg Asp Leu Asn Ile Ser Glu Gly Arg		350
	355	360
Met Ala Glu Leu Lys Cys Arg Thr Pro Pro Met Ser Ser Val Lys Trp		365
	370	375
Leu Leu Pro Asn Gly Thr Val Leu Ser His Ala Ser Arg His Pro Arg		380
385	390	395
Ile Ser Val Leu Asn Asp Gly Thr Leu Asn Phe Ser His Val Leu Leu		400
	405	410
Ser Asp Thr Gly Val Tyr Thr Cys Met Val Thr Asn Val Ala Gly Asn		415
	420	425
Ser Asn Ala Ser Ala Tyr Leu Asn Val Ser Thr Ala Glu Leu Asn Thr		430
	435	440
Ser Asn Tyr Ser Phe Phe Thr Thr Val Thr Val Glu Thr Thr Glu Ile		445
	450	455
Ser Pro Glu Asp Thr Thr Arg Lys Tyr Lys Pro Val Pro Thr Thr Ser		460
465	470	475
Thr Gly Tyr Gln Pro Ala Tyr Thr Thr Ser Thr Thr Val Leu Ile Gln		480
	485	490
Thr Thr Arg Val Pro Lys Gln Val Ala Val Pro Ala Thr Asp Thr Thr		495
	500	505
Asp Lys Met Gln Thr Ser Leu Asp Glu Val Met Lys Thr Thr Lys Ile		510
	515	520
Ile Ile Gly Cys Phe Val Ala Val Thr Leu Leu Ala Ala Ala Met Leu		525
	530	535
Ile Val Phe Tyr Lys Leu Arg Lys Arg His Gln Gln Arg Ser Thr Val		540
545	550	555
Thr Ala Ala Arg Thr Val Glu Ile Ile Gln Val Asp Glu Asp Ile Pro		560
	565	570
Ala Ala Thr Ser Ala Ala Ala Thr Ala Ala Pro Ser Gly Val Ser Gly		575
	580	585
Glu Gly Ala Val Val Leu Pro Thr Ile His Asp His Ile Asn Tyr Asn		590
	595	600
Thr Tyr Lys Pro Ala His Gly Ala His Trp Thr Glu Asn Ser Leu Gly		605
	610	615
Asn Ser Leu His Pro Thr Val Thr Thr Ile Ser Glu Pro Tyr Ile Ile		620

625 630 635 640
Gln Thr His Thr Lys Asp Lys Val Gln Glu Thr Gln Ile
 645 650

```
<210> 26
<211> 70
<212> PRT
<213> Homo sapiens
```

```

Met Val Ser Val Cys Arg Pro Trp Pro Ala Val Ala Ile Ala Leu Leu
  1              5              10              15
Ala Leu Leu Val Cys Leu Gly Ala Leu Val Asp Thr Cys Pro Ile Lys
      20              25              30
Pro Glu Ala Pro Gly Glu Asp Glu Ser Leu Glu Glu Leu Ser His Tyr
      35              40              45
Tyr Ala Ser Leu Cys His Tyr Leu Asn Val Val Thr Arg Gln Trp Trp
      50              55              60
Glu Gly Ala Asp Met Trp
65              70

```

```
<210> 27
<211> 130
<212> PRT
<213> Homo sapiens
```

<400> 27															
Met	Lys	Leu	Ala	Phe	Leu	Phe	Leu	Gly	Pro	Met	Ala	Leu	Leu	Leu	Leu
1				5					10					15	
Ala	Gly	Tyr	Gly	Cys	Val	Leu	Gly	Ala	Ser	Ser	Gly	Asn	Leu	Arg	Thr
			20					25					30		
Phe	Val	Gly	Cys	Ala	Val	Arg	Glu	Phe	Thr	Phe	Leu	Ala	Lys	Lys	Pro
		35					40					45			
Gly	Cys	Arg	Gly	Leu	Arg	Ile	Thr	Thr	Asp	Ala	Cys	Trp	Gly	Arg	Cys
	50					55					60				
Glu	Thr	Trp	Glu	Lys	Pro	Ile	Leu	Glu	Pro	Pro	Tyr	Ile	Glu	Ala	His
65				70						75					80
His	Arg	Val	Cys	Thr	Tyr	Asn	Glu	Thr	Lys	Gln	Val	Thr	Val	Lys	Leu
			85						90					95	
Pro	Asn	Cys	Ala	Pro	Gly	Val	Asp	Pro	Phe	Tyr	Thr	Tyr	Pro	Val	Ala
			100					105					110		
Ile	Arg	Cys	Asp	Cys	Gly	Ala	Cys	Ser	Thr	Ala	Thr	Thr	Glu	Cys	Glu

115 120 125
 Thr Ile
 130

 <210> 28
 <211> 676
 <212> PRT
 <213> Homo sapiens

 <400> 28
 Ile Pro Asn Ala Phe Lys Pro Gly Asp Leu Val Phe Pro Lys Ile Lys
 1 5 10 15
 Gly Tyr Pro Gln Trp Pro Ser Arg Ile Asp Asp Ile Ala Asp Gly Ala
 20 25 30
 Val Lys Pro Pro Pro Asn Lys Tyr Pro Ile Phe Phe Phe Gly Thr His
 35 40 45
 Glu Thr Ala Phe Leu Gly Pro Lys Asp Leu Phe Pro Tyr Asp Lys Cys
 50 55 60
 Lys Asp Lys Tyr Gly Lys Pro Asn Lys Arg Lys Gly Phe Asn Glu Gly
 65 70 75 80
 Leu Trp Glu Ile Gln Asn Asn Pro His Ala Ser Tyr Ser Ala Pro Pro
 85 90 95
 Pro Val Ser Ser Ser Asp Ser Glu Ala Pro Glu Ala Asn Pro Ala Asp
 100 105 110
 Gly Ser Asp Ala Asp Glu Asp Asp Glu Asp Arg Gly Val Met Ala Val
 115 120 125
 Thr Ala Val Thr Ala Thr Ala Ala Ser Asp Arg Met Glu Ser Asp Ser
 130 135 140
 Asp Ser Asp Lys Ser Ser Asp Asn Ser Gly Leu Lys Arg Lys Thr Pro
 145 150 155 160
 Ala Leu Lys Met Ser Val Ser Lys Arg Ala Arg Lys Ala Ser Ser Asp
 165 170 175
 Leu Asp Gln Ala Ser Val Ser Pro Ser Glu Glu Glu Asn Ser Glu Ser
 180 185 190
 Ser Ser Glu Ser Glu Lys Thr Ser Asp Gln Asp Phe Thr Pro Glu Lys
 195 200 205
 Lys Ala Ala Val Arg Ala Pro Arg Arg Gly Pro Leu Gly Gly Arg Lys
 210 215 220
 Lys Lys Lys Ala Pro Ser Ala Ser Asp Ser Asp Ser Lys Ala Asp Ser
 225 230 235 240
 Asp Gly Ala Lys Pro Glu Pro Val Ala Met Ala Arg Ser Ala Ser Ser
 245 250 255

Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Asp	Ser	Asp	Val	Ser	Val	Lys	Lys
			260						265					270		
Pro	Pro	Arg	Gly	Arg	Lys	Pro	Ala	Glu	Lys	Pro	Leu	Pro	Lys	Pro	Arg	
		275					280					285				
Gly	Arg	Lys	Pro	Lys	Pro	Glu	Arg	Pro	Pro	Ser	Ser	Ser	Ser	Ser	Ser	Asp
	290					295					300					
Ser	Asp	Ser	Asp	Glu	Val	Asp	Arg	Ile	Ser	Glu	Trp	Lys	Arg	Arg	Arg	Asp
305					310					315						320
Glu	Ala	Arg	Arg	Arg	Glu	Leu	Glu	Ala	Arg	Arg	Arg	Arg	Glu	Gln	Glu	
			325					330						335		
Glu	Glu	Leu	Arg	Arg	Leu	Arg	Glu	Gln	Glu	Lys	Glu	Glu	Lys	Glu	Arg	
		340						345					350			
Arg	Arg	Glu	Arg	Ala	Asp	Arg	Gly	Glu	Ala	Glu	Arg	Gly	Ser	Gly	Gly	
	355						360					365				
Ser	Ser	Gly	Asp	Glu	Leu	Arg	Glu	Asp	Asp	Glu	Pro	Val	Lys	Lys	Arg	
	370					375					380					
Gly	Arg	Lys	Gly	Arg	Gly	Arg	Gly	Pro	Pro	Ser	Ser	Ser	Asp	Ser	Glu	
385					390					395					400	
Pro	Glu	Ala	Glu	Leu	Glu	Arg	Glu	Ala	Lys	Lys	Ser	Ala	Lys	Lys	Pro	
			405						410					415		
Gln	Ser	Ser	Ser	Thr	Glu	Pro	Ala	Arg	Lys	Pro	Gly	Gln	Lys	Glu	Lys	
			420					425					430			
Arg	Val	Arg	Pro	Glu	Glu	Lys	Gln	Gln	Ala	Lys	Pro	Val	Lys	Val	Glu	
	435						440					445				
Arg	Thr	Arg	Lys	Arg	Ser	Glu	Gly	Phe	Ser	Met	Asp	Arg	Lys	Val	Glu	
	450					455				460						
Lys	Lys	Lys	Glu	Pro	Ser	Val	Glu	Glu	Lys	Leu	Gln	Lys	Leu	His	Ser	
465					470					475					480	
Glu	Ile	Lys	Phe	Ala	Leu	Lys	Val	Asp	Ser	Pro	Asp	Val	Lys	Arg	Cys	
			485					490						495		
Leu	Asn	Ala	Leu	Glu	Glu	Leu	Gly	Thr	Leu	Gln	Val	Thr	Ser	Gln	Ile	
		500						505						510		
Leu	Gln	Lys	Asn	Thr	Asp	Val	Val	Ala	Thr	Leu	Lys	Lys	Ile	Arg	Arg	
	515						520						525			
Tyr	Lys	Ala	Asn	Lys	Asp	Val	Met	Glu	Lys	Ala	Ala	Glu	Val	Tyr	Thr	
	530					535					540					
Arg	Leu	Lys	Ser	Arg	Val	Leu	Gly	Pro	Lys	Ile	Glu	Ala	Val	Gln	Lys	
545					550					555					560	
Val	Asn	Lys	Ala	Gly	Met	Glu	Lys	Glu	Lys	Ala	Glu	Glu	Lys	Leu	Ala	
			565					570						575		
Gly	Glu	Glu	Leu	Ala	Gly	Glu	Glu	Leu	Ala	Gly	Glu	Glu	Ala	Pro	Gln	
			580					585						590		

Glu Lys Ala Glu Asp Lys Pro Ser Thr Asp Leu Ser Ala Pro Val Asn
 595 600 605
 Gly Glu Ala Thr Ser Gln Lys Gly Glu Ser Ala Glu Asp Lys Glu His
 610 615 620
 Glu Glu Gly Arg Asp Ser Glu Glu Gly Pro Arg Cys Gly Ser Ser Glu
 625 630 635 640
 Asp Leu His Asp Ser Val Arg Glu Gly Pro Asp Leu Asp Arg Pro Gly
 645 650 655
 Ser Asp Arg Gln Glu Arg Glu Arg Ala Arg Gly Asp Ser Glu Ala Leu
 660 665 670
 Asp Glu Glu Ser
 675

<210> 29

<211> 717

<212> PRT

<213> Homo sapiens

<400> 29

Met Ala Val Leu Asp Leu Arg Glu Leu Arg Arg Gly Asp Leu Gly Gly
 1 5 10 15
 Val Gln Gly Leu Lys Glu Leu Arg Arg Gln Trp Ser Gly Gly Pro Gly
 20 25 30
 Pro Glu Glu Ala Ala Leu Trp Gly Ser Gly Ala Ser Val Pro Glu Gly
 35 40 45
 Ala Ala Pro Trp Gly Ser Gly Val Ala Leu Ala Gln Arg Glu Pro Arg
 50 55 60
 Leu Ile Asp Asp Ile Ala Asp Gly Ala Val Lys Pro Pro Pro Asn Lys
 65 70 75 80
 Tyr Pro Ile Phe Phe Phe Gly Thr His Glu Thr Ala Phe Leu Gly Pro
 85 90 95
 Lys Asp Leu Phe Pro Tyr Asp Lys Cys Lys Asp Lys Tyr Gly Lys Pro
 100 105 110
 Asn Lys Arg Lys Gly Phe Asn Glu Gly Leu Trp Glu Ile Gln Asn Asn
 115 120 125
 Pro His Ala Ser Tyr Ser Ala Pro Pro Pro Val Ser Ser Ser Asp Ser
 130 135 140
 Glu Ala Pro Glu Ala Asn Pro Ala Asp Gly Ser Asp Ala Asp Glu Asp
 145 150 155 160
 Asp Glu Asp Arg Gly Val Met Ala Val Thr Ala Val Thr Ala Thr Ala
 165 170 175
 Ala Ser Asp Arg Met Glu Ser Asp Ser Asp Ser Asp Lys Ser Ser Asp

180	185	190
Asn Ser Gly Leu Lys Arg Lys Thr Pro Ala Leu Lys Met Ser Val Ser		
195	200	205
Lys Arg Ala Arg Lys Ala Ser Ser Asp Leu Asp Gln Ala Ser Val Ser		
210	215	220
Pro Ser Glu Glu Glu Asn Ser Glu Ser Ser Ser Glu Ser Glu Lys Thr		
225	230	235
Ser Asp Gln Asp Phe Thr Pro Glu Lys Lys Ala Ala Val Arg Ala Pro		
245	250	255
Arg Arg Gly Pro Leu Gly Gly Arg Lys Lys Lys Lys Ala Pro Ser Ala		
260	265	270
Ser Asp Ser Asp Ser Lys Ala Asp Ser Asp Gly Ala Lys Pro Glu Pro		
275	280	285
Val Ala Met Ala Arg Ser Ala Ser Ser Ser Ser Ser Ser Ser Ser Ser		
290	295	300
Ser Asp Ser Asp Val Ser Val Lys Lys Pro Pro Arg Gly Arg Lys Pro		
305	310	315
Ala Glu Lys Pro Leu Pro Lys Pro Arg Gly Arg Lys Pro Lys Pro Glu		
325	330	335
Arg Pro Pro Ser Ser Ser Ser Ser Asp Ser Asp Ser Asp Glu Val Asp		
340	345	350
Arg Ile Ser Glu Trp Lys Arg Arg Asp Glu Ala Arg Arg Arg Glu Leu		
355	360	365
Glu Ala Arg Arg Arg Arg Glu Gln Glu Glu Glu Leu Arg Arg Leu Arg		
370	375	380
Glu Gln Glu Lys Glu Glu Lys Glu Arg Arg Arg Glu Arg Ala Asp Arg		
385	390	395
Gly Glu Ala Glu Arg Gly Ser Gly Gly Ser Ser Gly Asp Glu Leu Arg		
405	410	415
Glu Asp Asp Glu Pro Val Lys Lys Arg Gly Arg Lys Gly Arg Gly Arg		
420	425	430
Gly Pro Pro Ser Ser Ser Asp Ser Glu Pro Glu Ala Glu Leu Glu Arg		
435	440	445
Glu Ala Lys Lys Ser Ala Lys Lys Pro Gln Ser Ser Ser Thr Glu Pro		
450	455	460
Ala Arg Lys Pro Gly Gln Lys Glu Lys Arg Val Arg Pro Glu Glu Lys		
465	470	475
Gln Gln Ala Lys Pro Val Lys Val Glu Arg Thr Arg Lys Arg Ser Glu		
485	490	495
Gly Phe Ser Met Asp Arg Lys Val Glu Lys Lys Lys Glu Pro Ser Val		
500	505	510
Glu Glu Lys Leu Gln Lys Leu His Ser Glu Ile Lys Phe Ala Leu Lys		

```

      515                      520                      525
Val Asp Ser Pro Asp Val Lys Arg Cys Leu Asn Ala Leu Glu Glu Leu
      530                      535                      540
Gly Thr Leu Gln Val Thr Ser Gln Ile Leu Gln Lys Asn Thr Asp Val
      545                      550                      555                      560
Val Ala Thr Leu Lys Lys Ile Arg Arg Tyr Lys Ala Asn Lys Asp Val
      565                      570                      575
Met Glu Lys Ala Ala Glu Val Tyr Thr Arg Leu Lys Ser Arg Val Leu
      580                      585                      590
Gly Pro Lys Ile Glu Ala Val Gln Lys Val Asn Lys Ala Gly Met Glu
      595                      600                      605
Lys Glu Lys Ala Glu Glu Lys Leu Ala Gly Glu Glu Leu Ala Gly Glu
      610                      615                      620
Glu Leu Ala Gly Glu Glu Ala Pro Gln Glu Lys Ala Glu Asp Lys Pro
      625                      630                      635                      640
Ser Thr Asp Leu Ser Ala Pro Val Asn Gly Glu Ala Thr Ser Gln Lys
      645                      650                      655
Gly Glu Ser Ala Glu Asp Lys Glu His Glu Glu Gly Arg Asp Ser Glu
      660                      665                      670
Glu Gly Pro Arg Cys Gly Ser Ser Glu Asp Leu His Asp Ser Val Arg
      675                      680                      685
Glu Gly Pro Asp Leu Asp Arg Pro Gly Ser Asp Arg Gln Glu Arg Glu
      690                      695                      700
Arg Ala Arg Gly Asp Ser Glu Ala Leu Asp Glu Glu Ser
      705                      710                      715

```

<210> 30

<211> 288

<212> PRT

<213> Homo sapiens

<400> 30

```

Met Phe Val Leu Leu Tyr Val Thr Ser Phe Ala Ile Cys Ala Ser Gly
  1                      5                      10                      15
Gln Pro Arg Gly Asn Gln Leu Lys Gly Glu Asn Tyr Ser Pro Arg Tyr
      20                      25                      30
Ile Cys Ser Ile Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Ala
      35                      40                      45
Asn Gly Ser Pro Gly Pro His Gly Arg Ile Gly Leu Pro Gly Arg Asp
      50                      55                      60
Gly Arg Asp Gly Arg Lys Gly Glu Lys Gly Glu Lys Gly Thr Ala Leu
      65                      70                      75                      80

```

Arg Gly Lys Thr Gly Pro Leu Gly Leu Ala Gly Glu Lys Gly Asp Gln
 85 90 95
 Gly Glu Thr Gly Lys Lys Gly Pro Ile Gly Pro Glu Gly Glu Lys Gly
 100 105 110
 Glu Val Gly Pro Ile Gly Pro Pro Gly Pro Lys Gly Asp Arg Gly Glu
 115 120 125
 Gln Gly Asp Pro Gly Leu Pro Gly Val Cys Arg Cys Gly Ser Ile Val
 130 135 140
 Leu Lys Ser Ala Phe Ser Val Gly Ile Thr Thr Ser Tyr Pro Glu Glu
 145 150 155 160
 Arg Leu Pro Ile Ile Phe Asn Lys Val Leu Phe Asn Glu Gly Glu His
 165 170 175
 Tyr Asn Pro Ala Thr Gly Lys Phe Ile Cys Ala Phe Pro Gly Ile Tyr
 180 185 190
 Tyr Phe Ser Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile Gly
 195 200 205
 Leu Val His Asn Gly Gln Tyr Arg Ile Lys Thr Phe Asp Ala Asn Thr
 210 215 220
 Gly Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu Gln Pro
 225 230 235 240
 Glu Asp Glu Val Trp Leu Glu Ile Phe Phe Thr Asp Gln Asn Gly Leu
 245 250 255
 Phe Ser Asp Pro Gly Trp Ala Asp Ser Leu Phe Ser Gly Phe Leu Leu
 260 265 270
 Tyr Val Asp Thr Asp Tyr Leu Asp Ser Ile Ser Glu Asp Asp Glu Leu
 275 280 285

<210> 31

<211> 303

<212> PRT

<213> Homo sapiens

<400> 31

Met Gly Lys Glu Asp Thr Gln Glu Thr Arg Thr Glu Pro Lys Met Phe
 1 5 10 15
 Val Leu Leu Tyr Val Thr Ser Phe Ala Ile Cys Ala Ser Gly Gln Pro
 20 25 30
 Arg Gly Asn Gln Leu Lys Gly Glu Asn Tyr Ser Pro Arg Tyr Ile Cys
 35 40 45
 Ser Ile Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Ala Asn Gly
 50 55 60
 Ser Pro Gly Pro His Gly Arg Ile Gly Leu Pro Gly Arg Asp Gly Arg

65		70		75		80
Asp Gly Arg Lys	Gly Glu Lys Gly Glu Lys	Gly Thr Ala Gly	Leu Arg			
	85		90		95	
Gly Lys Thr Gly	Pro Leu Gly Leu Ala Gly	Glu Lys Gly Asp	Gln Gly			
	100		105		110	
Glu Thr Gly Lys	Lys Gly Pro Ile Gly	Pro Glu Gly Glu	Lys Gly Glu			
	115		120		125	
Val Gly Pro Ile	Gly Pro Pro Gly	Pro Lys Gly Asp	Arg Gly Glu	Gln		
	130		135		140	
Gly Asp Pro Gly	Leu Pro Gly Val Cys	Arg Cys Gly Ser	Ile Val Leu			
145		150		155		160
Lys Ser Ala Phe	Ser Val Gly Ile Thr	Thr Ser Tyr Pro	Glu Glu Arg			
	165		170		175	
Leu Pro Ile Ile	Phe Asn Lys Val Leu	Phe Asn Glu Gly	Glu His Tyr			
	180		185		190	
Asn Pro Ala Thr	Gly Lys Phe Ile Cys	Ala Phe Pro Gly	Ile Tyr Tyr			
	195		200		205	
Phe Ser Tyr Asp	Ile Thr Leu Ala Asn	Lys His Leu Ala	Ile Gly Leu			
	210		215		220	
Val His Asn Gly	Gln Tyr Arg Ile Lys	Thr Phe Asp Ala	Asn Thr Gly			
225		230		235		240
Asn His Asp Val	Ala Ser Gly Ser Thr	Val Ile Tyr Leu	Gln Pro Glu			
	245		250		255	
Asp Glu Val Trp	Leu Glu Ile Phe Phe	Thr Asp Gln Asn	Gly Leu Phe			
	260		265		270	
Ser Asp Pro Gly	Trp Ala Asp Ser Leu	Phe Ser Gly Phe	Leu Leu Tyr			
	275		280		285	
Val Asp Thr Asp	Tyr Leu Asp Ser Ile	Ser Glu Asp Asp	Glu Leu			
	290		295		300	

<210> 32

<211> 88

<212> PRT

<213> Homo sapiens

<400> 32

Met Ser Leu Gln	Ala Asp Phe Asp	Met Val Thr	Glu Asp Val	Arg Lys
1	5	10	15	
Leu Lys Thr Arg	Pro Asp Asp Glu	Glu Leu Lys	Glu Leu Tyr	Gly Leu
	20	25	30	
Tyr Lys Gln Ala	Val Ile Gly Asn	Ile Asn Ile	Glu Cys Ser	Glu Met
	35	40	45	

Leu Glu Leu Lys Gly Lys Ala Lys Trp Glu Ala Gln Asn Pro Gln Lys
 50 55 60
 Gly Leu Ser Glu Glu Asp Met Met Arg Ala Phe Ile Ser Lys Ala Glu
 65 70 75 80
 Glu Leu Ile Glu Lys Tyr Gly Ile
 85

<210> 33
 <211> 422
 <212> PRT
 <213> Homo sapiens

<400> 33
 Met His Gly Gly Ser Trp Gly Ser Val Cys Asp Asp Asp Trp Asp Val
 1 5 10 15
 Val Asp Ala Asn Val Val Cys Arg Gln Leu Gly Cys Gly Leu Ala Leu
 20 25 30
 Pro Val Pro Arg Pro Leu Ala Phe Gly Gln Gly Arg Gly Pro Ile Leu
 35 40 45
 Leu Asp Asn Val Glu Cys Arg Gly Gln Glu Ala Ala Leu Ser Glu Cys
 50 55 60
 Gly Ser Arg Gly Trp Gly Val His Asn Cys Phe His Tyr Glu Asp Val
 65 70 75 80
 Ala Val Leu Cys Asp Gly Glu Gly Ser Val Arg Leu Val Gly Gly Ala
 85 90 95
 Asn Leu Cys Gln Gly Arg Val Glu Ile Leu His Ser Gly Leu Trp Gly
 100 105 110
 Thr Val Cys Asp Asp Asp Trp Gly Leu Pro Asp Ala Ala Val Val Cys
 115 120 125
 Arg Gln Leu Gly Cys Gly Ala Ala Met Ala Ala Thr Thr Asn Ala Phe
 130 135 140
 Phe Gly Tyr Gly Thr Gly His Ile Leu Leu Asp Asn Val His Cys Glu
 145 150 155 160
 Gly Gly Glu Pro Arg Leu Ala Ala Cys Gln Ser Leu Gly Trp Gly Val
 165 170 175
 His Asn Cys Gly His His Glu Asp Ala Gly Ala Leu Cys Ala Gly Ala
 180 185 190
 Gly Ser Arg Gly Asp Gly Arg Gly Arg Gly Ser Pro Ser Gly Arg Gly
 195 200 205
 Pro Val Arg Pro Ala Gly Gly Arg Leu Arg Leu Val Gly Gly Pro Gly
 210 215 220
 Pro Cys Arg Gly Arg Val Glu Val Leu His Ala Gly Gly Trp Gly Thr

225 230 235 240
 Val Cys Asp Asp Asp Trp Asp Phe Ala Asp Ala Arg Val Ala Cys Arg
 245 250 255
 Glu Ala Gly Cys Gly Pro Ala Leu Gly Ala Thr Gly Leu Gly His Phe
 260 265 270
 Gly Tyr Gly Arg Gly Pro Val Leu Leu Asp Asn Val Gly Cys Ala Gly
 275 280 285
 Thr Glu Ala Arg Leu Ser Asp Cys Phe His Leu Gly Trp Gly Gln His
 290 295 300
 Asn Cys Gly His His Glu Asp Ala Gly Ala Leu Cys Ala Gly His Leu
 305 310 315 320
 Arg Leu Val Asn Gly Ala His Arg Cys Glu Gly Arg Val Glu Leu Tyr
 325 330 335
 Leu Gly Gln Arg Trp Gly Thr Val Cys Asp Asp Ala Trp Asp Leu Arg
 340 345 350
 Ala Ala Gly Val Leu Cys Arg Gln Leu Gly Cys Gly Gln Ala Leu Ala
 355 360 365
 Ala Pro Gly Glu Ala His Phe Gly Pro Gly Arg Gly Pro Ile Leu Leu
 370 375 380
 Asp Asn Val Lys Cys Arg Gly Glu Glu Ser Ala Leu Leu Leu Cys Ser
 385 390 395 400
 His Ile Arg Trp Asp Ala His Asn Cys Asp His Ser Glu Asp Ala Ser
 405 410 415
 Val Leu Cys Gln Pro Ser
 420

<210> 34

<211> 552

<212> PRT

<213> Homo sapiens

<400> 34

Met Ala Thr Leu Pro Glu Lys Ala Leu Lys Glu Ala Trp Lys Gly Leu
 1 5 10 15
 Ile Pro Arg Phe Pro Trp Leu His Gly Lys Ala Glu Leu Arg Leu Val
 20 25 30
 Gly Gly Pro Ser Arg Cys Arg Gly Arg Leu Glu Val Met His Gly Gly
 35 40 45
 Ser Trp Gly Ser Val Cys Asp Asp Asp Trp Asp Val Val Asp Ala Asn
 50 55 60
 Val Val Cys Arg Gln Leu Gly Cys Gly Leu Ala Leu Pro Val Pro Arg
 65 70 75 80

Pro Leu Ala Phe Gly Gln Gly Arg Gly Pro Ile Leu Leu Asp Asn Val
 85 90 95
 Glu Cys Arg Gly Gln Glu Ala Ala Leu Ser Glu Cys Gly Ser Arg Gly
 100 105 110
 Trp Gly Val His Asn Cys Phe His Tyr Glu Asp Val Ala Val Leu Cys
 115 120 125
 Asp Glu Phe Leu Pro Thr Gln Pro Pro Thr Arg Lys Met Leu Thr Ser
 130 135 140
 Arg Ala Pro Pro Thr Thr Leu Pro Asn Gly Lys Ser Glu Gly Ser Val
 145 150 155 160
 Arg Leu Val Gly Gly Ala Asn Leu Cys Gln Gly Arg Val Glu Ile Leu
 165 170 175
 His Ser Gly Leu Trp Gly Thr Val Cys Asp Asp Asp Trp Gly Leu Pro
 180 185 190
 Asp Ala Ala Val Val Cys Arg Gln Leu Gly Cys Gly Ala Ala Met Ala
 195 200 205
 Ala Thr Thr Asn Ala Phe Phe Gly Tyr Gly Thr Gly His Ile Leu Leu
 210 215 220
 Asp Asn Val His Cys Glu Gly Gly Glu Pro Arg Leu Ala Ala Cys Gln
 225 230 235 240
 Ser Leu Gly Trp Gly Val His Asn Cys Gly His His Glu Asp Ala Gly
 245 250 255
 Ala Leu Cys Ala Gly Leu Gly Pro Pro Thr Leu Thr Ala Leu Pro Ser
 260 265 270
 Ser Ala Thr Arg Glu Asp Trp Ala Trp Gln Thr Asp Pro Ser Ala Thr
 275 280 285
 Gly Val Gly Pro Gln Pro Ser Arg Glu Thr Ala Leu Leu Thr Thr Ala
 290 295 300
 Ala Trp Ala Ala Gly Lys Lys Ser Gly Arg Leu Arg Leu Val Gly Gly
 305 310 315 320
 Pro Gly Pro Cys Arg Gly Arg Val Glu Val Leu His Ala Gly Gly Trp
 325 330 335
 Gly Thr Val Cys Asp Asp Asp Trp Asp Phe Ala Asp Ala Arg Val Ala
 340 345 350
 Cys Arg Glu Ala Gly Cys Gly Pro Ala Leu Gly Ala Thr Gly Leu Gly
 355 360 365
 His Phe Gly Tyr Gly Arg Gly Pro Val Leu Leu Asp Asn Val Gly Cys
 370 375 380
 Ala Gly Thr Glu Ala Arg Leu Ser Asp Cys Phe His Leu Gly Trp Gly
 385 390 395 400
 Gln His Asn Cys Gly His His Glu Asp Ala Gly Ala Leu Cys Ala Gly
 405 410 415

Glu Ala Asp Ser Glu Gly Pro Glu Glu Leu Gly Leu Gln Val Gln Gln
 420 425 430
 Asp Gly Ser Glu Thr Thr Arg Val Pro Thr Pro Arg Pro Arg Asp Gly
 435 440 445
 His Leu Arg Leu Val Asn Gly Ala His Arg Cys Glu Gly Arg Val Glu
 450 455 460
 Leu Tyr Leu Gly Gln Arg Trp Gly Thr Val Cys Asp Asp Ala Trp Asp
 465 470 475 480
 Leu Arg Ala Ala Gly Val Leu Cys Arg Gln Leu Gly Cys Gly Gln Ala
 485 490 495
 Leu Ala Ala Pro Gly Glu Ala His Phe Gly Pro Gly Arg Gly Pro Ile
 500 505 510
 Leu Leu Asp Asn Val Lys Cys Arg Gly Glu Glu Ser Ala Leu Leu Leu
 515 520 525
 Cys Ser His Ile Arg Trp Asp Ala His Asn Cys Asp His Ser Glu Asp
 530 535 540
 Ala Ser Val Leu Cys Gln Pro Ser
 545 550

<210> 35

<211> 1709

<212> PRT

<213> Homo sapiens

<400> 35

Met Gly Phe Leu Pro Lys Leu Leu Leu Leu Ala Ser Phe Phe Pro Ala
 1 5 10 15
 Gly Gln Ala Ser Trp Gly Val Ser Ser Pro Gln Asp Val Gln Gly Val
 20 25 30
 Lys Gly Ser Cys Leu Leu Ile Pro Cys Ile Phe Ser Phe Pro Ala Asp
 35 40 45
 Val Glu Val Pro Asp Gly Ile Thr Ala Ile Trp Tyr Tyr Asp Tyr Ser
 50 55 60
 Gly Gln Arg Gln Val Val Ser His Ser Ala Asp Pro Lys Leu Val Glu
 65 70 75 80
 Ala Arg Phe Arg Gly Arg Thr Glu Phe Met Gly Asn Pro Glu His Arg
 85 90 95
 Val Cys Asn Leu Leu Leu Lys Asp Leu Gln Pro Glu Asp Ser Gly Ser
 100 105 110
 Tyr Asn Phe Arg Phe Glu Ile Ser Glu Val Asn Arg Trp Ser Asp Val
 115 120 125
 Lys Gly Thr Leu Val Thr Val Thr Glu Glu Pro Arg Val Pro Thr Ile

130		135		140
Ala Ser Pro Val Glu Leu Leu Glu Gly Thr Glu Val Asp Phe Asn Cys				
145		150		155
Ser Thr Pro Tyr Val Cys Leu Gln Glu Gln Val Arg Leu Gln Trp Gln				160
	165		170	175
Gly Gln Asp Pro Ala Arg Ser Val Thr Phe Asn Ser Gln Lys Phe Glu				
	180		185	190
Pro Thr Gly Val Gly His Leu Glu Thr Leu His Met Ala Met Ser Trp				
	195		200	205
Gln Asp His Gly Arg Ile Leu Arg Cys Gln Leu Ser Val Ala Asn His				
	210		215	220
Arg Ala Gln Ser Glu Ile His Leu Gln Val Lys Tyr Ala Pro Lys Gly				
225		230		235
Val Lys Ile Leu Leu Ser Pro Ser Gly Arg Asn Ile Leu Pro Gly Glu				240
	245		250	255
Leu Val Thr Leu Thr Cys Gln Val Asn Ser Ser Tyr Pro Ala Val Ser				
	260		265	270
Ser Ile Lys Trp Leu Lys Asp Gly Val Arg Leu Gln Thr Lys Thr Gly				
	275		280	285
Val Leu His Leu Pro Gln Ala Ala Trp Ser Asp Ala Gly Val Tyr Thr				
	290		295	300
Cys Gln Ala Glu Asn Gly Val Gly Ser Leu Val Ser Pro Pro Ile Ser				
305		310		315
Leu His Ile Phe Met Ala Glu Val Gln Val Ser Pro Ala Gly Pro Ile				
	325		330	335
Leu Glu Asn Gln Thr Val Thr Leu Val Cys Asn Thr Pro Asn Glu Ala				
	340		345	350
Pro Ser Asp Leu Arg Tyr Ser Trp Tyr Lys Asn His Val Leu Leu Glu				
	355		360	365
Asp Ala His Ser His Thr Leu Arg Leu His Leu Ala Thr Arg Ala Asp				
	370		375	380
Thr Gly Phe Tyr Phe Cys Glu Val Gln Asn Val His Gly Ser Glu Arg				
385		390		395
Ser Gly Pro Val Ser Val Val Val Asn Leu Leu Thr Ala Phe Leu Glu				
	405		410	415
Thr Gln Ala Gly Leu Val Gly Ile Leu His Cys Ser Val Val Ser Glu				
	420		425	430
Pro Leu Ala Thr Leu Val Leu Ser His Gly Gly His Ile Leu Ala Ser				
	435		440	445
Thr Ser Gly Asp Ser Asp His Ser Pro Arg Phe Ser Gly Thr Ser Gly				
	450		455	460
Pro Asn Ser Leu Arg Leu Glu Ile Arg Asp Leu Glu Glu Thr Asp Ser				

465		470		475		480									
Gly	Glu	Tyr	Lys	Cys	Ser	Ala	Thr	Asn	Ser	Leu	Gly	Asn	Ala	Thr	Ser
			485						490					495	
Thr	Leu	Asp	Phe	His	Ala	Asn	Ala	Ala	Arg	Leu	Leu	Ile	Ser	Pro	Ala
			500						505					510	
Ala	Glu	Val	Val	Glu	Gly	Gln	Ala	Val	Thr	Leu	Ser	Cys	Arg	Ser	Gly
		515						520					525		
Leu	Ser	Pro	Thr	Pro	Asp	Ala	Arg	Phe	Ser	Trp	Tyr	Leu	Asn	Gly	Ala
		530					535						540		
Leu	Leu	His	Glu	Gly	Pro	Gly	Ser	Ser	Leu	Leu	Leu	Pro	Ala	Ala	Ser
545					550					555					560
Ser	Thr	Asp	Ala	Gly	Ser	Tyr	His	Cys	Arg	Ala	Arg	Asp	Gly	His	Ser
			565						570					575	
Ala	Ser	Gly	Pro	Ser	Ser	Pro	Ala	Val	Leu	Thr	Val	Leu	Tyr	Pro	Pro
			580						585					590	
Arg	Gln	Pro	Thr	Phe	Thr	Thr	Arg	Leu	Asp	Leu	Asp	Ala	Ala	Gly	Ala
		595					600							605	
Gly	Ala	Gly	Arg	Arg	Gly	Leu	Leu	Leu	Cys	Arg	Val	Asp	Ser	Asp	Pro
		610				615						620			
Pro	Ala	Arg	Leu	Gln	Leu	Leu	His	Lys	Asp	Arg	Val	Val	Ala	Thr	Ser
625					630					635					640
Leu	Pro	Ser	Gly	Gly	Gly	Cys	Ser	Thr	Cys	Gly	Gly	Cys	Ser	Pro	Arg
			645						650					655	
Met	Lys	Val	Thr	Lys	Ala	Pro	Asn	Leu	Leu	Arg	Val	Glu	Ile	His	Asn
		660						665						670	
Pro	Leu	Leu	Glu	Glu	Glu	Gly	Leu	Tyr	Leu	Cys	Glu	Ala	Ser	Asn	Ala
		675					680							685	
Leu	Gly	Asn	Ala	Ser	Thr	Ser	Ala	Thr	Phe	Asn	Gly	Gln	Ala	Thr	Val
		690				695								700	
Leu	Ala	Ile	Ala	Pro	Ser	His	Thr	Leu	Gln	Glu	Gly	Thr	Glu	Ala	Asn
705					710					715					720
Leu	Thr	Cys	Asn	Val	Ser	Arg	Glu	Ala	Ala	Gly	Ser	Pro	Ala	Asn	Phe
			725						730					735	
Ser	Trp	Phe	Arg	Asn	Gly	Val	Leu	Trp	Ala	Gln	Gly	Pro	Leu	Glu	Thr
		740						745						750	
Val	Thr	Leu	Leu	Pro	Val	Ala	Arg	Thr	Asp	Ala	Ala	Leu	Tyr	Ala	Cys
		755					760							765	
Arg	Ile	Leu	Thr	Glu	Ala	Gly	Ala	Gln	Leu	Ser	Thr	Pro	Val	Leu	Leu
		770				775								780	
Ser	Val	Leu	Tyr	Pro	Pro	Asp	Arg	Pro	Lys	Leu	Ser	Ala	Leu	Leu	Asp
785					790					795					800
Met	Gly	Gln	Gly	His	Met	Ala	Leu	Phe	Ile	Cys	Thr	Val	Asp	Ser	Arg

Pro Leu Ala Leu Leu Ala Leu Phe His Gly Glu His Leu Leu Ala Thr
 820 825 830
 Ser Leu Gly Pro Gln Val Pro Ser His Gly Arg Phe Gln Ala Lys Ala
 835 840 845
 Glu Ala Asn Ser Leu Lys Leu Glu Val Arg Glu Leu Gly Leu Gly Asp
 850 855 860
 Ser Gly Ser Tyr Arg Cys Glu Ala Thr Asn Val Leu Gly Ser Ser Asn
 865 870 875 880
 Thr Ser Leu Phe Phe Gln Val Arg Gly Ala Trp Val Gln Val Ser Pro
 885 890 895
 Ser Pro Glu Leu Gln Glu Gly Gln Ala Val Val Leu Ser Cys Gln Val
 900 905 910
 His Thr Gly Val Pro Glu Gly Thr Ser Tyr Arg Trp Tyr Arg Asp Gly
 915 920 925
 Gln Pro Leu Gln Glu Ser Thr Ser Ala Thr Leu Arg Phe Ala Ala Ile
 930 935 940
 Thr Leu Thr Gln Ala Gly Ala Tyr His Cys Gln Ala Gln Ala Pro Gly
 945 950 955 960
 Ser Ala Thr Thr Ser Leu Ala Ala Pro Ile Ser Leu His Val Ser Tyr
 965 970 975
 Ala Pro Arg His Val Thr Leu Thr Thr Leu Met Asp Thr Gly Pro Gly
 980 985 990
 Arg Leu Gly Leu Leu Leu Cys Arg Val Asp Ser Asp Pro Pro Ala Gln
 995 1000 1005
 Leu Arg Leu Leu His Gly Asp Arg Leu Val Ala Ser Thr Leu Gln Gly
 1010 1015 1020
 Val Gly Gly Pro Glu Gly Ser Ser Pro Arg Leu His Val Ala Val Ala
 1025 1030 1035 1040
 Pro Asn Thr Leu Arg Leu Glu Ile His Gly Ala Met Leu Glu Asp Glu
 1045 1050 1055
 Gly Val Tyr Ile Cys Glu Ala Ser Asn Thr Leu Gly Gln Ala Ser Ala
 1060 1065 1070
 Ser Ala Asp Phe Asp Ala Gln Ala Val Asn Val Gln Val Trp Pro Gly
 1075 1080 1085
 Ala Thr Val Arg Glu Gly Gln Leu Val Asn Leu Thr Cys Leu Val Trp
 1090 1095 1100
 Thr Thr His Pro Ala Gln Leu Thr Tyr Thr Trp Tyr Gln Asp Gly Gln
 1105 1110 1115 1120
 Gln Arg Leu Asp Ala His Ser Ile Pro Leu Pro Asn Val Thr Val Arg
 1125 1130 1135
 Asp Ala Thr Ser Tyr Arg Cys Gly Val Gly Pro Pro Gly Arg Ala Pro

1140	1145	1150
Arg Leu Ser Arg Pro Ile Thr Leu Asp Val Leu Tyr Ala Pro Arg Asn		
1155	1160	1165
Leu Arg Leu Thr Tyr Leu Leu Glu Ser His Gly Gly Gln Leu Ala Leu		
1170	1175	1180
Val Leu Cys Thr Val Asp Ser Arg Pro Pro Ala Gln Leu Ala Leu Ser		
1185	1190	1195
His Ala Gly Arg Leu Leu Ala Ser Ser Thr Ala Ala Ser Val Pro Asn		1200
1205	1210	1215
Thr Leu Arg Leu Glu Leu Arg Gly Pro Gln Pro Arg Asp Glu Gly Phe		
1220	1225	1230
Tyr Ser Cys Ser Ala Arg Ser Pro Leu Gly Gln Ala Asn Thr Ser Leu		
1235	1240	1245
Glu Leu Arg Leu Glu Gly Val Arg Val Ile Leu Ala Pro Glu Ala Ala		
1250	1255	1260
Val Pro Glu Gly Ala Pro Ile Thr Val Thr Cys Ala Asp Pro Ala Ala		
1265	1270	1275
His Ala Pro Thr Leu Tyr Thr Trp Tyr His Asn Gly Arg Trp Leu Gln		1280
1285	1290	1295
Glu Gly Pro Ala Ala Ser Leu Ser Phe Leu Val Ala Thr Arg Ala His		
1300	1305	1310
Ala Gly Ala Tyr Ser Cys Gln Ala Gln Asp Ala Gln Gly Thr Arg Ser		
1315	1320	1325
Ser Arg Pro Ala Ala Leu Gln Val Leu Tyr Ala Pro Gln Asp Ala Val		
1330	1335	1340
Leu Ser Ser Phe Arg Asp Ser Arg Ala Arg Ser Met Ala Val Ile Gln		
1345	1350	1355
Cys Thr Val Asp Ser Glu Pro Pro Ala Glu Leu Ala Leu Ser His Asp		1360
1365	1370	1375
Gly Lys Val Leu Ala Thr Ser Ser Gly Val His Ser Leu Ala Ser Gly		
1380	1385	1390
Thr Gly His Val Gln Val Ala Arg Asn Ala Leu Arg Leu Gln Val Gln		
1395	1400	1405
Asp Val Pro Ala Gly Asp Asp Thr Tyr Val Cys Thr Ala Gln Asn Leu		
1410	1415	1420
Leu Gly Ser Ile Ser Thr Ile Gly Arg Leu Gln Val Glu Gly Ala Arg		
1425	1430	1435
Val Val Ala Glu Pro Gly Leu Asp Val Pro Glu Gly Ala Ala Leu Asn		1440
1445	1450	1455
Leu Ser Cys Arg Leu Leu Gly Gly Pro Gly Pro Val Gly Asn Ser Thr		
1460	1465	1470
Phe Ala Trp Phe Trp Asn Asp Arg Arg Leu His Ala Glu Pro Val Pro		

1475					1480					1485					
Thr	Leu	Ala	Phe	Thr	His	Val	Ala	Arg	Ala	Gln	Ala	Gly	Met	Tyr	His
1490					1495					1500					
Cys	Leu	Ala	Glu	Leu	Pro	Thr	Gly	Ala	Ala	Ala	Ser	Ala	Pro	Val	Met
1505					1510					1515					1520
Leu	Arg	Val	Leu	Tyr	Pro	Pro	Lys	Thr	Pro	Thr	Met	Met	Val	Phe	Val
1525					1530					1535					
Glu	Pro	Glu	Gly	Gly	Leu	Arg	Gly	Ile	Leu	Asp	Cys	Arg	Val	Asp	Ser
1540					1545					1550					
Glu	Pro	Leu	Ala	Ser	Leu	Thr	Leu	His	Leu	Gly	Ser	Arg	Leu	Val	Ala
1555					1560					1565					
Ser	Ser	Gln	Pro	Gln	Gly	Ala	Pro	Ala	Glu	Pro	His	Ile	His	Val	Leu
1570					1575					1580					
Ala	Ser	Pro	Asn	Ala	Leu	Arg	Val	Asp	Ile	Glu	Ala	Leu	Arg	Pro	Ser
1585					1590					1595					1600
Asp	Gln	Gly	Glu	Tyr	Ile	Cys	Ser	Ala	Ser	Asn	Val	Leu	Gly	Ser	Ala
1605					1610					1615					
Ser	Thr	Ser	Thr	Tyr	Phe	Gly	Val	Arg	Ala	Leu	His	Arg	Leu	His	Gln
1620					1625					1630					
Phe	Gln	Gln	Leu	Leu	Trp	Val	Leu	Gly	Leu	Leu	Val	Gly	Leu	Leu	Leu
1635					1640					1645					
Leu	Leu	Leu	Gly	Leu	Gly	Ala	Cys	Tyr	Thr	Trp	Arg	Arg	Arg	Arg	Val
1650					1655					1660					
Cys	Lys	Gln	Ser	Met	Gly	Glu	Asn	Ser	Val	Glu	Met	Ala	Phe	Gln	Lys
1665					1670					1675					1680
Glu	Thr	Thr	Gln	Gly	Phe	Leu	Cys	Gly	Lys	Leu	Ile	Asp	Pro	Asp	Ala
1685					1690					1695					
Ala	Thr	Cys	Glu	Thr	Ser	Thr	Cys	Ala	Pro	Pro	Leu	Gly			
1700					1705										

<210> 36

<211> 1694

<212> PRT

<213> Homo sapiens

<400> 36

Met	Gly	Phe	Leu	Pro	Lys	Leu	Leu	Leu	Leu	Ala	Ser	Phe	Phe	Pro	Ala
1				5					10					15	
Gly	Gln	Ala	Ser	Trp	Gly	Val	Ser	Ser	Pro	Gln	Asp	Val	Gln	Gly	Val
			20					25					30		
Lys	Gly	Ser	Cys	Leu	Leu	Ile	Pro	Cys	Ile	Phe	Ser	Phe	Pro	Ala	Asp
		35					40					45			

Val	Glu	Val	Pro	Asp	Gly	Ile	Thr	Ala	Ile	Trp	Tyr	Tyr	Asp	Tyr	Ser	50	55	60	
Gly	Gln	Arg	Gln	Val	Val	Ser	His	Ser	Ala	Asp	Pro	Lys	Leu	Val	Glu	65	70	75	80
Ala	Arg	Phe	Arg	Gly	Arg	Thr	Glu	Phe	Met	Gly	Asn	Pro	Glu	His	Arg	85	90	95	
Val	Cys	Asn	Leu	Leu	Leu	Lys	Asp	Leu	Gln	Pro	Glu	Asp	Ser	Gly	Ser	100	105	110	
Tyr	Asn	Phe	Arg	Phe	Glu	Ile	Ser	Glu	Val	Asn	Arg	Trp	Ser	Asp	Val	115	120	125	
Lys	Gly	Thr	Leu	Val	Thr	Val	Thr	Glu	Glu	Pro	Arg	Val	Pro	Thr	Ile	130	135	140	
Ala	Ser	Pro	Val	Glu	Leu	Leu	Glu	Gly	Thr	Glu	Val	Asp	Phe	Asn	Cys	145	150	155	160
Ser	Thr	Pro	Tyr	Val	Cys	Leu	Gln	Glu	Gln	Val	Arg	Leu	Gln	Trp	Gln	165	170	175	
Gly	Gln	Asp	Pro	Ala	Arg	Ser	Val	Thr	Phe	Asn	Ser	Gln	Lys	Phe	Glu	180	185	190	
Pro	Thr	Gly	Val	Gly	His	Leu	Glu	Thr	Leu	His	Met	Ala	Met	Ser	Trp	195	200	205	
Gln	Asp	His	Gly	Arg	Ile	Leu	Arg	Cys	Gln	Leu	Ser	Val	Ala	Asn	His	210	215	220	
Arg	Ala	Gln	Ser	Glu	Ile	His	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Gly	225	230	235	240
Val	Lys	Ile	Leu	Leu	Ser	Pro	Ser	Gly	Arg	Asn	Ile	Leu	Pro	Gly	Glu	245	250	255	
Leu	Val	Thr	Leu	Thr	Cys	Gln	Val	Asn	Ser	Ser	Tyr	Pro	Ala	Val	Ser	260	265	270	
Ser	Ile	Lys	Trp	Leu	Lys	Asp	Gly	Val	Arg	Leu	Gln	Thr	Lys	Thr	Gly	275	280	285	
Val	Leu	His	Leu	Pro	Gln	Ala	Ala	Trp	Ser	Asp	Ala	Gly	Val	Tyr	Thr	290	295	300	
Cys	Gln	Ala	Glu	Asn	Gly	Val	Gly	Ser	Leu	Val	Ser	Pro	Pro	Ile	Ser	305	310	315	320
Leu	His	Ile	Phe	Met	Ala	Glu	Val	Gln	Val	Ser	Pro	Ala	Gly	Pro	Ile	325	330	335	
Leu	Glu	Asn	Gln	Thr	Val	Thr	Leu	Val	Cys	Asn	Thr	Pro	Asn	Glu	Ala	340	345	350	
Pro	Ser	Asp	Leu	Arg	Tyr	Ser	Trp	Tyr	Lys	Asn	His	Val	Leu	Leu	Glu	355	360	365	
Asp	Ala	His	Ser	His	Thr	Leu	Arg	Leu	His	Leu	Ala	Thr	Arg	Ala	Asp	370	375	380	

Thr	Gly	Phe	Tyr	Phe	Cys	Glu	Val	Gln	Asn	Val	His	Gly	Ser	Glu	Arg	385	390	395	400
Ser	Gly	Pro	Val	Ser	Val	Val	Val	Asn	Leu	Leu	Thr	Ala	Phe	Leu	Glu	405	410	415	
Thr	Gln	Ala	Gly	Leu	Val	Gly	Ile	Leu	His	Cys	Ser	Val	Val	Ser	Glu	420	425	430	
Pro	Leu	Ala	Thr	Leu	Val	Leu	Ser	His	Gly	Gly	His	Ile	Leu	Ala	Ser	435	440	445	
Thr	Ser	Gly	Asp	Ser	Asp	His	Ser	Pro	Arg	Phe	Ser	Gly	Thr	Ser	Gly	450	455	460	
Pro	Asn	Ser	Leu	Arg	Leu	Glu	Ile	Arg	Asp	Leu	Glu	Glu	Thr	Asp	Ser	465	470	475	480
Gly	Glu	Tyr	Lys	Cys	Ser	Ala	Thr	Asn	Ser	Leu	Gly	Asn	Ala	Thr	Ser	485	490	495	
Thr	Leu	Asp	Phe	His	Ala	Asn	Ala	Ala	Arg	Leu	Leu	Ile	Ser	Pro	Ala	500	505	510	
Ala	Glu	Val	Val	Glu	Gly	Gln	Ala	Val	Thr	Leu	Ser	Cys	Arg	Ser	Gly	515	520	525	
Leu	Ser	Pro	Thr	Pro	Asp	Ala	Arg	Phe	Ser	Trp	Tyr	Leu	Asn	Gly	Ala	530	535	540	
Leu	Leu	His	Glu	Gly	Pro	Gly	Ser	Ser	Leu	Leu	Leu	Pro	Ala	Ala	Ser	545	550	555	560
Ser	Thr	Asp	Ala	Gly	Ser	Tyr	His	Cys	Arg	Ala	Arg	Asp	Gly	His	Ser	565	570	575	
Ala	Ser	Gly	Pro	Ser	Ser	Pro	Ala	Val	Leu	Thr	Val	Leu	Tyr	Pro	Pro	580	585	590	
Arg	Gln	Pro	Thr	Phe	Thr	Thr	Arg	Leu	Asp	Leu	Asp	Ala	Ala	Gly	Ala	595	600	605	
Gly	Ala	Gly	Arg	Arg	Gly	Leu	Leu	Leu	Cys	Arg	Val	Asp	Ser	Asp	Pro	610	615	620	
Pro	Ala	Arg	Leu	Gln	Leu	Leu	His	Lys	Asp	Arg	Val	Val	Ala	Thr	Ser	625	630	635	640
Leu	Pro	Ser	Gly	Gly	Gly	Cys	Ser	Thr	Cys	Gly	Gly	Cys	Ser	Pro	Arg	645	650	655	
Met	Lys	Val	Thr	Lys	Ala	Pro	Asn	Leu	Leu	Arg	Val	Glu	Ile	His	Asn	660	665	670	
Pro	Leu	Leu	Glu	Glu	Glu	Gly	Leu	Tyr	Leu	Cys	Glu	Ala	Ser	Asn	Ala	675	680	685	
Leu	Gly	Asn	Ala	Ser	Thr	Ser	Ala	Thr	Phe	Asn	Gly	Gln	Ala	Thr	Val	690	695	700	
Leu	Ala	Ile	Ala	Pro	Ser	His	Thr	Leu	Gln	Glu	Gly	Thr	Glu	Ala	Asn	705	710	715	720

Leu Thr Cys Asn Val Ser Arg Glu Ala Ala Gly Ser Pro Ala Asn Phe			
	725	730	735
Ser Trp Phe Arg Asn Gly Val Leu Trp Ala Gln Gly Pro Leu Glu Thr			
	740	745	750
Val Thr Leu Leu Pro Val Ala Arg Thr Asp Ala Ala Leu Tyr Ala Cys			
	755	760	765
Arg Ile Leu Thr Glu Ala Gly Ala Gln Leu Ser Thr Pro Val Leu Leu			
	770	775	780
Ser Val Leu Tyr Pro Pro Asp Arg Pro Lys Leu Ser Ala Leu Leu Asp			
	785	790	795
Met Gly Gln Gly His Met Ala Leu Phe Ile Cys Thr Val Asp Ser Arg			
	805	810	815
Pro Leu Ala Leu Leu Ala Leu Phe His Gly Glu His Leu Leu Ala Thr			
	820	825	830
Ser Leu Gly Pro Gln Val Pro Ser His Gly Arg Phe Gln Ala Lys Ala			
	835	840	845
Glu Ala Asn Ser Leu Lys Leu Glu Val Arg Glu Leu Gly Leu Gly Asp			
	850	855	860
Ser Gly Ser Tyr Arg Cys Glu Ala Thr Asn Val Leu Gly Ser Ser Asn			
	865	870	875
Thr Ser Leu Phe Phe Gln Val Arg Gly Ala Trp Val Gln Val Ser Pro			
	885	890	895
Ser Pro Glu Leu Gln Glu Gly Gln Ala Val Val Leu Ser Cys Gln Val			
	900	905	910
His Thr Gly Val Pro Glu Gly Thr Ser Tyr Arg Trp Tyr Arg Asp Gly			
	915	920	925
Gln Pro Leu Gln Glu Ser Thr Ser Ala Thr Leu Arg Phe Ala Ala Ile			
	930	935	940
Thr Leu Thr Gln Ala Gly Ala Tyr His Cys Gln Ala Gln Ala Pro Gly			
	945	950	955
Ser Ala Thr Thr Ser Leu Ala Ala Pro Ile Ser Leu His Val Ser Tyr			
	965	970	975
Ala Pro Arg His Val Thr Leu Thr Thr Leu Met Asp Thr Gly Pro Gly			
	980	985	990
Arg Leu Gly Leu Leu Leu Cys Arg Val Asp Ser Asp Pro Pro Ala Gln			
	995	1000	1005
Leu Arg Leu Leu His Gly Asp Arg Leu Val Ala Ser Thr Leu Gln Gly			
	1010	1015	1020
Val Gly Gly Pro Glu Gly Ser Ser Pro Arg Leu His Val Ala Val Ala			
	1025	1030	1035
Pro Asn Thr Leu Arg Leu Glu Ile His Gly Ala Met Leu Glu Asp Glu			
	1045	1050	1055

Gly Val Tyr Ile Cys Glu Ala Ser Asn Thr Leu Gly Gln Ala Ser Ala
 1060 1065 1070
 Ser Ala Asp Phe Asp Ala Gln Ala Val Asn Val Gln Val Trp Pro Gly
 1075 1080 1085
 Ala Thr Val Arg Glu Gly Gln Leu Val Asn Leu Thr Cys Leu Val Trp
 1090 1095 1100
 Thr Thr His Pro Ala Gln Leu Thr Tyr Thr Trp Tyr Gln Asp Gly Gln
 1105 1110 1115 1120
 Gln Arg Leu Asp Ala His Ser Ile Pro Leu Pro Asn Val Thr Val Arg
 1125 1130 1135
 Asp Ala Thr Ser Tyr Arg Cys Gly Val Gly Pro Pro Gly Arg Ala Pro
 1140 1145 1150
 Arg Leu Ser Arg Pro Ile Thr Leu Asp Val Leu Tyr Ala Pro Arg Asn
 1155 1160 1165
 Leu Arg Leu Thr Tyr Leu Leu Glu Ser His Gly Gly Gln Leu Ala Leu
 1170 1175 1180
 Val Leu Cys Thr Val Asp Ser Arg Pro Pro Ala Gln Leu Ala Leu Ser
 1185 1190 1195 1200
 His Ala Gly Arg Leu Leu Ala Ser Ser Thr Ala Ala Ser Val Pro Asn
 1205 1210 1215
 Thr Leu Arg Leu Glu Leu Arg Gly Pro Gln Pro Arg Asp Glu Gly Phe
 1220 1225 1230
 Tyr Ser Cys Ser Ala Arg Ser Pro Leu Gly Gln Ala Asn Thr Ser Leu
 1235 1240 1245
 Glu Leu Arg Leu Glu Gly Val Arg Val Ile Leu Ala Pro Glu Ala Ala
 1250 1255 1260
 Val Pro Glu Gly Ala Pro Ile Thr Val Thr Cys Ala Asp Pro Ala Ala
 1265 1270 1275 1280
 His Ala Pro Thr Leu Tyr Thr Trp Tyr His Asn Gly Arg Trp Leu Gln
 1285 1290 1295
 Glu Gly Pro Ala Ala Ser Leu Ser Phe Leu Val Ala Thr Arg Ala His
 1300 1305 1310
 Ala Gly Ala Tyr Ser Cys Gln Ala Gln Asp Ala Gln Gly Thr Arg Ser
 1315 1320 1325
 Ser Arg Pro Ala Ala Leu Gln Val Leu Tyr Ala Pro Gln Asp Ala Val
 1330 1335 1340
 Leu Ser Ser Phe Arg Asp Ser Arg Ala Arg Ser Met Ala Val Ile Gln
 1345 1350 1355 1360
 Cys Thr Val Asp Ser Glu Pro Pro Ala Glu Leu Ala Leu Ser His Asp
 1365 1370 1375
 Gly Lys Val Leu Ala Thr Ser Ser Gly Val His Ser Leu Ala Ser Gly
 1380 1385 1390

Thr Gly His Val Gln Val Ala Arg Asn Ala Leu Arg Leu Gln Val Gln
 1395 1400 1405
 Asp Val Pro Ala Gly Asp Asp Thr Tyr Val Cys Thr Ala Gln Asn Leu
 1410 1415 1420
 Leu Gly Ser Ile Ser Thr Ile Gly Arg Leu Gln Val Glu Gly Ala Arg
 1425 1430 1435 1440
 Val Val Ala Glu Pro Gly Leu Asp Val Pro Glu Gly Ala Ala Leu Asn
 1445 1450 1455
 Leu Ser Cys Arg Leu Leu Gly Gly Pro Gly Pro Val Gly Asn Ser Thr
 1460 1465 1470
 Phe Ala Trp Phe Trp Asn Asp Arg Arg Leu His Ala Glu Pro Val Pro
 1475 1480 1485
 Thr Leu Ala Phe Thr His Val Ala Arg Ala Gln Ala Gly Met Tyr His
 1490 1495 1500
 Cys Leu Ala Glu Leu Pro Thr Gly Ala Ala Ala Ser Ala Pro Val Met
 1505 1510 1515 1520
 Leu Arg Val Leu Tyr Pro Pro Lys Thr Pro Thr Met Met Val Phe Val
 1525 1530 1535
 Glu Pro Glu Gly Gly Leu Arg Gly Ile Leu Asp Cys Arg Val Asp Ser
 1540 1545 1550
 Glu Pro Leu Ala Ser Leu Thr Leu His Leu Gly Ser Arg Leu Val Ala
 1555 1560 1565
 Ser Ser Gln Pro Gln Gly Ala Pro Ala Glu Pro His Ile His Val Leu
 1570 1575 1580
 Ala Ser Pro Asn Ala Leu Arg Val Asp Ile Glu Ala Leu Arg Pro Ser
 1585 1590 1595 1600
 Asp Gln Gly Glu Tyr Ile Cys Ser Ala Ser Asn Val Leu Gly Ser Ala
 1605 1610 1615
 Ser Thr Ser Thr Tyr Phe Gly Val Arg Ala Leu His Arg Leu His Gln
 1620 1625 1630
 Phe Gln Gln Leu Leu Trp Val Leu Gly Leu Leu Val Gly Leu Leu Leu
 1635 1640 1645
 Leu Leu Leu Gly Leu Gly Ala Cys Tyr Thr Trp Arg Asp Trp Val Leu
 1650 1655 1660
 Pro Tyr Trp Pro Leu Gln Glu Trp Arg Ala Asp Thr Asp Val Val Ser
 1665 1670 1675 1680
 Ile Leu Ile Pro Ala Pro Asp Ala Ser Leu Phe Met Thr Val
 1685 1690

<210> 37

<211> 745

<212> PRT

<213> Homo sapiens

<400> 37

```

Met Phe Pro Leu Arg Ala Leu Trp Leu Val Trp Ala Leu Leu Gly Val
 1           5           10           15
Ala Gly Ser Cys Pro Glu Pro Cys Ala Cys Val Asp Lys Tyr Ala His
          20           25           30
Gln Phe Ala Asp Cys Ala Tyr Lys Glu Leu Arg Glu Val Pro Glu Gly
          35           40           45
Leu Pro Ala Asn Val Thr Thr Leu Ser Leu Ser Ala Asn Lys Ile Thr
          50           55           60
Val Leu Arg Arg Gly Ala Phe Ala Asp Val Thr Gln Val Thr Ser Leu
65           70           75           80
Trp Leu Ala His Asn Glu Val Arg Thr Val Glu Pro Gly Ala Leu Ala
          85           90           95
Val Leu Ser Gln Leu Lys Asn Leu Asp Leu Ser His Asn Phe Ile Ser
          100          105          110
Ser Phe Pro Trp Ser Asp Leu Arg Asn Leu Ser Ala Leu Gln Leu Leu
          115          120          125
Lys Met Asn His Asn Arg Leu Gly Ser Leu Pro Arg Asp Ala Leu Gly
          130          135          140
Ala Leu Pro Asp Leu Arg Ser Leu Arg Ile Asn Asn Asn Arg Leu Arg
145          150          155          160
Thr Leu Ala Pro Gly Thr Phe Asp Ala Leu Ser Ala Leu Ser His Leu
          165          170          175
Gln Leu Tyr His Asn Pro Phe His Cys Gly Cys Gly Leu Val Trp Leu
          180          185          190
Gln Ala Trp Ala Ala Ser Thr Arg Val Ser Leu Pro Glu Pro Asp Ser
          195          200          205
Ile Ala Cys Ala Ser Pro Pro Ala Leu Gln Gly Val Pro Val Tyr Arg
          210          215          220
Leu Pro Ala Leu Pro Cys Ala Pro Pro Ser Val His Leu Ser Ala Glu
225          230          235          240
Pro Pro Leu Glu Ala Pro Gly Thr Pro Leu Arg Ala Gly Leu Ala Phe
          245          250          255
Val Leu His Cys Ile Ala Asp Gly His Pro Thr Pro Arg Leu Gln Trp
          260          265          270
Gln Leu Gln Ile Pro Gly Gly Thr Val Val Leu Glu Pro Pro Val Leu
          275          280          285
Ser Gly Glu Asp Asp Gly Val Gly Ala Glu Glu Gly Glu Gly Glu Gly
          290          295          300
Asp Gly Asp Leu Leu Thr Gln Thr Gln Ala Gln Thr Pro Thr Pro Ala

```

305		310		315		320									
Pro	Ala	Trp	Pro	Ala	Pro	Pro	Ala	Thr	Pro	Arg	Phe	Leu	Ala	Leu	Ala
		325				330								335	
Asn	Gly	Ser	Leu	Leu	Val	Pro	Leu	Leu	Ser	Ala	Lys	Glu	Ala	Gly	Val
		340						345						350	
Tyr	Thr	Cys	Arg	Ala	His	Asn	Glu	Leu	Gly	Ala	Asn	Ser	Thr	Ser	Ile
		355						360						365	
Arg	Val	Ala	Val	Ala	Ala	Thr	Gly	Pro	Pro	Lys	His	Ala	Pro	Gly	Ala
		370						375						380	
Gly	Gly	Glu	Pro	Asp	Gly	Gln	Ala	Pro	Thr	Ser	Glu	Arg	Lys	Ser	Thr
		385				390							395		400
Ala	Lys	Gly	Arg	Gly	Asn	Ser	Val	Leu	Pro	Ser	Lys	Pro	Glu	Gly	Lys
				405						410				415	
Ile	Lys	Gly	Gln	Gly	Leu	Ala	Lys	Val	Ser	Ile	Leu	Gly	Glu	Thr	Glu
				420						425				430	
Thr	Glu	Pro	Glu	Glu	Asp	Thr	Ser	Glu	Gly	Glu	Glu	Ala	Glu	Asp	Gln
		435						440						445	
Ile	Leu	Ala	Asp	Pro	Ala	Glu	Glu	Gln	Arg	Cys	Gly	Asn	Gly	Asp	Pro
		450				455								460	
Ser	Arg	Tyr	Val	Ser	Asn	His	Ala	Phe	Asn	Gln	Ser	Ala	Glu	Leu	Lys
		465				470								475	480
Pro	His	Val	Phe	Glu	Leu	Gly	Val	Ile	Ala	Leu	Asp	Val	Ala	Glu	Arg
				485						490				495	
Glu	Ala	Arg	Val	Gln	Leu	Thr	Pro	Leu	Ala	Ala	Arg	Trp	Gly	Pro	Gly
			500							505				510	
Pro	Gly	Gly	Ala	Gly	Gly	Ala	Pro	Arg	Pro	Gly	Arg	Arg	Pro	Leu	Arg
		515						520						525	
Leu	Leu	Tyr	Leu	Cys	Pro	Ala	Gly	Gly	Gly	Ala	Ala	Val	Gln	Trp	Ser
		530				535								540	
Arg	Val	Glu	Glu	Gly	Val	Asn	Ala	Tyr	Trp	Phe	Arg	Gly	Leu	Arg	Pro
		545				550				555				560	
Gly	Thr	Asn	Tyr	Ser	Val	Cys	Leu	Ala	Leu	Ala	Gly	Glu	Ala	Cys	His
				565						570				575	
Val	Gln	Val	Val	Phe	Ser	Thr	Lys	Lys	Glu	Leu	Pro	Ser	Leu	Leu	Val
			580							585				590	
Ile	Val	Ala	Val	Ser	Val	Phe	Leu	Leu	Val	Leu	Ala	Thr	Val	Pro	Leu
		595						600						605	
Leu	Gly	Ala	Ala	Cys	Cys	His	Leu	Leu	Ala	Lys	His	Pro	Gly	Lys	Pro
		610				615								620	
Tyr	Arg	Leu	Ile	Leu	Arg	Pro	Gln	Ala	Pro	Asp	Pro	Met	Glu	Lys	Arg
		625				630							635		640
Ile	Ala	Ala	Asp	Phe	Asp	Pro	Arg	Ala	Ser	Tyr	Leu	Glu	Ser	Glu	Lys

				645						650					655				
Ser	Tyr	Pro	Ala	Gly	Gly	Glu	Ala	Gly	Gly	Glu	Glu	Pro	Glu	Asp	Val				
				660						665					670				
Gln	Gly	Glu	Gly	Leu	Asp	Glu	Asp	Ala	Glu	Gln	Gly	Asp	Pro	Ser	Gly				
				675						680					685				
Asp	Leu	Gln	Arg	Glu	Glu	Ser	Leu	Ala	Ala	Cys	Ser	Leu	Val	Glu	Ser				
				690						695					700				
Gln	Ser	Lys	Ala	Asn	Gln	Glu	Glu	Phe	Glu	Ala	Gly	Ser	Glu	Tyr	Ser				
				705						710					715				720
Asp	Arg	Leu	Pro	Leu	Gly	Ala	Glu	Ala	Val	Asn	Ile	Ala	Gln	Glu	Ile				
				725						730					735				
Asn	Gly	Asn	Tyr	Arg	Gln	Thr	Ala	Gly											
				740						745									

<210> 38

<211> 251

<212> PRT

<213> Homo sapiens

<400> 38

Met	Ser	Ala	Tyr	Gly	Met	Pro	Met	Tyr	Lys	Ser	Gly	Asp	Leu	Val	Phe				
1				5					10					15					
Ala	Lys	Leu	Lys	Gly	Tyr	Ala	His	Trp	Pro	Ala	Arg	Ile	Glu	His	Met				
				20					25					30					
Thr	Gln	Pro	Asn	Arg	Tyr	Gln	Val	Phe	Phe	Phe	Gly	Thr	His	Glu	Thr				
				35				40					45						
Ala	Phe	Leu	Ser	Pro	Lys	Arg	Leu	Phe	Pro	Tyr	Lys	Glu	Cys	Lys	Glu				
				50			55				60								
Lys	Phe	Gly	Lys	Pro	Asn	Lys	Arg	Arg	Gly	Phe	Ser	Ala	Gly	Leu	Trp				
				65			70			75				80					
Glu	Ile	Glu	Asn	Asn	Pro	Thr	Val	Gln	Ala	Ser	Asp	Cys	Pro	Leu	Ala				
				85					90					95					
Ser	Glu	Lys	Gly	Ser	Gly	Asp	Gly	Pro	Trp	Pro	Glu	Pro	Glu	Ala	Ala				
				100				105					110						
Glu	Gly	Asp	Glu	Asp	Lys	Pro	Thr	His	Ala	Gly	Gly	Gly	Gly	Asp	Glu				
				115				120					125						
Leu	Gly	Lys	Pro	Asp	Asp	Asp	Lys	Pro	Thr	Glu	Glu	Glu	Lys	Gly	Pro				
				130			135						140						
Leu	Lys	Arg	Ser	Ala	Gly	Asp	Pro	Pro	Glu	Asp	Ala	Pro	Lys	Arg	Pro				
				145			150			155				160					
Lys	Glu	Ala	Ala	Pro	Asp	Gln	Glu	Glu	Glu	Ala	Glu	Ala	Glu	Arg	Ala				
				165						170				175					

Ala Glu Ala Glu Arg Ala Ala Ala Ala Ala Ala Thr Ala Val Asp
 180 185 190
 Glu Glu Ser Pro Phe Leu Val Ala Val Glu Asn Gly Ser Ala Pro Ser
 195 200 205
 Glu Pro Gly Leu Val Cys Glu Pro Pro Gln Pro Glu Glu Glu Glu Leu
 210 215 220
 Arg Glu Glu Glu Val Ala Asp Glu Glu Ala Ser Gln Glu Trp His Ala
 225 230 235 240
 Glu Ala Pro Gly Gly Gly Asp Arg Asp Ser Leu
 245 250

<210> 39

<211> 408

<212> PRT

<213> Homo sapiens

<400> 39

Phe Leu Ile Ser Asp Arg Asp Pro Gln Cys Asn Leu His Cys Ser Arg
 1 5 10 15
 Thr Gln Pro Lys Pro Ile Cys Ala Ser Asp Gly Arg Ser Tyr Glu Ser
 20 25 30
 Met Cys Glu Tyr Gln Arg Ala Lys Cys Arg Asp Pro Thr Leu Gly Val
 35 40 45
 Val His Arg Gly Arg Cys Lys Asp Ala Gly Gln Ser Lys Cys Arg Leu
 50 55 60
 Glu Arg Ala Gln Ala Leu Glu Gln Ala Lys Lys Pro Gln Glu Ala Val
 65 70 75 80
 Phe Val Pro Glu Cys Gly Glu Asp Gly Ser Phe Thr Gln Val Gln Cys
 85 90 95
 His Thr Tyr Thr Gly Tyr Cys Trp Cys Val Thr Pro Asp Gly Lys Pro
 100 105 110
 Ile Ser Gly Ser Ser Val Gln Asn Lys Thr Pro Val Cys Ser Gly Ser
 115 120 125
 Val Thr Asp Lys Pro Leu Ser Gln Gly Asn Ser Gly Arg Lys Asp Asp
 130 135 140
 Gly Ser Lys Pro Thr Pro Thr Met Glu Thr Gln Pro Val Phe Asp Gly
 145 150 155 160
 Asp Glu Ile Thr Ala Pro Thr Leu Trp Ile Lys His Leu Val Ile Lys
 165 170 175
 Asp Ser Lys Leu Asn Asn Thr Asn Ile Arg Asn Ser Glu Lys Val Tyr
 180 185 190
 Ser Cys Asp Gln Glu Arg Gln Ser Ala Leu Glu Glu Ala Gln Gln Asn

195	200	205
Pro Arg Glu Gly Ile Val Ile	Pro Glu Cys Ala	Pro Gly Gly Leu Tyr
210	215	220
Lys Pro Val Gln Cys His Gln	Ser Thr Gly Tyr	Cys Trp Cys Val Leu
225	230	235
Val Asp Thr Gly Arg Pro Leu	Pro Gly Thr Ser Thr Arg Tyr Val Met	
245	250	255
Pro Ser Cys Glu Ser Asp Ala Arg	Ala Lys Thr Thr Glu Ala Asp Asp	
260	265	270
Pro Phe Lys Asp Arg Glu Leu	Pro Gly Cys Pro Glu Gly Lys Lys Met	
275	280	285
Glu Phe Ile Thr Ser Leu Leu	Asp Ala Leu Thr Thr Asp Met Val Gln	
290	295	300
Ala Ile Asn Ser Ala Ala Pro Thr	Gly Gly Gly Arg Phe Ser Glu Pro	
305	310	315
Asp Pro Ser His Thr Leu Glu Glu	Arg Val Val His Trp Tyr Phe Ser	
325	330	335
Gln Leu Asp Ser Asn Ser Ser Asn	Asp Ile Asn Lys Arg Glu Met Lys	
340	345	350
Pro Phe Lys Arg Tyr Val Lys Lys	Lys Ala Lys Pro Lys Lys Cys Ala	
355	360	365
Arg Arg Phe Thr Asp Tyr Cys Asp	Leu Asn Lys Asp Lys Val Ile Ser	
370	375	380
Leu Pro Glu Leu Lys Gly Cys Leu	Gly Val Ser Lys Glu Gly Gly Ser	
385	390	395
Leu Gly Ser Phe Pro Gln Ala Lys		400
405		

<210> 40

<211> 434

<212> PRT

<213> Homo sapiens

<400> 40

Met Ala Gly Ser Gly Pro Pro Leu	Pro Thr Cys Asn Ala Glu Val Gly
1	5 10 15
Trp Glu Asn Met Ala Glu Asp Gly	Lys Ala Phe Leu Ile Ser Asp Arg
20	25 30
Asp Pro Gln Cys Asn Leu His Cys	Ser Arg Thr Gln Pro Lys Pro Ile
35	40 45
Cys Ala Ser Asp Gly Arg Ser Tyr	Glu Ser Met Cys Glu Tyr Gln Arg
50	55 60

Ala	Lys	Cys	Arg	Asp	Pro	Thr	Leu	Gly	Val	Val	His	Arg	Gly	Arg	Cys	65	70	75	80
Lys	Asp	Ala	Gly	Gln	Ser	Lys	Cys	Arg	Leu	Glu	Arg	Ala	Gln	Ala	Leu	85	90	95	
Glu	Gln	Ala	Lys	Lys	Pro	Gln	Glu	Ala	Val	Phe	Val	Pro	Glu	Cys	Gly	100	105	110	
Glu	Asp	Gly	Ser	Phe	Thr	Gln	Val	Gln	Cys	His	Thr	Tyr	Thr	Gly	Tyr	115	120	125	
Cys	Trp	Cys	Val	Thr	Pro	Asp	Gly	Lys	Pro	Ile	Ser	Gly	Ser	Ser	Val	130	135	140	
Gln	Asn	Lys	Thr	Pro	Val	Cys	Ser	Gly	Ser	Val	Thr	Asp	Lys	Pro	Leu	145	150	155	160
Ser	Gln	Gly	Asn	Ser	Gly	Arg	Lys	Asp	Asp	Gly	Ser	Lys	Pro	Thr	Pro	165	170	175	
Thr	Met	Glu	Thr	Gln	Pro	Val	Phe	Asp	Gly	Asp	Glu	Ile	Thr	Ala	Pro	180	185	190	
Thr	Leu	Trp	Ile	Lys	His	Leu	Val	Ile	Lys	Asp	Ser	Lys	Leu	Asn	Asn	195	200	205	
Thr	Asn	Ile	Arg	Asn	Ser	Glu	Lys	Val	Tyr	Ser	Cys	Asp	Gln	Glu	Arg	210	215	220	
Gln	Ser	Ala	Leu	Glu	Glu	Ala	Gln	Gln	Asn	Pro	Arg	Glu	Gly	Ile	Val	225	230	235	240
Ile	Pro	Glu	Cys	Ala	Pro	Gly	Gly	Leu	Tyr	Lys	Pro	Val	Gln	Cys	His	245	250	255	
Gln	Ser	Thr	Gly	Tyr	Cys	Trp	Cys	Val	Leu	Val	Asp	Thr	Gly	Arg	Pro	260	265	270	
Leu	Pro	Gly	Thr	Ser	Thr	Arg	Tyr	Val	Met	Pro	Ser	Cys	Glu	Ser	Asp	275	280	285	
Ala	Arg	Ala	Lys	Thr	Thr	Glu	Ala	Asp	Asp	Pro	Phe	Lys	Asp	Arg	Glu	290	295	300	
Leu	Pro	Gly	Cys	Pro	Glu	Gly	Lys	Lys	Met	Glu	Phe	Ile	Thr	Ser	Leu	305	310	315	320
Leu	Asp	Ala	Leu	Thr	Thr	Asp	Met	Val	Gln	Ala	Ile	Asn	Ser	Ala	Ala	325	330	335	
Pro	Thr	Gly	Gly	Gly	Arg	Phe	Ser	Glu	Pro	Asp	Pro	Ser	His	Thr	Leu	340	345	350	
Glu	Glu	Arg	Val	Val	His	Trp	Tyr	Phe	Ser	Gln	Leu	Asp	Ser	Asn	Ser	355	360	365	
Ser	Asn	Asp	Ile	Asn	Lys	Arg	Glu	Met	Lys	Pro	Phe	Lys	Arg	Tyr	Val	370	375	380	
Lys	Lys	Lys	Ala	Lys	Pro	Lys	Lys	Cys	Ala	Arg	Arg	Phe	Thr	Asp	Tyr	385	390	395	400

Cys Asp Leu Asn Lys Asp Lys Val Ile Ser Leu Pro Glu Leu Lys Gly
 405 410 415
 Cys Leu Gly Val Ser Lys Glu Gly Gly Ser Leu Gly Ser Phe Pro Gln
 420 425 430
 Ala Lys

<210> 41
 <211> 250
 <212> PRT
 <213> Homo sapiens

<400> 41
 Met Ala Cys Trp Trp Pro Leu Leu Leu Glu Leu Trp Thr Val Met Pro
 1 5 10 15
 Thr Trp Ala Gly Asp Glu Leu Leu Asn Ile Cys Met Asn Ala Lys His
 20 25 30
 His Lys Arg Val Pro Ser Pro Glu Asp Lys Leu Tyr Glu Glu Cys Ile
 35 40 45
 Pro Trp Lys Asp Asn Ala Cys Cys Thr Leu Thr Thr Ser Trp Glu Ala
 50 55 60
 His Leu Asp Val Ser Pro Leu Tyr Asn Phe Ser Leu Phe His Cys Gly
 65 70 75 80
 Leu Leu Met Pro Gly Cys Arg Lys His Phe Ile Gln Ala Ile Cys Phe
 85 90 95
 Tyr Glu Cys Ser Pro Asn Leu Gly Pro Trp Ile Gln Pro Val Gly Ser
 100 105 110
 Leu Gly Trp Glu Val Ala Pro Ser Gly Gln Gly Glu Arg Val Val Asn
 115 120 125
 Val Pro Leu Cys Gln Glu Asp Cys Glu Glu Trp Trp Glu Asp Cys Arg
 130 135 140
 Met Ser Tyr Thr Cys Lys Ser Asn Trp Arg Gly Gly Trp Asp Trp Ser
 145 150 155 160
 Gln Gly Lys Asn Arg Cys Pro Lys Gly Ala Gln Cys Leu Pro Phe Ser
 165 170 175
 His Tyr Phe Pro Thr Pro Ala Asp Leu Cys Glu Lys Thr Trp Ser Asn
 180 185 190
 Ser Phe Lys Ala Ser Pro Glu Arg Arg Asn Ser Gly Arg Cys Leu Gln
 195 200 205
 Lys Trp Phe Glu Pro Ala Gln Gly Asn Pro Asn Val Ala Val Ala Arg
 210 215 220
 Leu Phe Ala Ser Ser Ala Pro Ser Trp Glu Leu Ser Tyr Thr Ile Met

225 230 235 240
 Val Cys Ser Leu Phe Leu Pro Phe Leu Ser
 245 250

 <210> 42
 <211> 257
 <212> PRT
 <213> Homo sapiens

 <400> 42
 Met Gly Thr Val Arg Pro Pro Arg Pro Ser Leu Leu Leu Val Ser Thr
 1 5 10 15
 Arg Glu Ser Cys Leu Phe Leu Leu Phe Cys Leu His Leu Gly Ala Ala
 20 25 30
 Cys Pro Gln Pro Cys Arg Cys Pro Asp His Ala Gly Ala Val Ala Val
 35 40 45
 Phe Cys Ser Leu Arg Gly Leu Gln Glu Val Pro Glu Asp Ile Pro Ala
 50 55 60
 Asn Thr Val Leu Leu Lys Leu Asp Ala Asn Lys Ile Ser His Leu Pro
 65 70 75 80
 Asp Gly Ala Phe Gln His Leu His Arg Leu Arg Glu Leu Asp Leu Ser
 85 90 95
 His Asn Ala Ile Glu Ala Ile Gly Ser Ala Thr Phe Ala Gly Leu Ala
 100 105 110
 Gly Gly Leu Arg Leu Leu Asp Leu Ser Tyr Asn Arg Ile Gln Arg Ile
 115 120 125
 Pro Lys Asp Ala Leu Gly Lys Leu Ser Ala Lys Ile Arg Leu Ser His
 130 135 140
 Asn Pro Leu His Cys Glu Cys Ala Leu Gln Glu Ala Leu Trp Glu Leu
 145 150 155 160
 Lys Leu Asp Pro Asp Ser Val Asp Glu Ile Ala Cys His Thr Ser Val
 165 170 175
 Gln Glu Glu Phe Val Gly Lys Pro Leu Val Gln Ala Leu Asp Ala Gly
 180 185 190
 Ala Ser Leu Cys Ser Val Pro His Arg Thr Thr Asp Val Ala Met Leu
 195 200 205
 Val Thr Met Phe Gly Trp Phe Ala Met Val Ile Ala Tyr Val Val Tyr
 210 215 220
 Tyr Val Arg His Asn Gln Glu Asp Ala Arg Arg His Leu Glu Tyr Leu
 225 230 235 240
 Lys Ser Leu Pro Ser Ala Pro Ala Ser Lys Asp Pro Ile Gly Pro Gly
 245 250 255

Pro

<210> 43
 <211> 148
 <212> PRT
 <213> Homo sapiens

<400> 43
 Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His
 20 25 30
 Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro
 35 40 45
 Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp
 50 55 60
 Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln
 65 70 75 80
 Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr
 85 90 95
 Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu
 100 105 110
 Ser Thr Glu Leu Asn Asn Val Arg Gln Asp Thr Ser Phe Pro Pro Gly
 115 120 125
 Tyr Ser Cys Gly Cys His Met Gly Cys Gly Val Gly Thr Gly Ala Thr
 130 135 140
 Asp Lys Glu Thr
 145

<210> 44
 <211> 355
 <212> PRT
 <213> Homo sapiens

<400> 44
 Met Gly Pro Lys Asp Ser Ala Lys Cys Leu His Arg Gly Pro Gln Pro
 1 5 10 15
 Ser His Trp Ala Ala Gly Asp Gly Pro Thr Gln Glu Arg Cys Gly Pro
 20 25 30
 Arg Ser Leu Gly Ser Pro Val Leu Gly Leu Asp Thr Cys Arg Ala Trp
 35 40 45

Asp His Val Asp Gly Gln Ile Leu Gly Gln Leu Arg Pro Leu Thr Glu
 50 55 60
 Glu Glu Glu Glu Glu Gly Ala Gly Ala Thr Leu Ser Arg Gly Pro Ala
 65 70 75 80
 Phe Pro Gly Met Gly Ser Glu Glu Leu Arg Leu Ala Ser Phe Tyr Asp
 85 90 95
 Trp Pro Leu Thr Ala Glu Val Pro Pro Glu Leu Leu Ala Ala Ala Gly
 100 105 110
 Phe Phe His Thr Gly His Gln Asp Lys Val Arg Cys Phe Phe Cys Tyr
 115 120 125
 Gly Gly Leu Gln Ser Trp Lys Arg Gly Asp Asp Pro Trp Thr Glu His
 130 135 140
 Ala Lys Trp Phe Pro Ser Cys Gln Phe Leu Leu Arg Ser Lys Gly Arg
 145 150 155 160
 Asp Phe Val His Ser Val Gln Glu Thr His Ser Gln Leu Leu Gly Ser
 165 170 175
 Trp Val Ser Ala Thr Ser Pro Arg Gly Ser Gly Trp Gln Trp Gly Pro
 180 185 190
 Ala Pro Pro Ile Ser Pro Arg Pro Asp Gly Leu Trp Leu Leu Pro Gly
 195 200 205
 Pro Val Gly Arg Thr Gly Arg Arg Ser Pro Cys Gly Pro Leu Arg Ser
 210 215 220
 Ser Leu Lys Val Pro Arg Ser Gln Val Gln Ala Arg Asp Pro Leu Gly
 225 230 235 240
 Glu Gly Trp Gly Arg Gly Gly Leu Arg Asp Pro Asp Leu Pro Trp Pro
 245 250 255
 Ile Glu Gly Gly Gly Gln Gly Val Gly Thr Phe Arg Arg Pro Val Leu
 260 265 270
 Leu Gly Gly Val Ser Pro Ala Glu Ala Gln Arg Ala Trp Trp Val Leu
 275 280 285
 Glu Pro Pro Gly Ala Arg Asp Val Glu Ala Gln Leu Arg Arg Leu Gln
 290 295 300
 Glu Glu Arg Thr Cys Lys Val Cys Leu Asp Arg Ala Val Ser Ile Val
 305 310 315 320
 Phe Val Pro Cys Gly His Leu Val Cys Ala Glu Cys Ala Pro Gly Leu
 325 330 335
 Gln Leu Cys Pro Ile Cys Arg Ala Pro Val Arg Ser Arg Val Arg Thr
 340 345 350
 Phe Leu Ser
 355

<210> 45

<211> 255

<212> PRT

<213> Homo sapiens

<400> 45

```

Met Gly Pro Lys Asp Ser Ala Lys Cys Leu His Arg Gly Pro Gln Pro
 1           5           10           15
Ser His Trp Ala Ala Gly Asp Gly Pro Thr Gln Glu Arg Cys Gly Pro
          20           25           30
Arg Ser Leu Gly Ser Pro Val Leu Gly Leu Asp Thr Cys Arg Ala Trp
      35           40           45
Asp His Val Asp Gly Gln Ile Leu Gly Gln Leu Arg Pro Leu Thr Glu
 50           55           60
Glu Glu Glu Glu Glu Gly Ala Gly Ala Thr Leu Ser Arg Gly Pro Ala
65           70           75           80
Phe Pro Gly Met Gly Ser Glu Glu Leu Arg Leu Ala Ser Phe Tyr Asp
          85           90           95
Trp Pro Leu Thr Ala Glu Val Pro Pro Glu Leu Leu Ala Ala Ala Gly
          100          105          110
Phe Phe His Thr Gly His Gln Asp Lys Val Arg Cys Phe Phe Cys Tyr
          115          120          125
Gly Gly Leu Gln Ser Trp Lys Arg Gly Asp Asp Pro Trp Thr Glu His
          130          135          140
Ala Lys Trp Phe Pro Leu Ser Val Pro Ala Pro Val Lys Arg Lys Arg
145          150          155          160
Leu Cys Pro Gln Cys Ala Gly Asp Ser Leu Pro Ala Ala Gly Leu Leu
          165          170          175
Gly Pro Val Gly Arg Thr Gly Arg Arg Ser Pro Cys Gly Pro Leu Arg
          180          185          190
Ser Gln Gly Cys Gly Gly Ala Ala Ala Ala Ala Gly Gly Glu Asp
          195          200          205
Val Gln Gly Val Pro Gly Pro Arg Arg Val His Arg Leu Cys Ala Val
          210          215          220
Arg Pro Pro Gly Leu Cys Val Cys Pro Arg Pro Ala Ala Val Pro His
225          230          235          240
Leu Gln Ser Pro Arg Pro Gln Pro Arg Ala His Leu Pro Val Leu
          245          250          255

```

<210> 46

<211> 251

<212> PRT

<213> Homo sapiens

<400> 46

```

Met Leu Gly Ala Arg Leu Arg Leu Trp Val Cys Ala Leu Cys Ser Val
 1           5           10           15
Cys Ser Met Ser Val Leu Arg Ala Tyr Pro Asn Ala Ser Pro Leu Leu
      20           25           30
Gly Ser Ser Trp Gly Gly Leu Ile His Leu Tyr Thr Ala Thr Ala Arg
      35           40           45
Asn Ser Tyr His Leu Gln Ile His Lys Asn Gly His Val Asp Gly Ala
 50           55           60
Pro His Gln Thr Ile Tyr Ser Ala Leu Met Ile Arg Ser Glu Asp Ala
65           70           75           80
Gly Phe Val Val Ile Thr Gly Val Met Ser Arg Arg Tyr Leu Cys Met
      85           90           95
Asp Phe Arg Gly Asn Ile Phe Gly Ser His Tyr Phe Asp Pro Glu Asn
      100           105           110
Cys Arg Phe Gln His Gln Thr Leu Glu Asn Gly Tyr Asp Val Tyr His
      115           120           125
Ser Pro Gln Tyr His Phe Leu Val Ser Leu Gly Arg Ala Lys Arg Ala
      130           135           140
Phe Leu Pro Gly Met Asn Pro Pro Pro Tyr Ser Gln Phe Leu Ser Arg
145           150           155           160
Arg Asn Glu Ile Pro Leu Ile His Phe Asn Thr Pro Ile Pro Arg Arg
      165           170           175
His Thr Arg Ser Ala Glu Asp Asp Ser Glu Arg Asp Pro Leu Asn Val
      180           185           190
Leu Lys Pro Arg Ala Arg Met Thr Pro Ala Pro Ala Ser Cys Ser Gln
      195           200           205
Glu Leu Pro Ser Ala Glu Asp Asn Ser Pro Met Ala Ser Asp Pro Leu
      210           215           220
Gly Val Val Arg Gly Gly Arg Val Asn Thr His Ala Gly Gly Thr Gly
225           230           235           240
Pro Glu Gly Cys Arg Pro Phe Ala Lys Phe Ile
      245           250

```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/04703

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 14/17; C12N 5/10, 15/12, 15/63, 15/64

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/41523 A1 (YEDA RESEARCH AND DEVELOPMENT CO., LTD.) 27 December 1996 (27/12/1996), see entire document, especially pages 7-9.	1-2, 5-9

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

"	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

16 APRIL 2001

Date of mailing of the international search report

13 JUN 2001

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/04703

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-2, 5-9 (SEQ ID NO:1, 24)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/04703

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-2, 5-9, drawn to a nucleic acid of SEQ ID NO:1 encoding a protein of SEQ ID NO:24, a vector, a host cell, a method of making the protein and the protein of SEQ ID NO:24.

Group II, claims 3-4, drawn to an antibody that binds the protein of SEQ ID NO:24.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, a nucleic acid encoding a protein of SEQ ID NO:24, a vector, a host cell, a method of making the protein of SEQ ID NO:24, and the protein of SEQ ID NO:59. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

the polynucleotides set forth in SEQ ID NO:1-23 encoding the polypeptides set forth in SEQ ID NO:24-46.